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ABSTRACT 
Extremes of brain growth have frequently been associated with impaired 
neurodevelopment and cognition. A significant contribution to our understanding 
of the processes involved in brain development has been made by the study of 
single gene disorders which are rare in the general population, but occur with 
increased frequency in certain endogamous populations. This project stems 
from findings of a long-running clinical-genetic program, called ‘Windows of 
Hope’, based amongst the Amish. The project aims were to clinically 
characterise three new autosomal recessive disorders of brain growth and 
development, to define the genes and mutations responsible for each, and to 
investigate the function of the molecules identified. A final further objective of 
the project in keeping with the wider aims of the Windows of Hope study was to 
translate the findings of this research into direct clinical benefits to the families 
and community involved. A combination of clinical phenotyping, autozygosity 
and linkage mapping, and functional studies, were used to investigate each 
disorder, which enabled the identification of the novel disease genes in each 
case. 
Chapter three describes the identification of a hypomorphic mutation in PCNA 
responsible for a novel DNA repair disorder. Thus, although it was considered 
by many that mutations in PCNA would not be compatible with life due to its 
crucial role in genomic stability and cell division, this study disproves this notion 
and describes a molecular ‘missing piece’ in DNA repair spectrum disorders. 
While the relationship between pervasive developmental disorders and 
megalencephaly is well described, very few single gene disorders associated 
with this clinical relationship have been identified. Chapter four documents the 
discovery of two founder mutations in the KPTN gene associated with such a 
phenotype. The functional data shows that the encoded wild type molecule 
(kaptin) associates with dynamic actin cytoskeletal structures in cultured 
neurons and that the causative mutations result in loss of function perturbing 
this interaction, defining kaptin as a new molecule which is crucial for normal 
human brain development and function. 
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Chapter five details the investigation of the eponymously named “Hershberger 
syndrome”, a disorder originally described by McKusick in the Ohio Amish in 
1967. Clinical and genetic studies of affected individuals revealed that the 
syndrome was comprised of two distinct disorders; Aicardi Goutières syndrome 
due to mutation in SAMHD1, and a new condition characterised by profound 
neurological impairment, cerebellar involvement and nephrosis. This condition, 
renamed “nephrocerebellar syndrome” was found to be caused by homozygous 
mutations in two closely linked genes, WHAMM and WDR73. The genetic and 
functional data supported the involvement of both molecules in the disease, 
suggesting that this is a composite phenotype.  
The identification and functional characterisation of three new genes 
responsible for abnormalities in brain growth provides an invaluable insight into 
disease pathogenesis and also identifies molecular pathways important for 
normal brain development. This is turn enables clinicians to provide a much 
needed diagnosis for affected individuals and their families as well as the wider 
community.  
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SNP  ……….Single nucleotide polymorphism 
SPR  ……….Surface plasmon resonance 
TAE  ……….Tris-acetate-EDTA 
TBE  ……….Tris-Borate-EDTA 
TC-NER ……….Transcription coupled nucleotide excision repair 
TE  ……….Tris-EDTA 
TEMED ……….N,N,N1,N1-tetramethyl-ethylenediamine 
TetR  ……….Tetracycline- and doxycycline-responsive repressor protein 
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Tris  ……….Tris(hydroxymethyl)aminomethane 
TTD  ……….Trichothiodystrophy 
Tween-20 ………. Polysorbate 20 
UCSC  ……….University of California, Santa Cruz  
UDS  ……….Unscheduled DNA synthesis 
UV  ……….Ultraviolet light 
V  ……….Volt 
Val  ……….Valine 
WDR73 ……….WD repeat domain 73 
WHAMM ……….WAS protein homolog associated with actin, golgi 
membranes and microtubules 
WHO  ……….World health organization 
WOH  ……….Windows of Hope Amish inherited disease project 
WT  ……….Wild type 
w/v  ……….Weight per volume 
X-Gal  ……….5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside 
XP  ………. Xeroderma pigmentosum 
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1 INTRODUCTION 
1.1 Brain embryological development 
The three germ cell layers: ectoderm, mesoderm and endoderm, are 
established by the end of the second week of human embryonic development. 
Each layer then gives rise to a particular subset of tissues and organs. It is the 
ectoderm that gives rise to the nervous system as well as the skin. 
Neurulation is the name given to the process of embryonic nervous system 
formation. The neural plate is formed from a thickening of the dorsal midline 
ectoderm during the third week of embryonic development, the lateral margins 
then elevate to create the neural folds. The neural folds subsequently come 
together and fuse forming the neural tube, which will be fully formed by the end 
of the 4th week (Figure 1). Some cells from the neural folds subsequently 
separate to form the neural crests which lie dorsolateral to the neural tube. 
The brain is formed from the rostral part of the neural tube, with the caudal part 
becoming the adult spinal cord. The central cavity of the neural tube will 
eventually become the spinal canal and the cerebral ventricles. As embryonic 
development progresses a longitudinal groove, the sulcus limitans develops on 
the inner surface of the lateral walls of the caudal part of the embryonic brain 
and inner surface of the lateral walls of the spinal cord. The dorsal and ventral 
cells become delineated as the alar and basal plates respectively (Figure 2). 
Cells within the alar plate will generally become part of the sensory system and 
those of the basal plate will have predominantly motor functions. Around the 
central part of the canal differentiation occurs to form the grey matter, with the 
white matter forming as an outer coat. 
During the fifth week of embryonic development, the three primary brain 
vesicles can be identified: the prosencephalon (forebrain), mesencephalon 
(midbrain) and rhombencephalon (hindbrain). Further differentiation and 
division of the primary vesicles creates five secondary brain vesicles. The 
prosencephalon becomes the telencephalon and the diencephalon and the 
rhombencephalon divides into the metencephalon and the myelencephalon.  
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Figure 1: Development of the neural tube. Reproduced from (Ranson, 1920) 
 
 
 
Figure 2: Schematic of the developing neural tube. Modified (Crossman and Neary, 2010) 
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In the adult brain, the cerebral hemispheres originate from the telencephalon, 
the thalamus is derived from the diencephalon, the midbrain from the 
mesencephalon, the pons and cerebellum develop from the metencephalon and 
the medulla oblongata is derived from the myelencephalon. 
The cerebral hemispheres consist of an inner layer of grey matter, termed the 
cerebral cortex, with the inner brain mass comprised of white matter. The two 
hemispheres are separated by a cleft, the great longitudinal fissure. The 
midbrain, pons and medulla oblongata are collectively referred to as the 
brainstem. The central cavity within the brain becomes the ventricular system 
containing cerebral spinal fluid (CSF) (Crossman and Neary, 2010). 
1.1.1 Cerebral cortex 
The cerebral cortex becomes highly convoluted forming a complex pattern of 
ridges (gyri) and furrows (sulci) in order to maximise the surface area. Each 
hemisphere is divided into four lobes: the frontal, parietal, temporal and occipital 
lobes. The evolutionary origins of the cerebral cortex relate to olfactory function. 
The phylogenetically old parts of the cortex (referred to as the paleocortex) 
which include parts of the temporal lobes and hypothalamus, retain an 
association with the olfactory system and have a primitive three layered 
cytoarchitecture. These parts of the brain are functionally involved with the 
emotional aspects of memory and behaviour. The phyogenetically more recent 
acquisition, the neocortex, comprises the majority of the cerebral cortex, and 
the neurones within it form a highly organised laminar and radial structure. The 
adult neocortex is comprised of six layers, within which lie specialised neurones 
with specific synaptic connections and phenotypes. The fundamental functions 
of the cerebral cortex are necessary for thought, memory, intellect and 
conscious awareness. The cerebral cortex also plays a central role in the motor 
system, as the site where actions are conceived and initiated.  
During the first half of human gestation, the neuronal cells that eventually make 
up the cerebral cortex undergo a process of migration from near the surface of 
the cerebral ventricles to reach the neocortex. After their last mitotic division, 
these neuronal cells migrate passed previously towards the pial surface of the 
cortex to form the cortical plate (Figure 3). 
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The cortical neurone progenitor cells are confined within a transient 
pseudoepithelium composed of the narrow ventricular and subventricular 
zones. These two zones also contain a population of elongated radial glial cells 
that span the entirety of the embryonic cerebral wall and only exist during the 
phase of neuronal migration. Each successive generation of neuronal cells 
migrate past previously formed cells towards the region between the marginal 
zone and cortical plate. During their migration the neurones use the radial glial 
cells as a scaffolding to guide their way through the different cortical layers. 
Radial glial cells can give rise to neurones and eventually astrocytes and 
oligodendrocytes (Campbell and Gotz, 2002, Rakic, 2007, Gorski et al., 2002). 
These glial cells typically undergo asymmetrical division producing a post 
mitotic neurone and a radial glial cell or alternatively a radial glial cell and an 
intermediate progenitor within the subventricular zone. Intermediate progenitors, 
like radial glial cells, are a significant neuroprogenic cell population and undergo 
a symmetrical division to produce two post mitotic neurones (Arnold et al., 2008, 
Sessa et al., 2010, Sessa et al., 2008). 
The radial unit hypothesis of cortical development postulates that the horizontal 
location of a cortical neurone is determined by the position of its precursor cells 
in the ventricular zone, and depth is determined by birth order. The 
consequences of this are that the earliest formed neurones are found in the 
deeper layers and the latest in the more superficial cortical layers forming 
columns of interrelated neurones. Consequently the characteristic six layered 
neocortex is formed from the inside out. Once neurones reach their final laminar 
positions, they develop synaptic connections with neurones close by as well as 
more distant neurones in associated regions of the cerebral cortex (Rakic and 
Lombroso, 1998). 
The size of the cortex is critically dependent on the number of neuroprogenitor 
cells. Any disruption to this cell pool at early stages of cortical development can 
result in significant differences in cortical size (Sun and Hevner, 2014). The 
regulation of cell cycle progression plays an important role in the control of 
neuroprogenitor expansion. For example, knockout of the cytoskeletal 
associated gene filamin A (flna) elongates the cell cycle and reduces the 
number of neuroprogenitors resulting in a subsequent reduction in cortical size   
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Figure 3: Normal development of the cerebral cortex.  
(A) Section through the developing primate forebrain showing distribution pattern of radial glial processes 
that span the fetal cerebral wall from the ventricle to the pial surface. (B) Enlargement of the boxed area in 
(A) to illustrate how neurons migrate from their birth place in the ventricular zone across the intermediate 
zone to their final destination at the interface between the marginal zone and the developing cortical plate. 
(C) Neuroblasts use the surface of elongated radial glial fibers as a guide during their migration. 
Reproduced with permission from (Rakic and Lombroso, 1998) 
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(Lian et al., 2012). 
Cilia are important for normal neuroprogenitor protein trafficking and also 
appear to have a possible role in the cell cycle. Perturbation of normal cilial  
function as is seen in the emerging group of ciliopathy disorders such as the 
genetically heterogeneous Joubert syndrome which encompases a range of 
different brain malformations (Romani et al., 2013). Increased rates of apoptosis 
in neuronal progenitor cells result in a reduction of cortical size, whereas a 
decreased rate has the obverse effect. Brca1 knockout mice have a substantial 
reduction in cortical size and thickness which results from apoptosis through the 
activation of p53 at the early stage of neurogenesis (Sun and Hevner, 2014). 
Caspase genes are an important part of the cellular apoptopic pathway. 
Knockout of Casp 9 in mice leads to a reduction in apoptosis during early brain 
development and enlargement and malformation of the brain with significant 
rates of perinatal mortality (Kuida et al., 1998). Neuroprogenitor cells can be 
either polarised or unpolarised, undergoing either symmetrical or assymetrical 
divisions respectively (Sun and Hevner, 2014). Consequently the orientation of 
mitotic spindles is an important aspect of normal cortical development. The 
dynein-associated nuclear distribution E homologue 1 (NDE1) plays a central 
role in microtubule organisation and mitotic spindle position and is highly 
expressed at the centrosome accumulating on the mitotic spindle of apical 
neural precursors in early neurogenesis (Alkuraya et al., 2011). Knockout of 
Nde1 in mice results in abnormal mitotic orientation and progression in cortical 
neuroprogenitors, leading to microcephaly, most significantly affecting the 
cerebral cortex (Feng and Walsh, 2004). 
1.1.2 Cerebellum 
The cerebellum originates from the dorsal aspect of the brain stem and is the 
largest part of the hindbrain. The cerebellum operates at an unconscious level 
and is solely involved in motor function. This part of the brain plays a 
fundamental part in the control and maintenance of balance, muscle tone, the 
coordination of movements and posture. 
The cerebellum consists of two hemispheres which are joined in the midline by 
the vermis. During embryonic development, the surface becomes highly 
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convoluted forming transverse folds called folia. Anatomically, the cerebellum is 
divided into three lobes: the small anterior lobe, larger posterior lobe and the 
flocculonodular lobe. The outer part of the cortex is comprised of grey matter 
with an inner core of white matter. 
The histological makeup of the cerebellar cortex is consistent throughout. It 
comprises three layers: an outer molecular layer, intermediate purkinje cell layer 
and an inner granular layer. The white matter of the cerebellum contains the 
four cerebellar nuclei (fastigal, globose, emboliform and dentate), which are the 
primary source of efferent fibres from the cerebellum to other parts of the brain. 
Clinical signs associated with disruption to normal cerebellar development or 
functions include dysarthria, cerebellar ataxia, intention tremor and nystagmus. 
Phylogenetically the cerebellum is divided into the archicerebellum, 
paleocerebellum and neocerebellum, with the oldest part in evolutionary terms 
being the archicerebellum and newest the neocerebellum. The archicerebellum 
is primarily concerned with normal balance maintenance and comprises the 
flocculonodular lobe and the fastigal nucleus. The paleocerebellum is central to 
normal maintenance of muscle tone and is equated with the midline vermis, 
surrounding paravermis and the globose and emboliform nuclei. The 
neocerebellum represents the largest part of the cerebellum approximates to 
the majority of the cerebellar hemispheres and the dentate nuclei, and is 
responsible for control of muscle coordination (Crossman and Neary, 2010). 
1.2 Abnormalities of brain growth 
Human brain growth and development involves a precisely controlled cascade 
of molecular and cellular events that involve genetic, epigenetic and 
environmental factors. The simplest definition of growth is an increase in size. 
One of the most important differences between organisms is their brain size. 
The expansion in size of the cortical surface of the brain that has occurred 
during evolution to humans is particularly remarkable. During the 23 million 
years since humans and macaque monkey diverged from a common ancestor, 
there has been around a 15 fold increase in the brain's cortical surface. Even 
more significantly, there is a more than 1000 fold difference in cortical size 
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between mice and humans (Rakic, 1995). Disorders of brain growth and 
development underlie a significant proportion of intellectual disability and 
autistic spectrum disorders (Mirzaa and Paciorkowski, 2014). 
1.3 Occipitofrontal circumference 
When age and sex are considered, head circumference, or occipitofrontal 
circumference (OFC), correlates well with intracranial volume and with cognitive 
function. OFC measurements can be a helpful indicator of underlying brain 
pathology to the clinician, however currently there remains a shortage of 
population specific occipitofrontal circumference data. Nevertheless, 
occipitofrontal circumference reference charts remain a useful clinical tool 
(Stevenson et al., 1997). 
Until the late 1990’s the Tanner-Whitehouse charts were the standard centile 
charts used to assess head circumference in the United Kingdom. To update 
the British growth reference, anthropometric data for weight, height, body mass 
index and head circumference from 17 distinct surveys representative of 
England, Scotland and Wales (37,700 children, age range 23 weeks gestation 
to 23 years) were analysed by maximum penalised likelihood using the LMS 
(lambda-mu-sigma) method. The British 1990 growth reference provides 
centiles for weight, height and body mass index from birth to 23 years. 
Measurements can be converted to normally distributed standard deviation 
scores. The reference sample comprised Caucasian British children with none 
excluded for health reasons making it a growth reference and not a growth 
standard. Included are 6444 head circumference measurements for boys and 
4917 for girls, aged between 23 weeks gestation to 18 years (males) or 17 
(females). The Edinburgh Growth Study, a longitudinal survey of children 
residing in Edinburgh followed from birth to age 20, was also included to 
provide additional head circumference reference data, the growth charts that 
resulted from this endeavour are referred to as the UK90 reference charts. 
(Cole et al., 1998). 
In 1992, Bushby et al also suggested that the use of the Tanner-Whitehouse 
charts for adult head circumference was inappropriate particularly for males, 
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given that reference data was only available up to the age of 16 and head 
growth would continue after this time, moreover others had previously 
concluded that head circumference and brain weight were correlated with 
height in adulthood as well as childhood (Bushby et al., 1992). They produced 
centile charts for head circumference against height based on the 
measurements of 354 adults in two British centres (Newcastle upon Tyne and 
Cardiff), 159 males and 195 females attending dental clinics were measured, 
those with conditions likely to affect cranial anatomy were excluded. The centile 
charts constructed from these measurements indicate that adult head 
circumference is related to height. The mean head circumference of a male of 
average height being above the 97th centile for a 16 year old on the Tanner-
Whitehouse charts. Unfortunately this study has never been repeated and the 
number used to construct the centile charts was small. 
In 2007 the World Health Organisation released growth charts intended as an 
international tool based on data produced from the Multicentre Growth 
Reference Study undertaken between 1997 and 2003. The study included 
children from 6 countries: Brazil, Ghana, India, Norway, Oman, and the United 
States. All the children included were healthy and environmental factors like 
breast feeding and exposure to smoking were tightly controlled. The resulting 
occipitofrontal charts only go to age 5 years and are a growth standard as 
opposed to a growth reference (Rollins et al., 2010). Moving to a different chart, 
such as UK90 after age 5 years creates difficulties in monitoring children’s head 
growth as the two tools are not directly comparable.  
Natale and Rajagopalan compared data from the World Health Organisation’s 
Multicentre Growth Reference Study with data from studies performed in 55 
countries or ethnic groups. They found that the mean head circumference 
varied widely between different national and ethnic groups. In many groups, 
means were consistently 0.5–1 standard deviation above the Multicentre 
Growth Reference Study mean. Head size in breastfed children at any age 
examined was far closer to local norms than to the Multicentre Growth 
Reference Study means. The differences between national or ethnic group 
head circumference means were large enough that using the WHO charts 
would put many children at risk for misdiagnosis of macrocephaly or 
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microcephaly. Their findings indicate that the use of a single international 
standard for head circumference is not justified (Natale and Rajagopalan, 
2014). 
Head circumference is not often measured routinely beyond infancy, and then 
usually only for monitoring of head growth. The Tanner-Whitehouse and UK90 
references show striking differences from each other beyond this age range, 
with the UK90 reference on average more than one standard deviation higher. 
The two curves differ significantly around the time of puberty. This means that 
neither of these references are robust for diagnosing micro or macrocephaly 
after the age of 2 years or for assessing head growth after the onset of puberty. 
1.4 Microcephaly 
Microcephaly is defined as a head circumference greater than or equal to three 
standard deviations (SDS) below the mean. Microcephaly can be either 
congenital or postnatal in onset and is either the consequence of impaired brain 
growth during early development, or a destructive neurological process. In itself 
microcephaly is a relatively non-specific finding, with a number of both 
environmental and genetic aetiologies including single gene disorders, 
chromosome anomalies, metabolic conditions, teratogen exposure, congenital 
infection and birth asphyxia (Murray and Jackson, 2012). 
1.4.1  Congenital Microcephaly 
Microcephaly is frequently associated with structural brain malformation or other 
developmental anomalies. However, rarely a significant and specific reduction 
in brain size with grossly preserved macroscopic appearance is seen in the 
absence of additional features. Typically this presentation is associated with 
autosomal recessive inheritance. This phenotype has been termed primary 
microcephaly (MCPH). Despite the marked reduction in cerebral volume to 
sometimes as little as a third of normal, intellect is often relatively preserved 
with most individuals only mild/moderately impaired (Murray and Jackson, 2012, 
Kaindl et al., 2010, Thornton and Woods, 2009). 
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To date a total of 11 genes have been shown to be associated with the primary 
microcephaly phenotype (Verloes et al., 1993). The majority of the protein 
products of these genes have related functions and play an important role in the 
mitotic phase of the cell cycle localising to the centrosomes and mitotic spindle 
poles. It is thus proposed that primary microcephaly is a disorder of neurogenic 
mitosis, with a reduction in neuroprogenitor cells resulting in fewer mature 
neurones and a reduced cerebral volume (Murray and Jackson, 2012). The 
centrosome is one of the main microtubule organising centres in the cell and 
centrosome duplication and maturation are intimately linked to cell-cycle 
progression (Thornton and Woods, 2009). Elucidation of the molecular causes 
of primary microcephaly have revealed a wide spectrum of phenotypes 
associated with the causative genes. WDR62, for example, also results in a 
variety of structural brain disorders including lissencephaly, cerebellar 
hypoplasia and hypoplasia of the corpus callosum (Yu et al., 2010). The most 
profound reduction in brain size is seen in patients homozygous for loss of 
function mutations in the centrosomal protein NDE1 with brain size less than 
10% of normal. Affected individuals are profoundly neurologically impaired and 
cortical lamination patterns are also abnormal with microlissencephaly seen on 
neuroimaging (Guven et al., 2012). 
Interestingly, two of the genes associated with primary microcephaly, CEP152 
(Kalay et al., 2011, Guernsey et al., 2010)  and CENPJ (Bond et al., 2005), 
have also been associated with the microcephalic primordial dwarfism family of 
disorders, a group of conditions with global growth failure. Other genes 
associated with microcephalic primordial dwarfism shown to cause defects in 
centrosomal and spindle microtubule function include: PCNT, CENPE and 
POC1A (Griffith et al., 2008, Shaheen et al., 2012, Mirzaa et al., 2014). 
However other genes implicated in microcephalic primordial dwarfism have 
more diverse functions and include disorders of genome replication associated 
with (ORC1, ORC4, ORC6, CDT1, and CDC6) (Bicknell et al., 2011b, Bicknell 
et al., 2011a), DNA damage response (ATR, Lig4) (O'Driscoll et al., 2003, 
Murray et al., 2014), growth hormone axis (IGF1)(Woods et al., 1996) and 
mRNA splicing (RNU4atac) (Edery et al., 2011). 
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Postnatal onset of microcephaly comprises a more diverse set of disorders 
including Angelman syndrome, Rett syndrome and Christianson syndrome. In 
some cases specific biological pathways in which defects lead to postnatal 
microcephaly can be identified for example the nucleotide excision DNA repair 
pathways discussed in more detail in chapter 3. (Seltzer and Paciorkowski 
2014). 
1.5 Megalencephaly 
The definition of Megalencephaly is a brain size of greater than 2 standard 
deviations of the age and sex related mean. Megalencephaly is divided into 
developmental/anatomical types and metabolic types (Olney, 2007) 
Neurometabolic syndromes such as cerebral organic acid disorders including 
Glutaric aciduria type I, disorders of lysine metabolism, lysosomal storage 
disorders, mucopolysacharidoses and  leukoencephalopathies cause 
megalencephaly as a result of accumulation of metabolic substrates, cellular 
hypertrophy or oedema (Mirzaa and Poduri, 2014). 
Anatomical megalencephaly can be an isolated feature or associated with a 
more generalised overgrowth phenotype such as in Soto’s syndrome, Weaver 
syndrome, Simpson Golabi Behmel (Olney, 2007) and DNMT3A related 
overgrowth (Tatton-Brown et al., 2014). 
The principle pathway implicated in isolated megalencephaly is PI3K-AKT-
mTOR, which includes PTEN related disorders. Molecules within this pathway 
have important roles to play in the regulation of both the cell cycle and 
apoptosis. Dysregulation can cause significant increase in brain size, typically 
4-5 SDS above the mean, but occasionally as much as 8 SDS. Mutations 
perturbing the PI3K-AKT-mTOR pathway can be germline as with PTEN and 
STRADA (Parker et al., 2013), but are predominantly somatic and mosaic. Post 
zygotic activating mutations in PIK3CA, AKT3 and mTOR have all been shown 
to result in unilateral hemispheric enlargement termed hemimegalencephaly 
(Lee et al., 2012, Poduri et al., 2012). Hemimegalencephaly is usually 
accompanied by profound neurological impairement and severe early onset 
intractable seizures (Mirzaa and Poduri, 2014). 
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1.6 Classification of intellectual disability  
The definitions of intellectual disability (previously termed mental retardation) 
and developmental delay are rather complex and have evolved over time. The 
reasons for this evolution relate to changes in public and professional 
acceptability of certain terminology, for example mental retardation. In addition 
there have been significant advances in our understanding of the underlying 
pathophysiology of these disorders much of which relates to the rapid progress 
made in the field of neurogenetics, neurobiology, neuroimaging and 
epidemiology (APA, 2013). 
The classification of mental disorders, known as psychiatric nosology is a key 
aspect of psychiatry. The responsibility for classification of neurodevelopmental 
disorders like intellectual disability has thus typically lain with this field. The two 
most widely recognised classification systems for mental disorders are ICD and 
DSM.  
The history of the International Statistical Classification of Diseases and Related 
Health Problems (ICD) dates back over a century and has been the 
responsibility of the World Health Organisation since it was founded in 1948, 
the current iteration is ICD-10, although this is under revision and ICD-11 is 
expected to be released in 2017.  
ICD used as the global health information standard for statistics relating to 
morbidity and mortality, which can then be used to identify global health trends. 
It is increasingly used as a diagnostic tool in healthcare and ICD-10 has been 
translated into 43 languages and is used by over 100 countries worldwide. 
Unlike the American Psychiatric Association’s Diagnostic and Statistical Manual 
of Mental Disorders (DSM), it is free to access through the worldwide web. 
Around 70% of health expenditures worldwide are allocated using statistics 
collected through use of the ICD (www.who.int/classifications/icd/factsheet/en/). 
The history of the DSM dates back to 1844, when the American Psychiatric 
Association published a statistical classification of institutionalised mental 
patients, the first predecessor to DSM. The aim of this was to improve 
communication between institutions about the different types of disorders they 
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saw. The DSM evolved to be a diagnostic classification system describing the 
full range of mental health disorders to guide diagnosis and inform management 
strategies, the recently revised 5th edition DSM-V was released towards the end 
of 2013 (APA, 2013). One of the most important differences between the ICD 
and DSM is that the ICD is produced by a global agency with a constitutional 
public health mission, whereas the DSM is produced a single national 
professional psychiatric association. Both the American Psychiatric Association 
and the World Health Organisation would like to see the harmonisation of DSM–
V and ICD–11. Small differences in wording, number of symptoms necessary 
for diagnosis as well as exclusion criteria can lead to significant diagnostic 
discordance. The WHO has formed a DSM–ICD Harmonisation Coordinating 
Group, which comprises members of the DSM–V Task Force and the 
International Advisory Group for the Revision of ICD–10 with the aim being to 
facilitate uniformity between the two classification schemes (First, 2009). 
The diagnosis of intellectual disability (intellectual developmental disorder) is 
revised from the DSM-IV diagnosis of mental retardation and will be similarly 
revised in ICD-11 to intellectual developmental disorders. Currently within ICD-
10 it remains under Chapter V – Mental and behavioural disorders, subsection; 
Mental retardation (F70-79), where is classified as mild, moderate, severe or 
profound with subdivisions to identify behavioural impairment. ICD-10 defines 
mental retardation as “A condition of arrested or incomplete development of the 
mind, which is especially characterised by impairment of skills manifested 
during the developmental period, skills which contribute to the overall level of 
intelligence, i.e. cognitive, language, motor, and social abilities. Retardation can 
occur with or without any other mental or physical condition.” The primary 
assessment tool suggested is a standardised Intelligence test, although it is 
also recommended that social adaption assessments can also be used to aid 
diagnosis. 
Within DSM-5 the importance of using both clinical assessment and 
standardised testing of intelligence when diagnosing intellectual disability is 
emphasised. The classification of severity of impairment is now based on 
adaptive functioning rather than Intelligence quotient (IQ) test scores alone. The 
overarching aim of this revision was to avoid an over emphasis of IQ scores and 
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to ensure that a person’s functional ability was the primary consideration by 
removing them from the diagnostic criteria but retaining them within the text. 
The American Psychiatric Association believe that these changes will permit a 
more comprehensive assessment across conceptual, social, and practical 
domains and result in a diagnosis that accurately reflects the impairment of an 
individual’s ability to function in day to day life resulting from their deficit in 
general mental abilities. Intellectual disability is listed in DSM-V under the 
chapter heading: Neurodevelopmental disorders, which they define as “ a group 
of conditions with onset in the developmental period”. Three criteria must be 
met for a diagnosis to be made including; (A) deficits in general intellectual 
functioning, (B) deficits in everyday adaptive functioning when compared to 
age, gender and socioculturally matched peers and (C) onset of these deficits in 
the developmental period. Severity is graded as with the ICD into mild, 
moderate, severe and profound. In summary, the significant changes within 
DSM-V address the naming of a disorder, diagnostic criteria and impact on an 
individual’s ability to function (APA, 2013). 
1.6.1 Developmental delay 
Developmental delay can be either specific or global. A specific developmental 
delay is when one area of development is affected. Significant delay is defined 
as performance of two standard deviations or more below the mean on age-
appropriate, standardised norm-referenced developmental screening or 
assessment tests. Global developmental delay is generally defined as a 
significant delay in two or more developmental domains: gross and fine motor; 
speech and language; cognition; personal and social development; or activities 
of daily living. The extent of delay can be classified as mild if functional age is 
33% below chronological age, moderate if functional age is 34–66% of 
chronological age, and severe if functional age is 66% below chronological age 
(McDonald et al., 2006, Silove et al., 2013, Shevell et al., 2000). Developmental 
assessment tools commonly used to assess the level of developmental 
functioning include the Griffiths Mental Development Scales and the Denver II 
Developmental screening test (Frankenburg et al., 1992). DSM-V lists global 
developmental delay as a diagnosis within neurodevelopmental disorders, but 
states clearly that is a term reserved for individuals < 5 years old. The DSM-V 
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classification of neurodevelopmental disorders is summarised in Figure 4 (APA, 
2013).  
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Figure 4: DSM-V classification of neurodevelopmental disorders. 
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1.7 The Amish 
The Amish are an Anabaptist Christian church that traces its roots to the 
Protestant Reformation in sixteenth-century Europe. The church arose in 1693 
after a schism within a group of Swiss Anabaptists in Alsace, led by the Bishop 
Jakob Amman. The term Anabaptist means “rebaptisers” and refers to the 
rejection of infant baptism, a practice that linked the church with citizenship, in 
favour of adult baptism where individuals could make their own decision about 
church membership. Amman wished to make a number of reforms to church 
practices; most controversially he wanted closer links between church discipline 
and social practices. If a member of the church was excommunicated because 
of an unrepented sin, Amman advocated that other members of the church 
should avoid, or shun the individual, in ways such as refusing to share a meal 
with them. This practice of shunning or “Meidung”, was not meant as a 
punishment, but was a lesson, a way of showing the person the seriousness of 
the offence to encourage them to confess and seek forgiveness. Taking his 
name, Amman’s followers were first called the “Amman-ish” group, and later 
became known as the Amish. In 1681 the Quaker William Penn founded the 
state of Pennsylvania on the principles of toleration and peace. The first wave 
of Amish migration to the state was between 1736 and 1770 and comprised 
around 500 individuals, largely seeking to avoid religious persecution. A second 
wave of Amish immigrants left Europe for the “New World” between 1815-1860. 
The number of migrants is estimated to have been around 3000. Compulsory 
military service was becoming commonplace in Europe and this combined with 
the economic opportunities in North America was a strong driving force to leave 
and seek a new life. The majority of these 3000 newcomers did not remain in 
Pennsylvania. Land prices were cheaper in the west and so they travelled to the 
states of Ohio, Indiana, Iowa and Illinois and Ontario in Canada.  It is important 
to remember that these original settlers were already part of related family 
groups, so the overall gene pool that founded the modern day Amish was 
particularly modest.  
The first three Amish settlements that were established were in eastern 
Pennsylvania, Indiana and Ohio. In 2014, 64% of the total Amish population still 
live in those three states. The Amish population doubles about every 18 to 20 
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years and grew by an estimated 46,000 from 235,000 to 282,000 between 2008 
and 2013 (http://www2.etown.edu/). 
Today, Amish people accept basic Christian beliefs but also have some of their 
own emphases and special interpretations that have emerged throughout their 
history. Professor Donald Kraybill, based at the Young Center for Anabaptist 
and Pietist Studies at Elizabethtown College, Pennsylvania is the world’s 
foremost expert on the Amish. Kraybill defines the modern day Amish as: “any 
group that affirms the basic tenants of Amish belief, including adult baptism, 
non-violence and separation from the outside world”, “uses horse-drawn 
transportation” (Figure 5), “speaks a German-derived dialect” and “considers 
itself Amish”. 
Until 1960, the majority of the Amish were farmers, now small business 
ownership and factory work has become commonplace. The number of different 
Amish affiliations has grown over the years to over 40, each comprising groups 
of church districts united by social and religious practices. The origin of this 
religious diversity is sometimes disagreement about religious or cultural 
practices and sometimes more to do with geographical origins. Affiliations range 
between low to high order dependent on the level of separation from modern 
society, with the most traditional termed “low order” and those most assimilated 
“high order”. 
The lowest orders would still milk their cows by hand and have outhouse 
latrines. The highest orders would use automatic milking machines, mobile 
phones and through third parties, use the internet to send emails and advertise 
their business. Aside from those noted by Professor Kraybill there are a number 
of additional practices that all the Amish groups have in common: education 
only up to eighth grade, rural living, selective use of technology, lay ministers, 
small local congregations with services held in the homes of members and no 
formal religious buildings. Although the style of dress differs between different 
affiliations, in all cases this is church-regulated, traditional and plain, hence the 
term “plain-people” which is frequently used to refer to the Amish (Hurst and 
McConnell, 2010, Kraybill et al., 2013). 
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Figure 5: Amish horse and buggy transportation  
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1.7.1 History of the Windows of Hope project 
Genetic studies of the Amish date back to 1962 when the world-renowned 
geneticist Victor McKusick first read an article written by a family doctor David 
Krusen with an extensive practice in Lancaster Pennsylvania. Krusen 
mentioned that achondroplasia was extremely common amongst the Amish. 
Later that year McKusick was asked to review a manuscript written by John 
Hostetler entitled “Amish Society”. It struck Mckusick then that the Amish 
community possessed many characteristics that made them an ideal group in 
which to study genetic traits, particularly autosomal recessive conditions. 
(Francomano et al., 2003). 
MIM (Mendelian Inheritance in Man) and it’s now online version OMIM date 
back to 1964 when Victor McKusick was working at Johns Hopkins University. 
The origins of MIM came from three sources, the first, Mckusick and colleagues 
annual reviews of Genetics between 1958-1963, the second a catalogue of X-
linked traits compiled by Mckusick in 1962, and thirdly a catalogue of autosomal 
recessive phenotypes prepared by Mckusick in 1963 to use as resource for 
identifying and studying recessive disorders amongst the Amish (McKusick, 
2007). Mckusick travelled to the Pennsylvanian Amish community with Krusen 
initially to study the different forms of dwarfism. Their studies found that in fact 
the majority did not have achondroplasia, and instead led to the description of 
the two predominate forms of recessive dwarfism amongst the Amish: Ellis-van 
Creveld syndrome, which had previously been reported and a newly recognised 
condition Cartilage Hair Hypoplasia (Francomano et al., 2003). 
In 1962, a young doctor approached him; Dr Harold Cross who wanted to study 
for a PhD. Dr Cross was raised amongst the Indiana Amish community and 
speaks the most common native Amish dialect, “Pennsylvania Dutch”. Together 
they studied inherited neurological conditions in the Ohio Amish. These studies 
led to publications describing a number of such disorders including the Troyer 
syndrome and the Mast syndrome (Cross and McKusick, 1967), two novel 
forms of complex hereditary spastic paraplegia. Dr Cross, now Professor, went 
on to study ophthalmology and is now based at the University of Arizona. 
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Over recent years researchers have begun to disentangle the genetic basis of 
the inherited disorders that occur within the Anabaptist communities.  In 2000 
Professor Andrew Crosby, a geneticist with a particular interest in neurological 
conditions, approached Dr Cross and suggested that given the advances in 
genetic technology since the original studies, identification of the genes 
responsible for the conditions studied by Mckusick and Cross would be 
possible. Crosby and Cross, initially identified the genetic basis of the Troyer 
(SPG20 gene), (Patel et al., 2002) and Mast (ACP33 gene) (Simpson et al., 
2003a) syndromes in 2002 and 2003 respectively. Recognising the potential 
impact of these studies in not only scientific terms but more importantly for the 
Amish community, Cross and Crosby established the Windows of Hope project 
(WOH, see ‘www.WOHproject.org’), the largest survey of inherited conditions 
amongst the Amish communities which together with the non-profit Amish-led 
Windows of Hope Genetic Information Centre (WHGIC), have since made 
significant headway in determining the molecular causes and clinical 
manifestations of inherited diseases amongst the Ohio Amish. WOH has a 
regional centre based in Holmes County, Ohio, the second largest Amish 
settlement in the USA (population 32,630, 251 church districts 
(http://www2.etown.edu/). The project aims to translate molecular genetic 
studies into direct community benefits through education, diagnostic testing, 
development of therapies and support of local clinicians, leading to improved 
clinical outcomes. 
As with any community arising from a limited number of founder individuals the 
Amish, together with other genealogically-related Anabaptist communities, have 
a unique genetic distinctiveness and heritage. A limited number of ancestors 
founded a rapidly expanding endogamous population (the average family size is 
7-9 children), in whom particular causal genetic variants have become enriched, 
unfortunately leading to a high incidence of particular genetic diseases in that 
population. The Amish are relatively immobile given the religious constraints on 
transportation; they also keep extensive genealogical records, which enable the 
construction of comprehensive pedigrees. These factors taken together greatly 
facilitate the discovery of genes responsible for inherited disease, which might 
otherwise have been impossible in studies of other populations due to the 
genetic and environmental complexities of a condition. 
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There is a high incidence of undiagnosed childhood developmental disorders 
amongst the Holmes County Amish, which place a significant social and 
financial burden on this community who for the most part are ineligible for the 
Medicaid program for religious regions. Although other community schemes 
such as the “Ohio Crippled Children Fund”, are available to the majority of the 
local Amish to help with medical expenses, the rising costs of medical care 
means that many Amish families are not able to be supported and go without 
important clinical investigations and treatments. Over the last 14 years, the 
WOH research team has identified the genes underlying 16 inherited diseases 
present amongst the Amish, including 8, which cause childhood developmental 
disorders, 3 of which are the focus of this thesis. 
Highlighting the global relevance and importance of studies of inherited 
conditions in such genetic isolates, virtually all of disease genes initially 
identified in the Amish have subsequently been shown to cause similar 
diseases occurring worldwide. 
1.7.2 History of the Clinic for Special Children 
In 1988 Dr Holmes Morton changed the face of medical care for the Amish 
community. Morton, a paediatrician with a special interest in metabolic 
medicine, saw his first Amish patient, a child who had been given a diagnosis of 
cerebral palsy that he subsequently diagnosed with glutaric aciduria type 1. 
Morton learned that there were many other Amish children with glutaric aciduria 
type 1 who had been diagnosed with Amish cerebral palsy but who actually had 
glutaric aciduria type 1 as well as other metabolic conditions which when 
treated appropriately could prevent devastating long term neurological 
sequelae. Many of the families of these children were unaware of the cause of 
their child’s medical problems and unable to seek the medical attention needed 
because of expense or the travel distances involved. Morton and his wife 
Carolyn decided to open a clinic in the heart of the Pennsylvania Amish 
community. The clinic was built following the Amish “barn raising” tradition and 
still remains on the original land donated by an Amish farmer whose children 
Morton had treated. (Morton et al., 2003). 
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Morton used his genetic knowledge of the community to diagnose and develop 
treatments for the inherited conditions found within the community. He and 
others developed a comprehensive in-house genetic and metabolic diagnostic 
service collocated with the not for profit clinical facilities. Many of the metabolic 
treatment strategies developed by Morton and co-workers have been taken up 
by clinicians treating those same disorders in individuals from outside of the 
Amish community. The enrichment of certain conditions within the community 
actually facilitates the development of therapies which would be difficult to do 
for the small numbers of children affected by rare disorders in the general 
population. This model of care has now been extended to other Amish 
communities including Indiana and Ohio. 
1.7.3 Disorders of brain growth and development identified amongst 
the Amish 
Amongst the Amish, chromosomal aberrations and autosomal dominant 
conditions such as fragile X syndrome, Angelman syndrome and Rett syndrome 
that can result in developmental delay, are seen at similar frequency as outside 
of this community. There are however a subset of rare autosomal recessive 
neurodevelopmental disorders which occur at increased frequency within this 
population as a result of the founder effect. Currently recognised autosomal 
recessive causes of inherited disorders of brain growth and development 
recognised amongst the North American Amish communities are summarised in 
Table 1 and Table 2. The tables have been split into metabolic and syndromic 
causes. 
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Table 1: Metabolic causes of disruption to normal brain growth and development identified amongst the North American Amish 
 
(Puffenberger et al., 2012), (Strauss and Puffenberger, 2009); 2, (Strauss et al., 2007); 3, (Harlalka et al., 2013b) 
Reference Metabolic Disorders Gene Clinical Features
1 Phenylketonuria PAH
Microcephaly, seizures, cognitive and behavioural abnormalities, light skin 
and hair
1 GM3 synthase deficiency ST3GAL5
Microcephaly, infantile onset of seizures, profound psychomotor 
retardation
1 Gutaric aciduria, type 1 GCDH Macrocephaly, basal ganglia degeneration, dystonia, retinal haemorrhages
2 Homocystinuria MTHFR Intellectual disability, dislocated lenses
1 Galactosemia GALT Cataract, liver damage, bleeding diathesis, intellectual disability
1 Biotinidase deficiency BTD Hypotonia, developmental regression, seizures, hearing loss, optic atrophy
1 3-methylcrotonylglycinuria MCCC2
Metabolic acidosis, hypotonia, seizures, variable intellectual disability, 
some asymptomatic
1 Crigler-Najjar syndrome UGT1A1
Dystonia, developmental delay, hypotonia, irritability and lack of muscle 
control
1 Maple syrup urine disease BCKDHA
Dystonia, seizures, apnoea, global developmental delay, growth 
deficiency 
3 GM2 synthase deficiency B4GALNT1 Complex spastic paraplegia, autistic features, intellectual disability
1 Propionic acidemia PCCB
Vomiting, seizures, hypotonia, developmental delay, dilated 
cardiomyopathy
1 Tyrosinemia, type 3 HPD Intellectual impairment,  Ataxia, seizures, confusion, hypotonia
1 Salla disease SLC17A5
Ataxia, hypotonicity, developmental delay/intellectual disability, growth 
deficiency
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Table 2: Syndromic causes of abnormal brain growth and development identified amongst the North American Amish. 
 
4,(McKusick and Cross, 1966); 5,(Puffenberger et al., 2012); 6,(Crosby et al., 2010); 7,(Xin et al., 2011); 8,(Xin et al., 2010); 9,(Falk et al., 2004); 10,(Edery et al., 2011); 11,(Nakabayashi et al., 
2005) 12,(Harlalka et al., 2013a)  
Reference Syndromic Disorders Gene Clinical Features
4 Ataxia telangiectasia ATM Ataxia, ocular and cutaneous telangiectasia, oculomotor apraxia
5 Neonatal rigidity and seizure syndrome BRAT1 Microcephaly, intractable epilepsy
5 Symptomatic epilepsy, skull dysplasia SNIP1 Seizures, skull dysplasia, microcephaly
6 MTPAP MTPAP Spastic ataxia, intellectual disability
7 Aicardi Goutieres SAMHD1
Microcephaly, large vessel vasculopathy, chilblain lesions, glaucoma, 
spasticity, arthropathy, intellectual disability
5 Non syndromic mental retardation CRADD Mild-moderate intellectual disability
8 TMCO1 defect TMCO1 Skeletal anomalies, intellectual disability characteristic features
5 Microcephaly with chorioretinopathy TUBGCP6 Microcephaly with pachygyria, developmental delay, chorioretinopathy
1 Amish microcephaly SLC25A19
Profound microcephaly, brain malformations,  progressive encephalopathy, 
profound psychomotor retardation
1 Bardet-Biedl syndrome BBS1
Rod-cone dystrophy, obesity, postaxial polydactyly, cognitive impairment, 
male hypogonadotrophic hypogonadism,  female genitourinary 
malformations, and renal abnormalities
9 Cohen Syndrome COH1
Microcephaly, retinal dystrophy, intellectual disability,  hypotonia, 
characteristic facial features
1 Cortical dysplasia and focal epilepsy CNTNAP2 Macrocephaly, seizures, intellectual disability, behavioural abnormalities
1 Troyer syndrome SPG20 Spastic paraplegia, learning difficulties, short stature
1 Cockayne syndrome ERCC6 Microcephaly, short stature, spasticity, premature aging, cataracts 
1 Pelizaeus-Merzbacher-like syndrome GJA12 Leukodystrophy, developmental delay, congenital nystagmus, hypertonia
1 Pretzel syndrome STRADA Polyhydramnios, megalencephaly, and symptomatic epilepsy
10 MOPD type 1 RNU4atac Primordial dwarfism, contractures, developmental stagnation
11 Brittle hair syndrome (trichothiodystrophy) C7ORF11 Brittle hair, dry skin, intellectual disability, autistic features
12
HERC2 deficiency (Blue eye delay 
syndrome, Angelman-like) HERC2
Intellectual disability, autistic features, broad based gait, prominent big toe, 
absence of the posterior part of the corpus callosum
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1.8 Autozygosity mapping 
A significant contribution to our understanding of the processes involved in 
human brain development have been made by the study of single gene 
disorders which are rare in the general population, but which occur with 
increased frequency in certain consanguineous populations or populations in 
which there is a high frequency of inter-community marriage (Amselem et al., 
1989, Ruiz-Perez et al., 2000). Genome scans to identify autozygous regions 
specific to the affected individuals in such families provides a powerful means to 
demarcate the chromosomal location of the disease locus. This concept of 
‘autozygosity mapping’ in endogamous communities and consanguineous 
families is based on the principle that affected individuals will be identical by 
descent for the disease causing variant and surrounding haplotype (Lander and 
Botstein, 1987), Figure 6. 
When the ancestry of a community comprises only a limited number of founder 
individuals, the frequency of autosomal recessive alleles that were present in 
the founders may increase within that population such that if any two individuals 
from that community are selected at random, the chance that both will be 
carriers will be high. This is known as the founder effect (Alkuraya, 2013). Aside 
from the Amish, Finland, is a good example of where a relatively small number 
of founders 100 generations back formed a current modern day population of 
5.4 million. Enrichment for founder mutations has caused an increased 
frequency in the population of rare diseases such as the so called Finnish 
nephropathy (NPHS1) and cartilage hair hypoplasia (RMRP) (de la Chapelle, 
1993). In consanguineous unions where the relationship between two 
individuals is more recent, such as first or second cousins, much larger and 
numerous blocks of autozygosity are likely to be present. Historically 
autozygosity mapping was dependent on the analysis of polymorphic 
microsatellite markers. Although these markers are often highly informative due 
to their highly polymorphic nature, performing a genome-wide analysis using 
microsatellite markers was costly and time consuming and may miss smaller 
autozygous sections due to wide marker spacing. The advent of single 
nucleotide polymorphism (SNP) genotyping panels and microarray technology 
has revolutionised autozygosity mapping, greatly increasing throughput. 
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Although the heterozygosity score for a SNP is typically much lower than that of 
a microsatellite marker, SNPs occur at much higher density throughout the 
genome, providing significantly increased power as markers. Although the 
original SNP mapping microarray platforms were comprised of 10,000 SNP’s, 
densities of 1,000,000 SNP microarray platforms are now commonly used. 
These more dense mapping platforms are preferred when analysing more 
distantly related individuals (such as in the Amish), due to the smaller sections 
of autozygosity cosegregating with the disease gene typically present in such 
cases (Alkuraya, 2010). Despite the power of autozygosity mapping to identify 
the locus for autosomal recessive diseases the process of identification of the 
disease gene by Sanger sequencing was still very laborious, particularly if the 
region was gene dense. More recently autozygosity mapping has been coupled 
with massively parallel sequencing techniques to more rapidly identify potential 
disease causing sequence alterations within the disease locus, which may 
require prioritisation for investigation. (Alkuraya, 2013, Carr et al., 2013). 
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Figure 6: Inheritance of autozygous regions  
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1.9 Aims 
The overarching aim of my studies was to clinically characterise and identify the 
underlying molecular cause of three new inherited disorders of brain growth and 
development identified amongst the Amish. To this end I pursued the following 
aims: 
 To perform detailed phenotyping of affected individuals with each 
condition with particular reference to brain growth and 
neurodevelopment. 
 To undertake in-depth genetic studies, including autozygosity mapping, 
linkage studies and traditional and next generation sequencing 
technologies, to identify the underlying molecular cause of each disorder. 
 To functionally characterise the putative disease genes and pathogenic 
variants identified.  
 To translate any findings into direct benefits to patients with improved 
diagnostic information, genetic counselling and eventually therapies. 
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2 
CHAPTER TWO 
MATERIALS AND METHODS 
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2 MATERIALS AND METHODS 
2.1 Buffers, reagents and stock solutions 
 Agarose loading buffer – 40% ficoll, 0.2% xylene cyanol, 0.2% 
bromophenol blue 
 Ampicillin (Melford) – 100mg/ml Amp in ddH2O sterilized using a 
0.22µM filter unit. 
 Kanamycin (Melford) – 50mg/ml Kan in ddH2O sterilized using a 
0.22µM filter unit 
 LB Agar – For 1 litre: 15g Agar, 25g LB broth base, ddH2O to final 
volume, pH adjusted with 5 N NaOH, then autoclaved 
 Luria Bertani (LB) broth (For medium) – For 1 litre: 25g of LB broth 
base (10g tryptone, 5g NaCl, 5g yeast extract), ddH2O to final volume, 
pH adjusted with 5 N NaOH, then autoclaved. 
 PBST – PBS with 0.1% TWEEN20 
 Phosphate buffered saline (PBS) – Dulbecco’s PBS with calcium and 
magnesium, bought from PAA 
 Ponceau stain – 1g Ponceau S, 15g trichloroacetic acid, 15g 
sulphosalicylic acid and ddH2O 
 Protease inhibitors (Roche) – Complete EDTA-free protease inhibitor 
cocktail tablets 
 SOC medium – For 100ml, supplement LB broth with the following: KCl 
2.5mM, MgCl2 10mM, MgSO4, 10mM, Glucose 20mM, sterilised using a 
0.2µM filter unit. 
 2x NuPAGE sample loading buffer – For 10ml: 5ml NuPAGE LDS 
sample buffer (4x), 2ml NuPAGE reducing agent (10x), 3ml ddH2O 
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2.2 Subjects and samples 
2.2.1 Recruitment to the Amish Windows of Hope (WOH) project 
All the WOH project studies were reviewed and approved (reference 10-0050-
01) by the Institutional Review Board of the Office for Responsible Conduct of 
Research, University of Arizona (Tuscon, Arizona, USA) and the University of 
Exeter Research Ethics Committee (reference 14/04/048), and were conducted 
in accordance with the principles of the Declaration of Helsinki. Recruitment to 
the WOH project requires submission of the appropriate signed consent, clinical 
details and a blood or buccal sample. 
2.2.2 Phenotyping of affected individuals  
Height and weight were measured barefoot in light clothing. The Leicester 
Height Measure MKII, recommended by the child growth foundation was used 
to measure height in the family homes. Occipitofrontal circumference (OFC) 
was measured following standard procedures. 
Height, weight and OFC standard deviations and Z-scores were calculated 
using a Microsoft Excel add-in to access growth references based on the LMS 
method (Pan H, Cole TJ. LMS growth, a Microsoft Excel add-in to access 
growth references based on the LMS method. Version 2.77, 
http://www.healthforallchildren.co.uk/;2012) using a reference European 
population (Cole et al., 1998). 
A full medical and developmental history and systemic examination for the 
purposes of the research study was obtained for all individuals recruited and 
photographic records of pertinent examination findings were taken with 
informed consent. Additional clinical records (including results of any 
investigations) and educational reports were requested using the appropriate 
information release form. Where possible Intelligence Quotient (IQ) was 
requested using the Wechsler Adult Intelligence Scale. Whenever possible 
original neuroimaging was requested for review locally by Dr Phillip Rich, 
Consultant Neuroradiologist, St George’s Hospital NHS Trust. Audiograms and 
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dermatology were reviewed by Dr Wendy Albuquerque and Dr Kristiana Gordon 
respectively, St George’s Healthcare NHS Trust. 
2.3 Data management 
On collection of a sample, each family is awarded a pedigree ID, each individual 
an individual ID, and each sample a sample ID. Clinical and molecular 
information is recorded in a password protected database. Family pedigrees are 
constructed using the online Swiss Anabaptist Geneological Association 
database (www.saga-omii.org).and stored using Progeny (800 Palm Trail, Suite 
200, Delray Beach, FL 33483 USA (http://www.progenygenetics.com/). 
2.4 Molecular methods 
2.4.1 DNA extraction 
Lymphocyte DNA was extracted from whole blood. 10-30ng of DNA was used 
per reaction. The protocol for DNA extraction and purification using the 
Promega ReliaPrepTM Blood gDNA Miniprep System is summarised below. 
The blood samples were stored at -20oC and were thawed completely and 
thoroughly mixed prior to DNA extraction. A volume of 200μl of whole blood was 
used. Filter tip pipette tips were used at all stages during the procedure to 
prevent contamination of samples and equipment. 
20μl of Proteinase K was dispensed into a 1.5ml microcentrifuge tube. 200μl of 
blood was mixed with the Proteinase K by repeat pipetting. 200μl of Cell Lysis 
Buffer was added to the microcentrifuge tube. The tube contents were vortexed 
for 10-20secs to ensure thorough mixing and incubated at 56oC for 10mins. 
After incubation 250μl of Binding Buffer A was added and the microcentrifuge 
tube contents vortexed for 10-20secs. The appearance of the lysate was 
checked to ensure that it was dark green in colour. The tube was briefly 
centrifuged to remove any residue from the tube lid. Using a pipette, the lysate 
was transferred to a Reliaprep binding column that was placed into a collection 
tube that was then placed in a microcentrifuge and spun at maximum speed 
(13,000rpm) for 1min. If any lysate was still visible on top of the column 
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membrane the tube was spun for a further 1min. The column was placed in a 
clean collection tube and the flow through was discarded as hazardous waste in 
a sharps bin. 500μl of Column Wash Solution was added to the column which 
was then spun for 3mins at maximum speed, if any solution was still visible after 
this then the column was spun for a further 1min, the flow through was 
discarded as hazardous waste. This step was repeated to complete a total of 3 
washes. The column was then placed in a clean 1.5ml microcentrifuge tube. 
200μl of nuclease-free water was added to the column which was then spun for 
1 minute at maximum speed to elute the DNA. After elution the DNA 
concentration and purity was measured using the nanodrop. To achieve the 
desired DNA concentration of 10-30ng/μl the DNA was diluted with molecular 
grade water. 
2.4.2 RNA extraction 
Lymphocyte RNA was extracted from whole blood collected in PAXgene 
collection tubes. The protocol for RNA extraction and purification using the 
Qiagen PAXgene blood RNA kit handbook is summarised below. Prior to 
commencing RNA extraction the lab bench top, tube racks and pipettes were 
cleaned with RNasezap (Ambion). Filter tip pipette tips were used at all stages 
during the procedure to prevent contamination of samples and equipment. 
The Paxgene RNA blood tube containing the blood sample was centrifuged at 
3000g for 10mins in a swing-out centrifuge. The supernatant was carefully 
removed by pipetting without disturbing the pellet. 4ml of RNase free water was 
added to the pellet and the blood tube was closed with a new BD Hemogard 
closure. The tube was vortexed until the pellet was entirely resuspended and 
then centrifuged at 3000g for 10mins. The supernatant was carefully removed 
by pipetting. 350μl of buffer BR1 was added to the pellet and then vortexed until 
the pellet was dissolved. The sample was transferred to a 1.5ml microcentrifuge 
using a pipette. 300μl of buffer BR2 and 40μl of proteinase K were added to the 
sample which was the vortexed for 5secs to achieve thorough mixing. The 
sample was incubated at 55oC in a shaker-incubator set at 1400rpm for 10 
mins. The sample was transferred by pipetting to a PAXgene shredder spin 
column placed in a 2ml processing tube and centrifuged at 14,000xg for 3mins. 
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The flow-through was then transferred to a fresh 1.5ml microcentrifuge tube 
using a pipette and without disturbing the pellet. 350μl of 100% purity grade 
ethanol was added to the sample and mixed by vortexing for 10secs. The tube 
was centrifuged briefly (1-2secs) to remove any fluid from the tube lid. 
700μl of sample was pipetted into a PAXgene RNA spin column which was 
placed in a 2ml processing tube and centrifuged for 1min at 14,000xg. The spin 
column was placed in a fresh processing tube and the flow-through discarded 
as hazardous waste. This step was repeated with the remainder of the sample. 
350μl of wash buffer 1 (BR3) was subsequently added to the PAXgene spin 
column which was centrifuged for 1 minute at 14,000xg. The spin column was 
then placed in a new 2ml processing tube and the old tube and flow-through 
were discarded. 
10μl of DNase I stock solution was added to 70μl of DNA digestion buffer In a 
1.5ml microcentrifuge tube (supplied with the kit). The solutions were gently 
mixed by flicking the tube to prevent denaturation of the enzyme. The tube was 
briefly centrifuged for 1-2secs to remove any liquid from the lid and the side of 
the tube. The 80μl solution was then carefully pipetted onto the spin column 
membrane and incubated at room temperature for 15mins. 350μl of wash buffer 
1 (BR3) was added to the spin column and centrifuged at 14,000xg for 1 minute 
and then transferred to a new processing tube, the old tube and flow through 
were discarded. 500μl of wash buffer 2 (BR4) was then added to the spin 
column and centrifuged at 14,000xg for 3mins. The spin column was placed in a 
fresh tube and centrifuged for a further 1 min at 14,000xg. The processing tube 
was discarded and the spin column was placed in a 1.5ml microcentrifuge tube. 
40μl of elution buffer (BR5) was pipetted onto the spin column membrane and 
centrifuged at 14,000xg for 1min to elute the RNA. This step was repeated 
using the same microcentrifuge tube and a further 40μl of elution buffer. The 
tube and contents were then incubated at 65oC for 5mins using the desk-top 
shaker-incubator, in order to denature the RNA. After the incubation period the 
eluted RNA was placed on ice and stored in the -80oC freezer until required.  
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2.4.3 Single nucleotide polymorphism (SNP) genotyping 
SNP genotyping was carried out using Illumina CytoSNP-12v2.1 330K arrays 
following the Infinium® HD Assay Ultra manual protocol. Each chip holds 12 
DNA samples. DNA was extracted from venous blood or buccal samples using 
the methodology described above. 
The assay requires 200ng of DNA per sample at a concentration of 50ng/µl and 
is carried out over a three day period, the methodology is summarised below: 
1. Day 1, the DNA samples were denatured using a buffer containing 0.1N 
NaOH and neutralised in the pre-PCR room prior to an overnight isothermal 
whole genome amplification step.  
2. Day 2, the DNA was fragmented using Illumina fragmentation buffer 
(FBS), and then precipitated using isopropanol. The DNA was then collected by 
centrifugation at 4oC before resuspension. The DNA was then denatured at 
95oC for 20mins. The samples were applied to a BeadChip and separated by an 
IntelliHyb® seal. The BeadChips were then placed in a humidified Hyb 
Chamber and subsequently incubated for 16-24hrs at 48oC in the Illumina 
Hybridisation Oven. The amplified and fragmented DNA samples anneal to 
locus-specific 50-mers 
3. Day 3, unhybridised and non-specifically hybridised DNA was washed 
away using PB1 a buffer containing an aliphatic amide. The BeadChip was then 
prepared for single base extension of the oligonucleotides and incorporation of 
detectable labels using the captured DNA on the BeadChip as a template. The 
BeadChips were then stained using the Illumina XStain HD BeadChip process 
before imaging on an Illumina BeadArray reader. 
The BeadArray reader uses a laser to excite the fluorophores of the single-base 
extension products on the beads and the scanner records images of the light 
emitted allowing the genotype to be determined. 
The Illumina GenomeStudio Integrated Informatics Platform was used to 
extract, visualise and analyse the genotyping data. The data was then analysed 
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and imported into Microsoft Excel for analysis using Excel macro or IBD finder 
software (http://dna.leeds.ac.uk/ibdfinder/), looking for notable regions of 
homozygosity (typically >1Mb) and to compare genotyping data across samples 
and patient cohorts.  
Assistance and support for SNP chip genotyping and analysis was provided by 
Dr Barry Chioza, University of Exeter and Dr Jayne Dennis, St George’s 
University of London. 
2.4.4 Primer design 
The Ensembl Genome Browser (February 2009 assembly) was used to obtain 
the gene sequences (website http://www.ensembl.org/index.html). Primers used 
for PCR amplification were designed either using Primer3 software version 
0.4.0 (website http://frodo.wi.mit.edu/primer3/) or the ExonPrimer link from the 
UCSC genome browser (http://genome.ucsc.edu/).  
Primers were designed following the criteria below: 
1. Primer sizes were 18-27 bases in length (the specificity and annealing 
temperature are dependent on the length of the primer).  
2. Melting temperatures were kept as similar as possible for both flanking 
primers to maintain PCR efficiency (ideally between 57 – 63oC).  
3. Where possible the guanine-cytosine (GC) base content was kept 
between 40-60%  
4. Primers with inter or intra-primer efficiency extending for more than 3 
bases were avoided, to prevent the formation of secondary structures 
and primer dimers.  
5. The primer sequences selected were specific and a 100% match to the 
region to be amplified. In silico PCR analysis and BLAST searches were 
performed using the UCSC Genome bioinformatics website. 
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2.4.5 Microsatellite marker design 
Microsatellite markers were chosen using the UCSC genome browser 
(February 2009 assembly). The region of interest was entered into the 
programme and "STS markers" and simple repeats and microsatellites" viewed. 
STS markers that are known to be polymorphic, with published primers were 
favoured.  
2.4.6 Polymerase chain reaction (PCR) 
PCR is an invitro method of cloning DNA that permits exponential amplification 
of specific lengths of DNA from only minute amounts of starting material. A 
touchdown PCR protocol was used. A “touchdown” PCR protocol was used to 
improve the specificity of the PCR by helping to avoid amplification of non-
specific products by incrementally lowering the initial annealing temperature (by 
2oC) every 2 cycles until the required melting temperature (Tm) is reached 
(Table 3). 
Table 3: Touchdown PCR program 
Number of cycles Temperature (oC) Time (Seconds) 
1 98 120 
 
2 
95 
Anneal plus 4 
72 
30 
45 
45 
 
2 
95 
Anneal plus 2 
72 
30 
45 
45 
 
35 
95 
Anneal 
72 
30 
45 
45 
1 72(elongation) 300 
 
A standard protocol for DNA amplification was followed, using a 20μl final 
volume mix (Table 4).   
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Table 4: Components of a 20μl PCR reaction 
Component Volume (μl) 
DNA 1 
Forward Primer (Sigma) 0.6 
Left Primer (Sigma) 0.6 
dNTPs (10mM) 0.6 
10xBuffer (15mM MgCl2, 
Thermoscientific) 
2.0 
Molecular grade H2O 15.1 
Red hot Taq polymerase (5U/μl)  0.1 
 
Primer pairs were initially trialled on control DNA samples that were known to 
amplify well in previous reactions. If the PCR reaction produced weak or no 
product then the contents of the mix and amplification conditions were altered 
(see optimisation of amplification conditions below). In order to ensure that the 
desired DNA template was being amplified and not a contaminant, a water 
control was included in each reaction. An Eppendorf 96 well mastercycler, 
thermal cycler machine was used for the PCR reactions. 
2.4.7 Optimisation of amplification conditions 
In order to determine the optimal annealing temperature for the primer pair a 
temperature gradient of 55-67oC across the PCR block was carried out. Where 
the GC content was above 60% a second gradient with 10% diMethyl sulfoxide 
(DMSO, Fisher Scientific) was performed. If amplification was still inadequate 
magnesium titration (1mM-3mM) across the temperature gradient was 
performed as well as increased primer concentration as required. 
2.4.8 Agarose gel electrophoresis 
To determine the adequacy of amplification of the DNA, the resulting products 
underwent agarose gel electrophoresis. For resolving smaller DNA fragments 
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such as most PCR products (typically,500bp), a 2% agarose gel was made by 
adding 2.0g of agarose to 100ml of 1x tri-acetate EDTA (TAE) buffer. The 
solution was warmed in a microwave until the agarose was dissolved. 2μl of of 
a 10mg/ml solution of ethidium bromide (Fisher Scientific) was added to the gel 
after cooling for 10mins. Ethidium bromide is a DNA intercalating agent that 
fluoresces brightly when exposed to ultraviolet light. The gel was then poured 
into a casting tray with combs in place to create wells. Once set the gel was 
placed into an electrophoresis tank filled with sufficient TAE buffer to cover the 
surface of the gel. A DNA ladder (1Kb Plus from Invitrogen) was used to assess 
the size of the PCR product. The ladder was made up with agarose gel loading 
buffer (final concentration 50ng/μl) and 2μl was loaded into one of the wells. 5μl 
of each PCR product was mixed with 5μl of loading dye and loaded into each 
subsequent well, then electrophoresed through the gel for 40mins at 100V. The 
gel was subsequently visualised on a UV transilluminator and photographs 
were taken with an orange filtered camera. Larger DNA fragments (>500bp) 
were resolved using lower concentration agarose gels (0.8%-1.0%) prepared 
similarly.  
2.4.9 Purification of PCR products 
Prior to sequencing it is necessary to remove unincorporated primers and 
dNTP’s. This was done using ExoSAP-IT a product that contains exonuclease-1 
(EXO) and shrimp alkaline phosphatase (SAP). Exonuclease-1 degrades single 
stranded DNA in a 3 prime to 5 prime direction, releasing deoxyribonucleoside 5 
prime-monophosphates in a stepwise manner. This releases dNTPs from the 
unincorporated primers. shrimp alkaline phosphatase (SAP) catalyses the 
release of 5 prime - and 3 prime-phosphate groups from extra nucleotides. 2μl 
of ExoSAP-IT were added to 5μl of each PCR product. The samples were then 
incubated at 37oC for 15mins the optimal temperature for the enzyme activity 
and subsequently at 85oC for 15mins to inactivate it. 
2.4.10 Sequencing reaction 
Purified PCR products were sequenced using BigDye Terminator Cycle 
Sequencing Kit v3.1 (ABI, Applied Biosystems) with the forward and reverse 
primers in separate reactions. The kit contains Taq DNA Polymerase, dNTPs, 
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ddNTPs-dye terminators, MgCl2 buffer. In dye-terminator sequencing, each of 
the four dideoxynucleotide chain terminators is labelled with fluorescent dyes, 
each of which emit light at different wavelengths. The protocol used for the 
sequencing reaction is detailed in Table 5 below. 
Table 5: Components of a 10μl sequencing reaction 
Component Volume (μl) 
Big Dye 0.5 
Big Dye Buffer 1.75 
Molecular grade H2O 4.25 
Forward or Reverse Primer(10mM) 0.5 
Cleaned PCR product 3.0 
 
Sequencing Reaction Program: 
1. 96oC for 30secs (denaturation)  
2. 50oC for 15secs (annealing)  
3. 60oC for 4mins (elongation)  
4. Steps 1-3 are repeated to complete 25 cycles.  
2.4.11 Sequencing reaction purification 
The products were purified prior to running on an automated DNA sequencer. 
The BigDye XTerminator purification kit protocol was followed (ABI, Applied 
Biosystems), briefly 45μl of SAM solution and 10μl of XTerminator solution were 
added to each sample in a 96 well plate. The contents of the plate were mixed 
thoroughly using a desk top shaker set at full speed for 30mins then centrifuged 
for 2mins at 1000xg. The samples were run on a sixteen capillary 3130XLA 
Applied Biosystems Automated Sequencer. A 36cm array POP7 polymer 
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programme setting was used on the sequencer. The genomic sequence was 
checked using Chromas light (Technelysium Pty Ltd), Gene tool (Biotool 
Incorporated) and Mutation Surveyor (Soft Genetics) software. 
2.4.12 Restriction digest 
A restriction fragment length polymorphism (RFLP) is a DNA polymorphism that 
creates or abolishes a recognition site for a particular restriction enzyme. Most 
restriction enzymes recognise a palindromic DNA sequence. RFLP analysis is a 
technique by which a variation in a DNA sequence can be detected by using 
restriction enzymes to fragment DNA. The resulting fragments are then sized by 
electrophoreses on agarose gels. This technique was used to assess if any 
previously unrecognised variant detected during sequencing was present in a 
control population. NEBcutter V2.0 website (http://tools.neb.com/NEBcutter2/) 
was used to select the restriction enzyme. The forward and reverse primer 
sequences with their intermediate sequence (wild-type and variant) were 
entered into the NEBcutter programme. Enzymes that cut the sequence 
containing the variant differently to the wild-type (WT) sequence were used. 
Prior to selection of an enzyme it was checked that the expected product sizes 
produced by the enzyme were sufficiently different between the WT sequence 
and the sequence containing the variant so that they would be clearly 
distinguishable when run on an agarose gel. If the variant had no effect on a 
recognised restriction site or the presence of pseudogenes complicated 
interpretation of results, then the controls were sequenced to look for the 
variant. 
Prior to performing a restriction digest, a 20μl PCR reaction was set-up for each 
sample to amplify the sequence where the variant was detected using the 
method previously described. 5μl of each PCR product was subsequently run 
on an agarose gel to check for successful amplification. A restriction digest was 
set-up using 5μl of PCR product and conditions determined by the specific 
enzyme to give a final volume of 30μl. Samples were incubated at the required 
temperature. In addition to the control DNA samples, a negative control (water 
replacing DNA) and a known homozygote and heterozygote for the variant were 
included. The latter provides control bands to confirm digestion and to aid 
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viewing fragments on agarose gels corresponding to both the WT and variant 
sequences. Following the incubation step samples were electrophoresed on a 
3% agarose gel for 60mins at 100V. The bands produced were analysed to 
identify if the specific variant under investigation was also present in the control 
DNA samples.  
2.4.13 Denaturing polyacrylamide gel electrophoresis (PAGE) 
Microsatellites (also known as short tandem repeat polymorphisms, STRPs) are 
repeats of 1-9 nucleotide sequences that are interspersed throughout the 
human genome. They serve as highly polymorphic markers which are typically 
significantly more informative in inheritance studies than single nucleotide 
polymorphisms (SNPs) due to the often large number of alleles in the 
population. DNA polymerase stuttering during replication can alter the length of 
microsatellites by one or two repeats and is also thought to be the primary 
mechanism for generating microsatellite polymorphism during meiosis 
(Strachan and Read, 2011). Microsatellite marker design has been described in 
section 2.4.5. PCR was carried out using the primers designed for each marker 
and DNA from affected individuals, parents and unaffected siblings (where 
available). To determine if the amplification was successful the PCR products 
were initially run on a 2% agarose gel as previously described. Successfully 
amplified products from each individual were then size fractionated by 
electrophoresis on a denaturing polyacrylamide gel. The size of an individual’s 
microsatellite DNA can be assessed to produce a genotype which can be 
compared to that of other family members.  
The polyacrylamide gel was made by mixing 50ml of 8% PAGE solution 
(contains acrylamide and BIS, Amresco products), 80μl TEMED (N’N’N’N’-
tetramethylenediamine) and 80μl of 25% APS (ammonium persulphate). The 
solution was mixed for 20secs using a magnetic stirrer and then poured in to the 
gel casting apparatus. Combs were inserted into the gel to create wells. The 
gels were then left to set for 40mins. The electrophoresis tank was assembled, 
each tank holds two gels. The tank was then filled with 1 litre of TBE (warmed in 
a microwave). 
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The PCR products were mixed with denaturing PAGE loading buffer 
(formamide, bromophenolblue and xylene cynol). The relative volumes of PCR 
product and loading buffer were determined depending on the strength of the 
PCR band on the agarose gel after UV transillumination, typically 2μl of PCR 
product: 2μl loading dye. The solution was then denatured by heating to 95oC 
for 4mins in a thermocycler and then stored on ice. Prior to loading the products 
each well is washed out with TBE buffer using a syringe and needle in order to 
remove the urea from the wells. 1.1μl of denatured product was loaded into 
subsequent wells. The gel was then run at 100mAmp, the length of running time 
is dependent on the expected size of the microsatellite PCR product 
(approximately 50mins per 100 base pairs). 
Once the electrophoresis was completed the gel was washed and silver 
stained. The gel was placed in the following solutions sequentially on a desk-
top shaker. Between each step the gel was washed thoroughly in distilled 
water.  
1. Solution 1 - 268.5ml dH20, 30ml ethanol and 1.5ml acetic acid (5-
10mins).  
2. Solution 2 - 300ml ddH20 and 0.3g silver nitrate (15mins).  
3. Solution 3 - 300ml ddH2O, 4.5g sodium hydroxide and 450μl 
formaldehyde (until visible bands appear, approximately 10-15mins).   
4. Solution 4 - 300ml ddH2O and 2.25g sodium carbonate (5mins, to 
prevent further development of the bands).   
The gel was then wrapped in Saran wrap, labelled and the bands read. 
2.4.14 Reverse transcription PCR (RT PCR) 
Reverse transcriptase PCR (RT PCR) is a method for indirectly amplifying RNA 
by initially making a complementary DNA (cDNA) copy. The amplified cDNA 
can subsequently be sequenced and the RNA sequence inferred. 
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Prior to starting the procedure the bench top, pipettes and racks were all 
cleaned with 70% ethanol and subsequently RNaseZap (Ambion) to remove 
any traces of RNase. Filter tip pipette tips were used for all RNA work. RNA was 
extracted from whole blood as previously described and stored on ice until 
required. The Titanium one-step RT-PCR kit and protocol (Clontech) were used. 
RT-PCR primers were designed to target exonic sequences that are separated 
by at least one intron. Primers were designed using Primer 3, programme 
settings were changed so that the primers would meet the following 
specifications:  
1. Primer melting temperature of approximately 70oC.  
2. Primer length at least 22 nucleotides (25-30 preferred).  
3. G-C content of 45-60%.  
Primers were diluted and a mix made with a final concentration of 45μM for 
each primer. A master mix was prepared as below: 
1ng - 1μg of patient RNA was added to each subsequent reaction and the total 
volume was made up to 50μl with RNase free water. In addition to a negative 
control, where water replaced RNA to control for contamination, a further 
negative control was included. A concern in RT-PCR is that genomic DNA is 
being amplified as opposed to RNA, to control for this the titanium taq was 
replaced with the standard taq used for PCR and the RNA was replaced with 
water. A positive control was also included, primers specific for mouse βactin 
were used to amplify βactin from mouse liver total RNA (supplied with the one-
step kit). 
See Table 6 for details of reaction set up.  
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Table 6: Components of a 50μl PCR reaction 
Component Volume (μl) 
Primer mix 45mM 1.0 
50x dNTP mix 1.0 
Recombinant RNase inhibitor (400u/ μl) 0.5 
Thermostabilizing reagent 25.0 
GC melt 10.0 
Oligo (dT) primer 1.0 
50x Titanium Taq RT enzyme mix 1.0 
 
The reactions were placed in a thermal cycler and the programme in Table 7 
below followed: 
Table 7: RT- PCR program 
Number of cycles Temperature (oC) Time 
1 50 1hr 
1 94 5mins 
 94 30secs 
40 65 30secs 
 68 1min 
1 68 2mins 
 
To determine successful cDNA amplification and the size of the products they 
were electrophoresed on a 2.5% agarose gel for 90mins with the appropriate 
DNA ladder. 
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2.4.15 Growth and maintenance of bacteria 
Transformed bacteria were propagated in liquid Luria Bertani (LB) broth or on 
solid media, supplemented with antibiotic and/or other additives where 
appropriate, at 37°C. Frozen stocks were made from liquid cultures by mixing 
0.5ml overnight culture with 0.5ml of 100% glycerol (sterile) followed by 
vortexing briefly and long-term storage at -80°C. 
2.4.16 Heat shock transformation of chemically competent bacteria 
In all cases the chemically competent bacteria were initially thawed on ice. 
With intact plasmid: 50ng DNA was gently mixed with 20μL chemically 
competent DH5α and incubated for 30min/ice. Cells were then heat pulsed for 
45 sec in a 42 oC water bath before being immediately transferred back to ice 
for 2mins to recover. 80µl of SOC medium was then added and the cells 
incubate at 37 oC for1hr.  Cells were then plated onto a pre-prepared LB agar 
plate containing antibiotic and incubated overnight at 37°C. 
XL-10-Gold® ultracompetent cells with intact plasmid: For each reaction 45µl of  
ultracompetent cells were aliquoted into a 15ml falcon kept on ice. 2µl of XL-10-
Gold® β-mercaptoethanol was then added to each falcoln tube and mixed with 
cells by swirling the tube before incubation on ice for 2mins. 2µl of Dpn treated 
DNA from each reaction was then gently mixed with the cells and incubated for 
30min on ice. The tubes were then heat pulsed for 30secs in a 42oC water bath 
before being immediately transferred back to ice for 2mins to recover. 0.5ml of 
preheated (42oC) SOC medium (used as a substitute for NZY+ broth) was 
added to each tube and tubes incubated 1 hr/37°C in a shaker incubator (250 
rpm). Cells (250 µl) were then plated onto prewarmed (37oC) LB agar plate 
containing antibiotic and 80 µg/ml X-gal and 20mM IPTG and incubated 
overnight at 37°C. 
With ligation mix: 2μl of the ligation reaction was added to 50μl of the DH5α 
competent cells and gently mixed by flicking the tube before being placed on ice 
for 5mins. The cells were subsequently placed in a water bath set at 42oC and 
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heat shocked for 45secs then immediately transferred back to the ice for 2mins 
in order to recover. 
1ml of pre-prepared LB broth was then added to the transformed cells which 
were incubated horizontally for 1hr at 37oC in a shaker incubator set at 
150rpm.The mixture was then briefly centrifuged for 5secs. The cells formed a 
pellet at the bottom of the tube and 950μl of the broth was removed with a 
pipette taking care not to disturb the pellet. The cells were resuspended by 
gently pipetting up and down. Using a sterile spreader the remaining 100μl of 
transformation culture was spread as evenly as possible across a pre-prepared 
LB/ampicillin/agar plate. The plate was then incubated overnight at 37oC.  
2.4.17 Cloning of PCR product 
In order to clearly visualise and interpret the effect of compound heterozygous 
changes, both individual DNA strands of the PCR product were cloned for DNA 
sequencing using the pGEM-T Easy Vector (Promega) and pGEM-T Easy 
Vector System II kit. The pGEM-T easy vector is a linearized vector with a 3 
prime terminal thymidine at both ends. This is compatible with the Thermoprime 
taq polymerase used for the PCR which adds an “A” nucleotide overhang to the 
PCR product. The ligation buffer and T4 DNA ligase were thawed on ice and 
the ligation buffer vortexed for 10secs to ensure it was thoroughly mixed. 
The ligation reaction mix was prepared as in Table 8 below in a 0.5ml tube. The 
solution was then incubated at room temperature for 1hr. 
Table 8: Components of a 5μl ligation reaction mix 
Component Volume (μl) 
2x Rapid ligation buffer 2.5 
pGEM-T easy vector 50ng/μl) 0.5 
T4 ligase (3 Weiss units/μl) 0.5 
Fresh (less than 1 day old) PCR product 1.5 
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50μl of chemically competent DH5α cells were thawed on ice and mixed by 
gently flicking the tube. The transformation reaction was carried out as 
described in section 2.4.16, in a 1.5ml microcentrifuge tube. 
16 wells of a 96 well plate were filled with 50μl of molecular grade water. A 
sterile 10μl pipette tip was used to remove individual colonies gently from the 
agar plate and each colony was placed into subsequent wells containing water 
(the pipette tip was agitated in the well to remove the cells). 1μl was taken from 
each well and used as template. PCR was carried out as previously described 
with appropriate forward and reverse primers. The products were then run on a 
2% agarose gel to determine successful amplification.  
2.4.18 Site-directed mutagenesis (SDM) to generate mutant constructs  
SDM was carried out using the Agilent QuikChange Lightning site-directed 
mutagenesis kit, following the manufacturer’s protocol which is summarised 
below. 
A 50μl reaction was prepared comprising, 5μl 10X reaction buffer, xμl dsDNA 
template (corresponding to between 10 - 100ng), yμl oligonucleotide primer 1 
(corresponding to 125ng) , yμl oligonucleotide primer 2 (corresponding to 
125ng) , 1μl dNTP mix ,1.5μl QuikSolution™ reagent, 1μl of Quikchange 
Lightening Enzyme (derivative of PfuUltra™ High Fidelity DNA polymerase) and 
ddH20. Reaction conditions: 95°C/2min, [95°C/20sec, 60°C/10sec, 
68°C/30sec/kb of plasmid length] x18 cycles, 68°C/5min. 
The amplification products were subsequently mixed with 2μl per reaction of 
DpnI enzyme provided in the kit. The reactions were then immediately 
incubated in a water bath at 37oC for 5mins, in order to digest the parental 
supercoiled dsDNA. XL10-Gold® ultracompetent cells were then used for 
transformation reactions (section 2.4.16). 
To assess the efficiency of mutant plasmid generation, a further reaction was 
set-up in parallel using the 4.5kb pWhitescript™ control plasmid (which contains 
a stop codon at the position where a glutamine codon would usually appear in 
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the β-galactosidase gene), and oligonucleotide control primers 1 and 2 
contained within the kit. XL10-Gold ultracompetent cells transformed with this 
plasmid appear white on LB-ampicillin agar plates containing IPTG and X-gal 
due to a lack of β-galactosidase activity. The oligonucleotide control primers 
create a point mutation that reverts the sequence back to the wild type β-
galactosidase gene sequence. Successful mutagenesis is indicated by the 
presence of blue colonies as opposed to white, following transformation. 
Expected results of the control reaction indicating successful mutagenesis and 
transformation were considered to be >100 colonies, >85% of which are blue. 
2.4.19 Plasmid preparation and DNA sequencing 
Single colonies were picked from the plate using a sterile inoculating loop and 
grown in 2-5ml LB containing the appropriate selective antibiotic for 8hrs at 
37oC in a shaker incubator (300rpm). Plasmid mini-preps were then carried out 
using the Qiagen plasmid Mini kit to extract DNA from the E.coli transformants, 
following the Qiagen plasmid purification handbook. The protocol is based on 
an alkaline lysis procedure, followed by binding of plasmid DNA to an anion-
exchange resin under low-salt and pH conditions. Impurities such as RNA and 
proteins are removed by medium salt washes. Elution of the plasmid DNA is by 
a high-salt buffer. DNA is subsequently precipitated and desalted with 
isopropanol. 
The plasmid DNA was subsequently sequence verified by dideoxy sequencing. 
Once the plasmid sequence was confirmed larger-scale preparations of the 
plasmid were performed.100µl of the 2-5ml starter culture was diluted 1 in 1000 
into selective media in a conical flask and grown overnight at 37oC in a shaker 
incubator (300rpm) followed by Midi-preps using the Qiagen plasmid Midi kit. 
2.5 Basic protein methods 
2.5.1 Denaturing SDS-PAGE using the Invitrogen NuPAGE gel system 
Denaturing SDS gels were used to separate proteins for western blot analysis. 
Invitrogen Bis Tris Noves NuPAGE 4-12% gradient gels were used. Protein gels 
were run using the Invitrogen system, the gel running apparatus was 
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assembled and the tank filled with fresh 1x NuPAGE MES running buffer, 435µl 
NuPAGE reducing agent was added to the buffer chamber just prior to 
electrophoresis. Samples were prepared for electrophoresis by mixing with 
NuPAGE loading buffer to a final concentration of 1x and boiling for 3mins at 
95oC prior to loading. 5µl of prestained broad range protein size markers (NEB) 
were loaded alongside the protein samples. Gels were routinely 
electrophoresed at 200V for 50mins at room temperature. 
2.5.2 Semi-dry transfer 
The proteins separated by SDS-PAGE were transferred directly onto 
nitrocellulose membrane (Whatman-Protran) using the BioRad Transblot semi-
dry transfer cell. The membrane and two sheets of extra thick blotting paper 
(BioRad) were cut according to the size of the gel, and soaked in 1x NuPAGE 
transfer buffer for 10mins prior to transfer. The gel was placed on top of the 
membrane, which was then sandwiched between the two sheets of blotting 
paper. A test tube was gently rolled over the gel sandwich to get rid of any 
trapped air bubbles. The proteins were transferred at 13V for 35mins. The 
membrane was soaked in Ponceau stain for 2-3mins and rinsed with ddH2O to 
visualise transferred proteins on the membrane. The stain was removed by 
washing twice in PBST. 
2.5.3 Western blotting 
Following the transfer of proteins, the membrane was blocked in 5% skimmed 
milk powder (w/v) in PBST. This was carried out at room temperature, with 
gentle agitation. The membrane was then incubated in the appropriate primary 
antibody (Table 9) for between 1 hour at room temperature and overnight at 4oC 
and washed 3x in PBST for 5mins/wash with gentle agitation. The membrane 
was then incubated in the respective goat-anti-mouse-IgG-HRP or goat-anti-
rabbit-IgG-HRP secondary antibody (Dako), used at a concentration of 1 in 
5000 in 1% skimmed milk in PBST for 1-2hrs at room temperature with gentle 
agitation. The transferred proteins were then detected using ECL reagents 
(Perkin-Elmer) according to the manufacturer’s protocol and digitally visualised 
and photographed on a Biorad imager. 
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Table 9: Primary antibodies and conditions used in western blot 
Antibody name Antibody type Primary 
 
Anti-PCNA: PC10 (Abcam) 
 
Mouse monoclonal 
 
 
1 in 4000, 1% milk 
 
Anti-PCNA  
(Abcam) 
 
Rabbit polyclonal  
 
1 in 1000, 1% milk 
 
 
Anti-Actin:Ac40 (A4700)  
(Sigma)  
 
Mouse monoclonal 
 
1 in 1000, 1% milk 
 
 Anti-Fen1: 4E7 
(GeneTex) 
 
Mouse monoclonal 
 
1 in 1000, 1% milk 
 
Anti-Fen1: EPR4459(2) 
(GeneTex) 
 
Rabbit monoclonal 
 
1 in 1000, 1% milk 
 
Anti-Lig1: 10H5 
(Thermo Scientific) 
 
Mouse monoclonal 
 
1 in 1000, 1% milk 
 
Anti-Lig1 
(Thermo Scientific) 
 
Rabbit polyclonal 
 
1 in 1000, 1% milk 
 
Anti-Lig1: 10G12 
(Abcam) 
 
Mouse monoclonal 
 
1 in 1000, 1% milk 
 
Anti-XPA: 5F12 
(Abcam) 
 
Mouse monoclonal 
 
1 in 1000, 1% milk 
 
Anti-XPG 
(Abcam) 
 
Rabbit polyclonal 
 
1 in 1000, 1% milk 
 
Anti-XPG: 8H7 
(Abcam) 
 
Mouse monoclonal 
 
1 in 1000, 1% milk 
 
2.5.4 Coomassie staining 
The gel was washed in ddH2O then stained with Coomassie SimplyBlue™ 
SafeStain (Invitrogen) overnight with gentle rocking, followed by repeated 
washes in ddH2O until the excess stain was removed and the gel could be 
analysed. 
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2.6 Cell culture techniques 
2.6.1 Cell Culture 
Human primary fibroblast cells were maintained in 5% CO2, at 37
oC in DMEM 
supplemented with 20% Foetal Calf Serum (FCS), 2mM Glutamine (Invitrogen) 
and 1% penicillin and streptomycin. 
Human lymphoblastoid cells lines were Epstein Barr virus (EBV) transformed by 
Public Health England (formerly Health Protection Agency) and grown in RPMI 
1640 (Sigma Aldrich) supplemented with 20% FCS, 2mM Glutamine 
(Invitrogen) and 1% penicillin and streptomycin and maintained in 5% CO2, 
37oC at a density of between 3x105 - 2x106 cells/ml. 
Human MRC5 lung fibroblast cells were grown at 37oC, 5% CO2 in MEM (Sigma 
Aldrich) supplemented with 10% FCS, 2mM Glutamine (Invitrogen) and 1% 
penicillin and streptomycin. 
2.6.2 Freezing cell line stocks  
Fibroblast or lymphoblastoid cells in exponential growth phase were harvested 
and resuspended in freezing medium before immediate transfer into 
CryoTubes, followed by overnight storage in a Mr. Frosty and long term storage 
in liquid nitrogen.  
2.6.3 Lymphoblastoid UV survival assay 
UV sensitivity of lymphoblastoid cells was determined by irradiating cells in PBS 
(1x106 viable cells in 1ml) with UVC (254nm, 1Jm-2sec-1), adding 4ml growth 
medium and counting viable cells using trypan blue exclusion after a 72hr 
recovery period. 
2.6.4 Fluorescence activated cell sorting (FACS) 
The BD LSRII flow cytometer fitted with Blue (488nm), Violet (405nm), Red 
(633nm) and UV lasers (35-60nm) at Barts and The London School of Medicine 
and Dentistry Flow Cytometry Core Facility or the CyAn ADP Analyser 
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(Beckman Coulter Inc) in the Flow Cytometry Core Facility of the Jenner 
Institute Oxford, was used to analyse and characterise primary fibroblast cells 
actively synthesising DNA (bromodeoxyuridine (BrdU) incorporation) in terms of 
their cell cycle position defined by a total DNA stain (7-amino-actinomycin D (7-
AAD) or propidium iodide (PI) intensities. 
Asynchronously growing primary fibroblast cells passage 10 (P10) or below 
were plated at a density of 4x 105 for 24hrs in 10ml of complete media in 10cm 
dishes. The cells were then pulse labelled for 30mins with BrdU at a final 
concentration of 10µM. Cells were subsequently trypsinised, fixed and stained 
using the BD PharmingenTM FITC BrdU Flow Kit (catalogue number 559619) 
The fixative in the kit is a mixture of paraformaldehyde and the detergent 
saponin which permeabilises the cells. DNase treatment of the cells exposes 
incorporated BrdU before staining with an FITC-conjugated anti-BrdU antibody 
and 7-AAD. The protocol was followed according to the manufactures 
instructions. In addition to the labelled cells, an aliquot of unlabelled cells was 
stained as a negative control. Samples were resuspended in BD PharmingenTM 
Stain Buffer (FBS) and kept at 4oC prior to FACS analysis. 
Alternatively the cells were fixed by the addition of methanol to 70%. After 
storage at -20 °C cells were treated with 0.2 mg/ml pepsin in 2M HCl for 
20mins, then incubated in 0.5% BSA in PBS with 0.5% tween 20 and a 1/50 
dilution of anti-BrdU antibody (Becton Dickinson) for 1hr. After washing in 0.5% 
BSA, incubation with 1/100 anti-mouse secondary antibody coupled to Alexa 
Fluor 488 (Molecular Probes) was for 30mins, followed by washing and 
resuspension in PBS with 0.5 mg/ml RNaseA for 15mins. Propidium iodide was 
added (10 µg/ml) just before analysis. 
The fixed samples were then analysed on the flow cytometer (20,000 events 
collected) to detect 7-AAD/PI and BrdU with the width parameter used to 
exclude doublets of cells. Histogram analysis of the signal allowed the 
determination of the percentage of cells in Sub G1, G1, S phase and G2M 
phases. Two-colour flow cytometric analysis permitted the enumeration and 
characterisation of cells that were actively synthesising DNA in terms of their 
cell cycle position. 
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Data was analysed by Summit software (Dako) in Oxford and BD FACSDiva 
software version 6.1.3 in London. 
FACS analysis was performed with Mr Gary Warnes (Flow Cytometry Core 
Facility, Blizard Institute, Barts and The London School of Medicine and 
Dentistry) and by Mr Drew Worth (Flow Cytometry Core Facility, Jenner Institute 
Oxford). 
2.6.5 Generation of mammalian cells stably expressing normal levels of 
His-PCNA 
To generate silence mutated His-PCNA and His-PCNA p.Ser228Ile expressing 
cell lines, MRC5 cells were transfected with DNA encoding wild-type PCNA or 
PCNA-Ser228Ile tagged with 6 histidine residues in pcDNA3.1 (G418 resistant) 
following the X-tremeGene 9 transfection protocol (Roche). The cDNA 
constructs carried in addition the following silent mutations to render them 
refractory to targeting by the small interfering (si)RNA. 
Wild type: GC CGA GAT CTC AGC CAT AT 
Mutant: GC AGG GAC TTA TCT CAT AT  
24hrs prior to transfection, 5x105 MRC5 cells were plated in each well of a 6 
well plate in 5ml of complete medium. 100µl of serum free medium containing 
1µg of DNA and 3µl of X-tremeGene 9 DNA transfection reagent was incubated 
for 15mins at room temperature and then added dropwise to the cells. A 
negative control with no plasmid was also included. Cells were trypsinised after 
40hrs and each well was resuspended in 5ml of medium containing 1200µg/ml 
G418 (Geneticin PAA). Cells were then moved into 10cm dishes with 10ml of 
G418 containing medium, 2ml of cells were added to 2 dishes, 200µl to 2 
dishes and 20µl to the last 2 dishes. The dishes were then agitated to spread 
the cells evenly and allowed to grow for 10 days at 37oC, with media change as 
appropriate. The negative control was checked to ensure that it did not contain 
any colonies. Well separated colonies were then selected using cloning 
cylinders (Bel-Art) and sterile silicone grease. Each colony was trypsinised and 
expanded into a single well of a 6 well plate. When the well reached confluence, 
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cells were trypsinised and half were expanded into a T25 flask, the remainder 
were analysed by western blot. 
2.6.6 Transfection of MRC5 cells with siRNA 
MRC5 cells stably expressing silence mutated His-PCNA at normal levels were 
transfected with 10nM PCNA siRNA [GCCGAGAUCUCAGCCAUAUTT(Eurofins 
MWG Operon)] or the non-specific siRNA pool (Eurofins MWG Operon), using 
the HiPerFect transfection reagent (Qiagen). 
The day before transfection, 1x104 cells were seeded per well of a 24 well plate 
in 500µl of appropriate complete medium without G418. The cells were 
incubated for 24hrs at 37oC, 5% CO2. On the day of transfection 75ng PCNA or 
non-specific control siRNA was diluted in 100µl MEM culture medium (without 
serum or antibiotics), 3µl of HiPerFect reagent was then added to the diluted 
siRNA and mixed by vortexing. The samples were incubated for 10mins at room 
temperature to allow transfection complexes to form. The complexes were then 
added dropwise on to the cells, plates were gently swirled to ensure uniform 
distribution of the transfection complexes. For each well transfected with PCNA 
siRNA two control wells were included, one with 100µl of culture medium alone 
and one with 100µl of medium and 3µl of HiPerFect reagent. Cells were then 
incubated for 72hrs, harvested and analysed by western blot. 
2.7 Protein Interaction analyses 
2.7.1 Purification of 6xHIS-tagged proteins from E.coli under denaturing 
conditions 
First pET16b-Lig1, pET16b-Lig1 PIP*, and pET16b-empty vector were 
transformed into BL21 competent E.coli on ampicillin containing plates. A single 
colony was picked into typically 6ml of ampicillin containing LB and grown for 
8hrs in the shaker incubator. This culture was then inoculated into a 100ml 
culture and left overnight until the optical density (OD) was 0.6-0.9. A 1ml 
sample (un-induced control) was taken, centrifuged at 3000xg for 2mins and 
stored at -20oC. 
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IPTG 0.5mM was added to each culture to induce protein expression and the 
temperature in the shaker incubator reduced to 24oC for the next 3hrs. A further 
1ml sample was taken (induced) and the rest of the cells were harvested by 
centrifuging at 3000g for 2mins. The bacterial cell pellets were stored at -20oC. 
The protocol below was modified from the Qiagen QIAexpressionist. 
Buffer composition 
100mM NaH2PO4 
10mMTris-Cl 
8M urea 
(B) pH adjusted to 8.0 using NaOH,  
(C) pH adjusted to 6.3 using HCL, 
(D) pH adjusted to 5.9 using HCL,  
(E) pH adjusted to 4.5 using NaOH. 
 
Bacterial cell pellets were thawed on ice for 15mins and then resuspended in 
buffer (B) at 5ml/g wet weight. The cells were then lysed at room temperature 
on a roller mixer, taking care to avoid foaming. Lysis was considered to be 
complete when the solution became translucent (about 60mins). The Lysate 
was then centrifuged at 10,000xg for 30mins at room temperature (to avoid 
precipitation of the urea) to pellet the cellular debris. 5µl of 2x NuPAGE loading 
buffer was added to 5µl of supernatant (cleared lysate). 
The appropriate volume of Ni-NTA resin was washed in buffer (B) (centrifuged 
at 300 x g for 3mins). 1ml of 50% Ni-NTA slurry was added to the total lysate 
and mixed at room temperature on a rotary mixer at 200rpm for 60mins. The 
Lysate-resin mixture was added to an empty polypropylene column. The flow-
through was kept for SDS-PAGE analysis. The column was washed twice with 
4ml of buffer (C). The pooled wash fractions were kept for SDS-PAGE analysis. 
The recombinant proteins were eluted four times with 0.5ml buffer (D), followed 
by four times with buffer (E). Each fraction was analysed by SDS-PAGE on a 4 - 
12% Bis Tris Noves NuPAGE gel which was subsequently stained with 
Coomassie. 
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2.7.2 Surface Plasmon Resonance (SPR) 
HBS-EP running buffer composition: 
 10mM Hepes pH7.4 
 150mM NaCl 
 3mM EDTA 
 0.005% (v/v) Tween 20 
 
TBS running buffer composition: 
 50mM Tris pH 8.5 
 150mM NaCl 
 1mM EDTA 
 0.005% Tween 20 
 
Gomes running buffer composition: 
 30mM HEPES–NaOH pH7.5 
 1mM EDTA 
 0.5% inositol 
 0.01% NP-40 
 8mM magnesium acetate 
 100mM NaCl. 
 
The SPR phenomenon occurs when polarised light, under conditions of total 
internal reflection, strikes an electrically conducting gold layer at the interface 
between media of different refractive index: the glass of a sensor surface (high 
refractive index) and a buffer (low refractive index). 
Surface plasmon resonance (SPR) experiments were performed using a 
Biacore T200 (Center for Cellular and Molecular Physiology, Wellcome Trust 
Human Genetics Unit, Oxford) to monitor the interactions between PCNA, Lig1 
and Fen1, following the manufacturer’s instructions and best practice guidelines 
recommended by (Myszka, 1999).  
Surface/pH scouting was performed by running recombinant wild type PCNA 
protein diluted 1 in 10,000 (stock concentration 0.25mg/ml) in 10mM sodium 
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actetate pH 4.0 (i.e. below the isoelectric point of PCNA, pH 4.57) over the chip. 
An increase in SPR signal (expressed in response units, RU) is looked for, 
indicating adherence to the chip, running buffer is then run over the chip surface 
and the SPR signal checked to ensure that it returns to baseline indicating that 
the adherence is reversible and experimental coupling conditions. 
About 500 response units (RU) (∼2 fmol) of either recombinant wild-type PCNA, 
PCNA IDCL* (Leu126Ala, Ile128Ala, mutations disrupt the PCNA Inter-domain 
connector loop) and PCNA Ser228Ile were immobilised on separate running 
channels on the surface of a BIAcore Series S Sensor CM5 or CM4 chip by the 
carbodiimide coupling method as per the manufacturer’s instructions. Channel 1 
was left empty. The running buffers used in the analysis were either HBS-EP, 
TBS or Gomes buffer, The pH and salt were also varied, pH was increased to 
8.8 and salt concentration to 300mM within these buffers with the aim of 
optimising experimental conditions. The PCNA–Fen1 and PCNA-Lig1 
interactions were measured by injecting 55µl/2mins of increasing 
concentrations of recombinant Fen1 PIP* (Leu340Ala, Phe343Ala, Phe344Ala 
mutations disrupt the PIP box), Lig1 PIP* (Ile5Ala, Phe8Ala, Phe9Ala mutations 
disrupt the PIP box), WT Fen1 or Lig1 over the immobilised WT or mutant 
PCNAs at a flow rate of 30µl/min. To determine the relative affinities of Fen1 or 
Lig1 for PCNA, steady-state binding levels (RUeq) were plotted as a function of 
Fen1 or Lig1 concentration. 
2.7.3 Investigation of the salt resistance of the PCNA-Fen1 interaction 
Interaction buffer (stored at 4oC): 
 10% Glycerol 
 25mM NaCl 
 0.01% NP-40 
 25mM Tris pH7.5 
 Protease inhibitors (Roche) 
 Volume adjusted with ddH2O 
HeLa nuclear extract and recombinant WT PCNA and PCNA p.Ser228Ile both 
stored in Gomes buffer were thawed gently on ice. HeLa nuclear extract was 
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then centrifuged at 1500xg for 15mins at 4oC to remove precipitate. 
Supernatant was then transferred to a new 1.5ml Eppendorf tube. 180µl of 
HeLa nuclear extract was added to each of four prechilled 1.5ml Eppendorf 
tubes. Equal concentrations of each PCNA protein (10µg) in IP buffer (total 
volume 30µl) were then combined with the HeLa nuclear extract in separate 
tubes and vortexed gently. The 3rd tube contained HeLa nuclear extract and 
30µl of IP buffer only as a negative control. Samples were incubated on ice for 
1 hour, prior to centrifuging associated extracts at 21,000xg for 10mins at 4oC. 
10µl of supernatant was removed and mixed with x2 NuPAGE loading buffer as 
start material. 40µl of 50% slurry Ni-NTA beads, prewashed in interaction 
buffer, were added to each sample, prior to incubation on a rotary mixer at 4oC 
for 1hr. Post-incubation samples were spun at 3,000rpm for 3mins, and tubes 
left on ice for 10mins to allow the beads to settle at the base of the tube. 10µl of 
flow-through was removed and combined with x2 LB, the remaining supernatant 
was removed carefully and discarded. Beads were then carefully washed 2x in 
100µl of interaction buffer followed by elutions at 100mM, 500mM and 1M NaCl. 
Beads were dried with 3MM blotting paper strips, resuspended and boiled in 
20µl of interaction buffer and 50µl 2x NuPAGE loading buffer. Proteins were 
separated by SDS-PAGE on a 4-12% NuPAGE gradient gel (200V for 50mins).   
2.7.4 Cell extract preparations 
Benzonase lysis buffer (made on ice): 
 40mM NaCl 
 50mM Hepes pH 8.5 
 2mM MgCl 
 0.1% NP-40 
 10% Glycerol 
 Protease inhibitors (Roche) 
 Volume adjusted with ddH2O 
1µl/ml Benzonase nuclease (Merck) was added immediately before use. 
Human lymphoblastoid cells were pelleted, washed in cold PBS and 
resuspended in benzonase lysis buffer (1ml per 108 cells) in chilled eppendorf 
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tubes on ice for 20mins.The NaCl concentration was adjusted to 150mM. The 
lysate was incubated on ice for 15mins and subsequently centrifuged at 4oC at 
20,000xg for 10mins. The supernatant was then transferred to a clean tube and 
buffer exchanged into interaction buffer using 5ml Zeba desalt spin columns 
(Thermo Scientific) according to the manufacturer instructions. Briefly, columns 
were centrifuged at 1,000xg at 4oC for 2mins to remove storage solution. The 
columns were prepared by adding 2.5ml of interaction buffer slowly to the resin 
and centrifuging at 1,000xg at 4oC for 2mins, then discarding the flow-through. 
This step was repeated three times. The supernatant was then slowly applied to 
the centre of the compacted resin bed. A stacker of 100µl of interaction buffer 
was added to samples <750µl. 
2.7.5 Bradford Assay 
Bradford assays were performed to determine protein concentration of the 
samples. 2µl of the cell extract was added to 800µl H2O and 200 µl of Bradford 
reagent (Sigma). The samples were mixed in an Eppendorf tube and 
transferred to plastic cuvettes, and the absorbance at 595nm determined using 
a spectrophotometer. The protein concentrations were then estimated in 
comparison to a standard curve plotted from the absorbance of known 
concentrations of BSA solutions. 
2.7.6 Co-immunoprecipitation assays - Interaction between 
endogenous PCNA and endogenous Fen1, Lig1, XPG, XPA 
Lymphoblastoid cell extracts were prepared as described above. Protein 
concentration was determined by Bradford assay and the concentration 
adjusted with interaction buffer. A sample was taken as input material. 
50µl of a 50:50 mix of protein A and G magnetic Dynabeads (Diagenode) 
blocked with 1% BSA for 1hr were used per sample. The beads were washed 
2x with interaction buffer and resuspended in the same buffer prior to use.  
1µg of antibody (Table 10) was used per cell extract sample (200-250µl 
containing 2-mg/ml protein), vortexed briefly and left incubating on ice for 1hr to 
allow binding, before centrifuging at 4oC at maximum speed for 15mins. A 
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control IgG was included for each extract. Each sample was then transferred to 
a new cold tube. (10µl of each sample was then removed as pre-cleared load 
material). 50µl of beads were added to each sample and allowed to bind at 4oC 
for 1 hour on the rotary tube mixer. The tubes were then placed on a chilled 
magnet and the supernatant removed (20µl of flow-through taken for each 
sample). The beads were then washed x4 in 500 µl of interaction buffer, using 
the magnet and on the last wash the beads were moved to a new tube. The 
supernatant was discarded and the beads resuspended in 30 µl of 1x NuPAGE 
loading buffer and boiled for 3mins.  
0.5-5% of input, pre-cleared load and flow-through material and 30-60% of bead 
material were loaded on a 4-12% gel and proteins were separated by SDS-
PAGE (200 volts for 40mins). Western blot analyses were performed as 
described in section 2.5.3. 
Table 10: Antibodies used in co-immunoprecipitation assays 
Antibody name Antibody type 
 
 Anti-Fen1: 4E7 
(GeneTex) 
 
Mouse monoclonal 
 
Anti-Fen1: EPR4459(2) 
(GeneTex) 
 
Rabbit monoclonal 
 
Anti-Lig1: 10H5 
(Thermo Scientific) 
 
Mouse monoclonal 
 
Anti-Lig1 
(Thermo Scientific) 
 
Rabbit polyclonal 
 
Anti-Lig1: 10G12 
(Abcam) 
 
Mouse monoclonal 
 
Anti-XPA: 5F12 
(Abcam) 
 
Mouse monoclonal 
 
Anti-XPG 
(Abcam) 
 
Rabbit polyclonal 
 
Anti-XPG: 8H7 
(Abcam) 
 
Mouse monoclonal 
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2.7.7 Interaction between glutathione S transferase (GST) tagged PCNA 
partner proteins and PCNA 
All of the expression vectors used in this assay were cloned by Dr Catherine 
Green using either standard cloning procedures or the Invitrogen Gateway 
system. 
Expression vectors used in this assay (pGEX vectors are all ampicillin 
resistant. All of the pET30a vectors are Kanamycin resistant): 
 pGEX4T – 1 empty vector  
 pGEX Fen1 PIP box (amino acids 328-355) 
 pGEX XPG PIP box (amino acids 981 -1009) 
 pGEX Lig1 PIP box (amino acids 1-21 with an 8 amino acid glycine-
serine space to maintain equal distance between the GST and PIP box in 
all cases) 
 pET30a – empty vector 
 pET30a PCNA WT 
 pET30a PCNA IDCL* (Leu126Ala, Ile128Ala, mutations disrupt the 
PCNA Inter-domain connector loop) 
 pET30a PCNA Ser228Ile 
 
Binding buffer composition: 
 50mM Tris 
 100mM KH2PO4/K2HPO4 pH7 
 2mM EDTA 
 150mM NaCl 
Lysates from E-Coli expressing one of the PCNA constructs or pET30a empty 
vector as a negative control (protein concentration was adjusted with PBS) were 
mixed with 250µl of binding buffer in an 1.5ml eppendorf and added pairwise to 
lysates from cells expressing either GST (empty vector, negative control). or 
fusion proteins comprising GST and the PIP boxes of Fen1, Lig1 or XPG. 25µl 
was removed from each as input and combined with 25µl of 2x NuPAGE 
loading buffer. Glutathione beads (GE) were washed with binding buffer. 50µl of 
bead slurry was used per reaction. The beads were added to the combined cell 
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lysates and allowed to bind at 4oC for 3hrs on a rotating shaker. The beads 
were then washed twice with binding buffer and subsequently with 50% binding 
buffer and 50% PBS (to remove the potassium and thus prevent SDS 
precipitation). Beads were then dried with 3MM blotting paper strips. Washed 
beads were resuspended in 37.5µl of 1.5 x NuPAGE loading buffer. 5µl of input 
and 10µl of bead material were loaded on a 4-12% gel and proteins were 
separated by SDS-PAGE. Gels were then washed 2 x in ddH2O for 5mins/wash 
and and stained with Coomassie as described in section 2.5.4. 
2.7.8 Interaction between S-tagged PCNA and endogenous Lig1 
S (Lys-Glu-Thr-Ala-Ala-Ala-Lys-Phe-Glu-Arg-Gln-His-Met-Asp-Ser) – fusion 
protein association studies were performed using lysates from E.coli harbouring 
pET30a empty vector as a negative control or PCNA (WT or p.Ser228Ile) 
expressed from pET30a (protein concentration was adjusted with PBS) 
A total volume of 250µl of S-agarose beads (Novagen) were washed in PBS 
and blocked with 3% BSA for 30mins before being washed and resuspended in 
PBS. 50µl HeLa nuclear extract (CilBiotech) resuspended in 200µl of binding 
buffer (as used in section 2.7.7) was added to each lysate, 5% was then 
removed as input. 50µl of S- agarose beads (previously washed and blocked) 
were added to each reaction and allowed to bind for 3 hrs at 4oC on a rotating 
shaker. The beads were then washed again 3x with PBS and dried with 3MM 
blotting paper strips. Beads were then boiled in 37.5µl of 1.5 x NuPAGE loading 
buffer. Proteins were separated by SDS-PAGE on a 4-12% gel and transferred 
onto a nitro-cellulose membrane. Western blot analyses were performed as 
described in section 2.5.3 and membranes probed with rabbit polyclonal anti-
Ligase antibody (PA5-27820), mouse monoclonal anti-PCNA antibody (PC10), 
mouse monoclonal anti-Actin antibody (Ac40) and the appropriate secondary 
antibody. 
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3 HYPOMORPHIC PCNA MUTATION UNDERLIES A 
NOVEL HUMAN DNA REPAIR DISORDER 
3.1 Summary 
A number of human disorders, including Cockayne syndrome, UV-sensitive 
syndrome, xeroderma pigmentosum and trichothiodystrophy, result from the 
mutation of genes encoding molecules important for nucleotide excision repair. 
We describe a novel DNA repair disorder identified amongst the Ohio Amish 
community. The cardinal clinical features of this disorder include postnatal 
growth retardation, hearing loss, premature aging, telangiectasia, 
neurodegeneration, photophobia, photosensitivity and predisposition to sun 
induced malignancy. Assuming autosomal recessive inheritance and that a 
founder mutation was responsible for the condition, we used a combination of 
autozygosity mapping and linkage analysis to identify the underlying molecular 
cause. Our genetic investigation identified a homozygous missense 
(p.Ser228Ile) sequence alteration of the proliferating cell nuclear antigen 
(PCNA) causing the disease phenotype. PCNA is a highly conserved sliding 
clamp protein essential for DNA replication and repair. Due to this fundamental 
role, mutations in PCNA that profoundly impair protein function would be 
incompatible with life. Interestingly, while the p.Ser228Ile alteration appears to 
have no effect on protein levels or DNA replication, patient cells exhibit 
significant abnormalities in response to UV irradiation displaying substantial 
reductions in both UV survival and RNA synthesis recovery. Importantly the 
defective transcriptional responses to UV light are completely rescued by wild-
type PCNA molecule, demonstrating that the mutation is causative. Furthermore 
we show that the p.Ser228Ile change profoundly alters the capacity of PCNA to 
interact with a specific subset of partner proteins. These proteins include XPG 
and the DNA metabolism enzymes Flap endonuclease 1 (Fen1) and DNA 
Ligase 1 (Lig1), molecules fundamental to genomic integrity, thus providing an 
explanation for the separation of function effect. Taken together our findings 
detail the first mutation of PCNA in humans, associated with a unique 
neurodegenerative disease displaying clinical and molecular features common 
to other DNA repair disorders, which we show to be attributable to a 
hypomorphic amino acid alteration. Further investigation of the altered 
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biological processes underlying this syndrome should provide valuable insight 
into the neurodegenerative disease mechanisms involved in DNA damage 
tolerance and repair disorders. 
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3.2 Introduction 
Maintenance of genomic integrity is fundamentally important for normal cell 
division and basic cellular biological processes.  The molecular characterization 
of human DNA damage sensitivity disorders such as ataxia telangiectasia, 
xeroderma pigmentosum (XP) and Cockayne syndrome (CS) has provided 
unique insight into the cellular mechanisms required for DNA damage tolerance 
and repair, and their importance for human health. The key features of such 
syndromes include predisposition to premature aging, malignancy, 
neurodegeneration, immunodeficiency, photosensitivity and growth insufficiency 
(DiGiovanna and Kraemer, 2012, Kamileri et al., 2012, Nance and Berry, 1992, 
Perlman et al., 2003). 
Cockayne syndrome is caused by mutations in the ERCC6/CSB or 
ERCC8/CSA genes. Patients with this condition present with postnatal growth 
retardation, acquired microcephaly, immature sexual development, progeria, 
cachexia, frequent dental caries, progressive sensorineural hearing loss and 
learning difficulties. Ocular abnormalities are progressive and include 
pigmentary retinopathy, cataracts and optic atrophy. Neurodegeneration with 
predominantly white matter involvement, frequently manifests as spasticity and 
ataxia, contractures develop with age. Characteristic neuroimaging findings 
include: hypomyelination, supratentorial white matter loss, cerebellar 
atrophy/hypoplasia and bilateral putaminal calcifications (Koob et al., 2010). 
Affected individuals exhibit marked photosensitivity but lack the predisposition 
to cutaneous malignancies that is seen in xeroderma pigmentosum.  The 
classic gestalt is described as “cachectic dwarfism” with deep set eyes, 
prominent ears and a pinched appearance of the nose, due to loss of 
subcutaneous tissue (Kraemer et al., 2007). Clinical presentation and 
diagnostic criteria are described in (Nance and Berry, 1992) 
Xeroderma pigmentosum is characterised by abnormal pigmentation changes, 
extreme photosensitivity and photophobia in some but not all individuals, and 
an estimated 10,000 fold increased risk of non-melanocytic skin cancer and 
2,000 fold risk of melanoma. Malignancies of the eye and oral cavity are also 
increased (Bradford et al., 2011, Lehmann et al., 2011). Ocular findings are 
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limited to sun-exposed structures and include chronic UV induced conjunctivitis, 
keratitis, corneal opacification and vascularisation and inflammatory lesions. 
Neurodegeneration is described in 20-30% of xeroderma pigmentosum 
patients. Findings include progressive intellectual deterioration, sensorineural 
hearing loss, peripheral neuropathy, areflexia, ataxia and speech abnormalities. 
The underlying pathological cause appears to be neuronal degeneration 
reflected by the cortical and cerebellar atrophy and sparing of the white matter 
seen on neuroimaging (Bradford et al., 2011, Kraemer et al., 2007, Lehmann et 
al., 2011). 
The process of nucleotide excision repair (NER, summarised in Figure 7) 
comprises two DNA repair pathways that are crucial for the removal of bulky 
lesions in DNA including photoproducts resulting from exposure to ultraviolet 
(UV) light. Transcription-coupled nucleotide excision repair (TC-NER) rapidly 
undertakes preferential repair of DNA lesions on actively transcribed DNA 
strands and is deficient in Cockayne syndrome and UV-sensitive syndrome 
(Cleaver, 2012). Global genome repair (GG-NER), removes photoproducts 
more slowly from across the genome and is deficient in xeroderma 
pigmentosum and trichothiodystrophy (Cleaver et al., 2009) 
There are 8 nucleotide excision repair-deficient complementation groups of 
xeroderma pigmentosum and trichothiodystrophy (TTD) (XP-A to G and TTD-
A). XP-C and XP-E are deficient only in GG-NER whereas the other groups are 
deficient in both TC-NER and GG-NER. There is a further xeroderma 
pigmentosum variant group that is not defective in nucleotide excision repair but 
has a defect in DNA polymerase  that is required for replication of UV-
damaged templates. A small number of patients have features of both 
xeroderma pigmentosum and Cockayne syndrome (xeroderma pigmentosum 
/Cockayne syndrome complex) and were found to harbour mutations in XPB, D, 
F or G. These patients have the dermatological and ocular findings 
characteristic of xeroderma pigmentosum and the neurological and 
developmental problems found in Cockayne syndrome (Kraemer et al., 2007, 
Lehmann et al., 2011). Genotype-phenotype correlations are observed, with 
XPD the best example where specific mutations are respectively associated   
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Figure 7: The process of nucleotide excision repair (NER). 
NER comprises two pathways, global-genome NER (GG-NER) and Transcription-Coupled NER (TC-
NER). In GG-NER, the XPC/hHR23 protein complex detects the DNA helix-distorting lesion. The XPE/UV–
DDB complex detects some less significant lesions not recognised by XPC/hHR23. TC-NER is initiated by 
the CSB protein, when RNA polymerase II progress is stalled by a distorting lesion in the template strand, 
and is later followed by the ERCC8/CSA gene product. In both GG-NER and TC-NER, TFIIH.recruitment 
follows lesion detection. The XPB and XPD helicases from the TFIIH complex unwind the DNA helix 
around the lesion. The complex is stabilised by XPG and XPA, which verify the lesion, and RPA which 
binds the opposite intact single-stranded DNA. The endonucleases XPG and ERCC1/XPF excise 3' and 5' 
of the lesion, respectively. This results in the excision of about 30 nucleotides encompassing the damaged 
DNA. PCNA plays a crucial role in the repair synthesis of the remaining single-strand gap. The nick is then 
ligated by DNA ligase I/III. This figure was adapted from (Diderich et al., 2011, Schumacher, 2009).  
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with xeroderma pigmentosum, xeroderma pigmentosum/Cockayne syndrome 
complex and trichothiodystrophy patients (Lehmann, 2001) 
After DNA damage is detected, both transcription-coupled nucleotide excision 
repair and global genome- nucleotide excision repair processes involve the 
excision of about 30 nucleotides encompassing the damaged DNA, this process 
requiring the xeroderma pigmentosum proteins to recognise (XPC, E), open up 
(XPB,D) and verify (XPA) the damaged site, and cleave the damaged strand on 
both the 5’ (XPF) and 3’ (XPG) sides. This is followed by repair synthesis of 
new DNA to replace the damaged section. Repair synthesis is absolutely 
dependent on the DNA polymerase accessory protein PCNA (Shivji et al., 
1992). This protein’s major cellular role is to recruit and retain the replicative 
DNA polymerases at the sites of DNA synthesis during DNA replication. It forms 
a homotrimeric ring encircling and freely sliding along the DNA helix. PCNA 
interacts with a large number of accessory proteins and acts as a protein 
recruitment platform to coordinate the multiple enzymatic activities that are 
required for DNA replication and repair (Moldovan et al., 2007).  
Due to the large size of its genome, eukaryotic DNA replication is initiated at 
numerous sites called replication origins. Licensing is a crucial step in the 
initiation of DNA replication, because it determines which origins of replication 
may be used (Blow and Dutta, 2005, Diffley, 2004). After licensing, the origin is 
activated in the S-phase of the cell cycle, to generate a replication fork. PCNA is 
present at the core of the replication fork and is required to tether and stimulate 
the processivity of the replicative polymerases on the DNA. Due to the 
antiparallel nature of DNA, replications of the two parental strands are by 
different mechanisms, named the leading and lagging strand. First the DNA is 
unwound by the helicase, the parental strand is replicated in the 5’-3’ direction 
in a continuous manner (same direction as the helicase) and is known as the 
leading strand. Polymerases cannot synthesis DNA in the 3’-5’ direction, thus 
the second strand which would need to be replicated in that direction is 
synthesised discontinuously in the form of short fragments in the 5’-3’ direction 
in order to overcome this problem. These fragments are called Okazaki 
fragments and the replicated strand is called the lagging strand (Tsurimoto and 
Stillman, 1991). Fen1 and Lig1 play an important part in Okazaki fragment 
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maturation and carry out their functions by interacting with PCNA. During 
lagging strand synthesis when the replicative polymerase reaches the end of a 
previous Okazaki fragment it displaces it generating a flap structure, this is then 
cleaved by Fen1 and the resulting nick sealed by Lig1 (Moldovan et al., 2007). 
An overview of the processes occurring at the replication fork is shown in Figure 
8.  
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Figure 8:Simplified overview of events occurring at the replication fork 
Once activated, the helicase moves along the replication fork unwinding the DNA. The clamp loader RFC, 
loads PCNA onto the primer template junction where it binds the replicative polymerases. Pol ε 
continuously synthesises DNA as the leading strand, and Pol δ synthesises DNA discontinuously as 
Okazaki fragments (lagging strand). The replication fork associated proteins Fen1 and Lig1 play an 
important role in the fragment maturation process during DNA replication. Additional proteins involved in 
chromatin maturation perform their functions during progression of the fork.  
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3.3 Methods 
3.3.1 Exome sequencing 
Whole exome sequencing was performed by the Otogenetics Corporation using 
the SureSelect Human All Exon V4 (Agilent Technologies) exome enrichment 
kit on an Illumina HiSeq2000. The exome sequencing produced 31,783,299 
mapped reads, corresponding to 93% of targeted sequences covered 
sufficiently for variant calling (>10X coverage, mean depth 45X). 
The fastq files were subsequently obtained from Otogenetics, BWA was used to 
align reads to the reference genome. SAM format was converted to binary SAM 
format (BAM). Duplicate reads were excluded. Variants were called using GATK 
UnifedGenotyper and subsequently quality filtered based on parameters 
including: mapping quality, strand bias, the average position of a variant in a 
read and SNP quality. The VCF file was annotated using the Alamut Software 
Suite (Interactive Biosoftware). Support for analysis of exome sequencing data 
was provided by Dr Barry Chioza and Dr Michael Weedon, based at the 
University of Exeter. 
3.3.2 Functional studies 
Functional studies were carried out in collaboration with Dr Catherine Green 
based at Cambridge University and subsequently at the Wellcome Trust Human 
Genetics Unit in Oxford. The aim of these studies was to ascertain whether the 
PCNA mutation disrupted the function of PCNA protein. These studies were 
carried out working closely with Dr Catherine Green and Dr Helen Chambers, a 
post-doctoral research fellow from the Green laboratory. Where specific 
experiments were performed solely by Dr Green or Dr Chambers this is 
mentioned in the figure legends. 
Assays assessing fibroblast responses to UV were carried out in collaboration 
with Professor Alan Lehmann, (Genome Damage and Stability Centre, 
University of Sussex and Professor Tomoo Ogi (Nagasaki University Research 
Centre for Genomic Instability and Carcinogenesis).  
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Exclusion of Ataxia Telangiectasia in the affected individuals was carried out in 
collaboration with Professor Alexander Malcolm Taylor based at the School of 
Cancer Sciences, University of Birmingham. Chromosome breakage studies 
were performed by GSTS Pathology, and karyotyping was performed at South 
West Thames Genetics Laboratory. 
  
 106 
3.4 Results 
3.4.1 Phenotype of Amish individuals with a previously unrecognised 
DNA repair disorder 
Four affected individuals aged between 11-31 years affected by a novel 
syndrome, were identified from a single extended pedigree comprising two 
kindreds within the Ohio Amish community (Figure 9). The principal features 
include neurodegeneration, postnatal growth retardation, prelingual 
sensorineural hearing loss, premature aging, ocular and cutaneous 
telangiectasia, learning difficulties, photophobia and photosensitivity with 
evidence of a predisposition to sun-induced malignancy. Phenotypic similarities 
with xeroderma pigmentosum, Cockayne syndrome and ataxia telangiectasia 
were noted (Table 11). All four affected individuals displayed short stature 
ranging from -3.8 to -5.2 SDS, with an absence of pubertal growth spurt in the 
two eldest individuals. Neurodegeneration was a consistent feature, 
characterised by progressive gait instability, muscle weakness, foot deformity, 
difficulties with speech and swallowing, learning difficulties and cognitive 
decline with advancing age. Prelingual onset of moderate to profound (worse at 
high frequency) sensorineural hearing loss was universal, a feature not 
commonly associated with the recognised DNA repair defects, and there was 
clear evidence of progression in VI:9. Muscle weakness was progressive (VI:6 
has been wheelchair bound since the age of 16 years with contractures in all 4 
limbs). Speech was unclear from onset and deteriorated with age (VI:6 currently 
has no speech and communicates with basic gestures). Progressive difficulty 
with swallowing solids/drooling was present in 3/4 affected subjects. 
Neuroimaging was only available in one case (VI:7) Magnetic resonance 
imaging of the brain aged eight years demonstrated cerebellar atrophy involving 
the cerebellar vermis and hemispheres. Inner ear abnormalities included 
bilateral mild labyrinthine dysplasia with mildly dilated vestibules.  
All affected individuals exhibited photophobia and photosensitivity, with 
evidence of premalignant changes in VI:11 (basal cell carcinoma in situ).  All 
have several cutaneous telangiectasias and 3/4 have conjunctival 
telangiectasia. Telangiectasia were not present from birth, but became apparent 
during early childhood. Images of affected individuals are shown in Figure 10. 
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Figure 9: Family pedigree showing PCNA c.683G>T genotype data. 
(A) simplified pedigree of the extended Amish family investigated, with pictorial representation of 
genotypes across ~6Mb of chromosome 20 encompassing the disease locus (2.7Mb autozygous section 
in affected females indicated by blue hashed box, and the common 0.78Mb region indicated by red box). 
All affected individuals were subsequently shown to be homozygous for the PCNA (NM_002592.2 
c.683G>T) variant (indicated). Parental samples were heterozygous and unaffected siblings were either 
wild type or heterozygous carriers. The genotype is shown in red under individuals in generations V and 
VI, with (+) denoting mutant and (-) wild type. (B) Electropherograms showing the DNA sequence at the 
position of the (NM_002592.2 c.683G>T) PCNA variant in a wild-type control, and homozygous affected 
individual. 
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Figure 10: Images of affected individuals homozygous for PCNA c.683G>T 
(A-H) The clinical features of individuals homozygous for PCNA c.683G>T. Individual VI:6 aged 8 years 
(A) and 31 years (B) showing signs of premature aging. (C) Individual VI:7 aged 11 years with bilateral 
hearing aids insitu. (D) Midline sagittal T1-weighted brain scan (individual VI:9 aged 8 years). There is 
atrophy of the cerebellar vermis resulting in enlargement of vermian sulci and mild widening of the fourth 
ventricle. The brainstem is normal in appearance and no supratentorial abnormality is shown. (E and F) 
Ocular and cutaneous telangiectasia (Individuals VI:7 and VI:11). (G) Pes Cavus (Individual VI:11). (H) 
Photosensitivity after minimal sun exposure (individual VI:11). 
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Table 11: A comparison of the clinical findings of individuals homozygous for PCNAc.683G>T and features of ataxia telangiectasia, Cockayne syndrome and the 
neurological form of xeroderma pigmentosum. 
 
Abbreviations: *, not possible to obtain accurate measurement; N/K, not known; ( ), indicates presence of a feature in an affected subject; (++), indicates traits that are hallmarks of the disease; (+), indicates  traits that 
are sometimes associated; (-), indicates traits that are absent or not associated, 
§ 
; aided, but not cognitive impairment prevented accurate assessment of severity,
 a 
; about 25% of XP patients (from groups A, D, F and 
G) have neurological abnormalities (the information in the table applies to the neurological form of the disorder). 
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3.4.2 Identification of a potentially pathogenic variant in PCNA 
3.4.2.1 Autozygosity mapping reveals a single notable autozygous 
region on chromosome 20p13 in affected individuals. 
Assuming that a founder mutation was responsible for the condition, we used a 
combination of autozygosity mapping and linkage analysis in order to study this 
novel syndrome and identify the underlying molecular cause. 
A genome-wide SNP microarray scan of DNA from affected individuals, 
unaffected siblings and parents was undertaken using Illumina Human 
CytoSNP-12v2.1 330K arrays. Inspection of the resultant genotypes identified a 
single notable region of homozygosity of ~2.72Mb on chromosome 20p13, 
shared solely by the three affected females. In the affected male, a de novo 
telomeric recombination event reduced this region to ~0.77Mb, delimited by 
markers rs404678 and rs6139841, NC_000020.10:g.5024237-5792923 (Figure 
9), likely to correspond to the disease locus and containing 13 genes, 3 of 
which are pseudogenes, 3 hypothetical proteins and 1 antisense RNA. 
Microsatellite marker analysis confirmed autozygosity across this region. 
Multipoint linkage analysis was performed with MERLIN (Abecasis and 
Wigginton, 2005) under a model of autosomal-recessive inheritance with full 
penetrance, assuming a disease allele frequency of 0.0001 which gave a 
LODmax of 6.4 for the putative disease locus. 
All six protein coding genes in the region were sequenced: PCNA, CDS2, 
PROKR2, GPCPD1, C20orf30 and C20orf196 (for primer sequences see 
appendix), revealing only a single potentially pathogenic sequence variant 
(NM_002592.2 c.683G>T) in exon 6 of PCNA. This variant, which cosegregated 
with the disease phenotype and was verified in the RNA transcript obtained 
from whole blood of an affected individual (VI:11), is predicted to result in a 
substitution of a stringently conserved serine at position 228 for isoleucine 
(p.Ser228Ile) (Figure 11). 
The variant was not detected in 360 control chromosomes of European 
ancestry and only two heterozygous carriers were detected in the analysis of 
310 Ohio Amish control chromosomes, which is not unexpected in this  
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Figure 11: Conservation of Ser228. 
A ClustalW2 alignment of amino acid sequences of PCNA in Homo sapiens and 9 other species, 
illustrating stringent conservation of the Ser228 residue, indicated with the red arrow (created using 
Jalview software). 
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endogamous community. Only a single heterozygous carrier of European origin 
was identified in online sequencing project databases (1000 genomes project 
and the Exome Variant Server, ESP6500SI release). This single mutation 
carrier in 7775 non-Amish individuals genotyped corresponds to a homozygous 
PCNA c.683T allele incidence in the region of ~1:241 million. 
3.4.2.2 Other possible genetic causes of the phenotype are 
comprehensively excluded using a combination of genetic and 
functional studies. 
Given that the phenotype of the affected individuals studied here has significant 
overlap with other DNA repair disorders, DNA from a single affected individual 
was subjected to whole exome sequence analysis to exclude other possible 
genetic causes.  
As expected this confirmed the presence of the PCNA variant but identified no 
other known or possible pathogenic variants elsewhere after excluding variants 
not compatible with recessive inheritance or cosegregating with the disease 
phenotype. The most significant phenotypic overlap was with ataxia 
telangiectasia and as such, further conclusive support for the exclusion of this 
diagnosis as well as “ataxia telangiectasia-like” disorders was sought. The 
typical γ-ray-induced chromosome breakage associated with ataxia 
telangiectasia was investigated in two of the affected individuals. Analysis of a 
peripheral blood sample from VI:11 and a primary fibroblast sample from (VI:7) 
revealed normal chromosomes (untreated or γ-ray-induced). Alpha fetoprotein 
levels are typically raised in ataxia telangiectasia and immunoglobulin patterns 
abnormal with often a specific reduction in IgA levels (Perlman et al., 2003) both 
were found to be within normal limits for age in samples obtained from VI:7 and 
9. Epstein-Barr virus (EBV) transformed lymphoblastoid cell lines were 
established from affected subjects VI:6 and VI:11. ATM and associated protein 
and kinase activity levels were measured in the two lymphoblastoid cells and 
found to be normal (Appendix). Taken together, these data provide robust and 
multi-layer exclusion of a diagnosis of ataxia telangiectasia. An increased 
number of sister chromatid exchanges after incubation with BrdU is observed in 
patients with Bloom syndrome who have a deficiency of the BLM RecQ DNA 
helicase a protein involved in several aspects of DNA repair and recombination. 
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No increase in sister chromatid exchanges was observed in peripheral blood 
lymphocyte’s derived from individual VI:13, implying no gross disturbance of this 
pathway.  
3.4.3 Functional studies of PCNA p.Ser228Ile 
3.4.3.1 Crystal structure analysis and in-silico modelling of the PCNA 
p.Ser228Ile variant 
Insilico analysis programs Polyphen-2 (HumVar), PROVEAN, SIFT and 
Mutation Taster were used to predict the possible impact of the p.Ser228Ile 
amino acid substitution on the structure and function of PCNA (Table 12). All 
but SIFT predicted that the variant was likely to be damaging. 
Table 12: Insilico prediction of the possible impact of the p.Ser228Ile substitution on the 
structure and function of the human PCNA protein. 
Insilico prediction tool 
Predicted pathogenicity of PCNA 
p.Ser228Ile variant 
Polyphen-2 (HumVar) Possibly Damaging 
PROVEAN Deleterious 
SIFT Tolerated 
Mutation Taster Disease causing 
 
PCNA is a member of the family of DNA sliding clamps and is an essential DNA 
replication accessory protein, highly conserved throughout evolution. 
Mammalian PCNA was initially identified as a cell-cycle dependent antigen, 
hence the name (Miyachi et al., 1978). Eukaryotic PCNA is a homotrimer 
comprised of three identical monomers containing two domains that can bind to 
each other in a head-to tail fashion to form a ring-shaped molecule that is 
loaded around the DNA (Krishna et al., 1994) (Figure 12). As described above, 
PCNA plays a central role at the replication fork, recruiting and retaining many 
of the enzymes required for DNA replication (Moldovan et al., 2007). Due to its 
fundamentally important cellular role, mutations that significantly affect PCNA   
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Figure 12: Crystal structure of human PCNA (PDP ID:1VYM, Kontopidis G et al. 2005). 
PCNA forms a homotrimeric ring structrure. The three monomers (coloured green, pink and blue) are 
identical to each other and are arranged in a head-to-tail fashion. Each of the monomers are made up of 
two similar globular domains connected by an interdomain connector loop (IDCL). This image was 
rendered using FirstGlance in Jmol. 
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protein function would be predicted to result in embryonic lethality. However the 
survival of PCNALys164Arg/Lys164Arg knock-in mice, generated to determine the role 
of PCNALys164 modifications in somatic hypermutation, demonstrates that certain 
hypomorphic mutations of PCNA can be tolerated in mammals (Langerak et al., 
2007). No inherited human disorder arising from PCNA mutation has been 
described previously. 
3.4.3.2 The PCNA p.Ser228Ile mutation does not have any significant 
effect on PCNA protein stability 
EBV-transformed lymphoblastoid cells (L-) were established from 2 
heterozygous carriers (L8 and L10), and 2 Amish WT controls (L7 and L9). 
The Ser228 residue affected by the c.683G>T sequence alteration is distant 
from the regions of PCNA that mediate the formation of the trimeric ring 
structure (Gulbis et al., 1996), thus we hypothesised that protein stability would 
be unaffected by the Ser228Ile mutation. To investigate this further, extracts 
were prepared from lymphoblastoid cells derived from affected, heterozygous 
and WT individuals. Equal numbers of cells from each different cell line were 
lysed. Western blot analysis of PCNA detected using mouse monoclonal anti-
PCNA antibody (PC10) did not reveal any difference between the levels of 
endogenous PCNA in the different cell lines. (Figure 13). 
3.4.3.3 Cells from individuals homozygous for PCNA p.Ser228Ile show 
increased sensitivity to UV irradiation 
 Primary fibroblasts (P-) were established from 3 affected individuals, patients 
VI:11, VI:9, and VI:7 (P1, P2, and P3, respectively), 2 heterozygous carriers 
(Het1 and Het2), and wild type (WT) controls. 
The reported photosensitivity in p.Ser228Ile homozygotes prompted us to 
examine the effect of the p.Ser228Ile substitution on cellular sensitivity to UV. 
Primary fibroblast line P3 cellular sensitivity to UV was compared to that of a 
WT cell line. Cell survival was measured by colony forming ability after 
exposure to doses of UV between 0-12 J/m2. (Figure 14A). P3 cells showed 
increased sensitivity to UV, most noticeable at higher levels of exposure.  
 116 
 
 
Figure 13: PCNA protein levels are not affected by the Ser228Ile alteration. 
Extracts from lymphoblastoid cell lines derived from affected individuals, PCNA p.Ser228Ile heterozygous 
family members, and unrelated WT Amish controls were analysed by Western blot for PCNA. β-actin was 
included as a loading control. Levels of PCNA in affected individuals were indistinguishable from those of 
heterozygotes or WT controls. 
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Figure 14: Abnormal cellular responses to UV. 
(A) Primary fibroblasts from an affected individual are sensitive to UV. Cell survival was measured by 
colony-forming ability following exposure to the indicated doses of UVC. (B) Lymphoblastoid cells from two 
different affected individuals are sensitive to UV. Viable cells were counted 72hrs after exposure to UVC 
using trypan blue exclusion. (C) Cells from affected individuals have reduced Unscheduled DNA synthesis 
(UDS). UDS activity was measured by incorporation of radiolabelled thymidine immediately after UV-
irradiation of non-dividing cells with the indicated doses of UVC. (D) RNA synthesis measured by the 
incorporation of radiolabelled uridine 24hrs after UVC-irradiation of non-dividing cells with indicated doses. 
The reference line in grey shows a typical response of cells from a Cockayne syndrome (CS) patient. (E) 
Defective RNA synthesis recovery (RRS) is complemented by lentiviral transduction of primary patient 
fibroblasts with wild-type PCNA. RRS was measured using EdU incorporation and automated high content 
microscopy in cells expressing high levels of ectopic PCNA. Values plotted are mean and range of 2 
experiments (A) or mean +/- SEM of 3 (B-D) or 4 (E) experiments. Data shown in A, C and D, courtesy of 
Professor Alan Lehmann, Mr Jon Wing and Ms Heather Fawcett, University of Sussex. Data in E was 
provided by Professor Tomoo Ogi, Nagasaki University. 
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Primary fibroblast cell lines have only limited viability in culture, in addition to 
this we had difficulties growing fibroblasts from affected individuals in the 
colonies required for the UV survival assay. In order to maintain these precious 
resources for assays where they are the only suitable cell type easily 
obtainable, we sought to optimise an assay for UV survival in lymphoblastoid 
cell lines. Initial attempts involved an assay using a WT lymphoblastoid cell line 
in 96 well plates. Ideally a dilution where half of the wells in each dish show 
growth at 7 days (p0 method) would be identified in order to ascertain an 
accurate plating efficiency. Lymphoblastoid cells grow in clumps when observed 
in culture and as such would only grow at very high cell densities of at least 500 
cells per well. Next cells were cultured in U bottomed 96 well plates, in which 
they grew at much lower densities of 10 cells per well. 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium 
(MTT) reduction assay is commonly used to assess cell viability. Live cells are 
capable of reducing MTT 3-diphenyltetrazolium bromide to its insoluble 
formazan, which has a purple color, when cells die they lose this capability 
(Riss et al., 2004). This assay is quite straightforward using fibroblasts. Given 
their relatively large size, it is possible to count the number of cells that are 
viable (contain purple formazan crystals) by eye using a light microscope. Due 
to the small size of the lymphoblastoid cells and their propensity to grow in 
clumps, cells could not be counted in this way. The MTT assay can be 
performed by lysing the cells and measuring changes in absorbance using a 
plate reading spectrophotometer. Unfortunately the spectrophotometer was not 
designed for U bottomed 96 well plates and we were concerned about the 
accuracy of the assay if we were to transfer the cells to a flat bottomed plate. 
Given that quite significant differences in UV sensitivity between cells derived 
from affected individuals and WT cell lines was expected, we next proceeded to 
use a less sensitive assay. Equal number of L5, L6 and WT (L7) lymphoblastoid 
cells were irradiated in PBS and then cultured as normal for 72 hrs, the number 
of viable cells for each cell line was determined by tryphan blue exclusion after 
the recovery period. Similar to the results seen when comparing UV survival in 
fibroblasts from affected individuals to those of WT controls, a significantly 
increased sensitivity to UV irradiation in cells homozygous for PCNA 
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p.Ser228Ile was observed, suggesting that the mutation specifically impairs the 
function of PCNA in DNA repair (Figure 14B). 
3.4.3.4 The PCNA p.Ser228Ile mutation causes a defect in nucleotide 
excision repair 
Repair synthesis and downstream events of nucleotide excision repair are 
absolutely dependent on PCNA (Shivji et al., 1992). To investigate this aspect 
further, we evaluated global genome-nucleotide excision repair which 
contributes to ∼90% of nucleotide excision repair activity, and is, termed 
unscheduled DNA synthesis (UDS). The unscheduled DNA synthesis assay 
measures the repair synthesis step of nucleotide excision repair and is 
standardly used for detecting defects in response to UV irradiation in xeroderma 
pigmentosum patients. Replicative DNA synthesis is abolished by using non-
dividing cells and the DNA replication inhibitor hydroxyurea. Cells were serum 
starved then incubated for 1 hr with hydroxyurea, UV irradiated and incubated 
for a further 3hrs with radiolabelled thymidine and hydroxyurea. Radiolabelled 
thymidine incorporation into repair patches was measured by liquid scintillation 
counting (Lehmann and Stevens, 1980). In primary fibroblast cells from affected 
individuals unscheduled DNA synthesis was reproducibly reduced to 
approximately 50-60% of normal values (Figure 14C). 
RNA synthesis recovery levels following UV radiation (RRS) are used as a 
marker of transcription-coupled repair (Mayne and Lehmann, 1982). Cells are 
UV-irradiated and 24hrs later RNA synthesis is measured by incorporation of 
uridine. This assay is standardly used as a measure of transcription-coupled 
repair which is deficient in Cockayne syndrome. The assay is done in serum 
starved non-proliferating cells, so is not associated with defects in DNA 
replication. RNA synthesis recovery was significantly decreased, to 
approximately 30-50% of normal in cells from affected individuals (Figure 14D, 
Appendix Figure). The deficiency approaches that of Cockayne syndrome cells, 
known to be defective in transcription-coupled nucleotide excision repair.  
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3.4.3.5 The deficient UV responses are due to the PCNA p.Ser228Ile 
sequence alteration 
In order to demonstrate that the observed cellular defects in nucleotide excision 
repair were due to the PCNA p.Ser228Ile sequence alteration, we sought to 
recapitulate the defect in MRC5 human fibroblasts by generating cell lines 
stably expressing His-tagged PCNA, either wild-type or mutated at Serine-228, 
at levels similar to those of endogenous PCNA and then knocking down the 
endogenous protein using small interfering RNA (siRNA). Given that responses 
to UV irradiation in cells heterozygous for PCNA p.Ser228Ile were 
indistinguishable from WT controls, it was difficult to predict to what extent 
endogenous PCNA would need to be knock down in order to recapitulate the 
defect seen in cells from affected individuals. Sustained knockdown of PCNA 
using small interfering siRNA approaches is complicated by the abundance and 
stability of the protein.  
Niimi et al. had previously optimised such an assay to demonstrate substantial 
UV sensitivity in cells expressing PCNA p.Lys164Arg. Depletion such that >80% 
of the PCNA expressed in the cells was from the transfected cDNA was 
achieved (Niimi et al., 2008). 
The His-tagged PCNA construct used in the PCNA p.Lys164Arg work, 
contained silent mutations to make it refractory to targeting by siRNA directed 
against endogenous PCNA. PCNA p.Ser228Ile mutant construct was generated 
from this siRNA resistant construct by site directed mutagenesis (primer 
sequences in Appendix). WT and Ser228Ile expression vectors were 
transfected into human MRC5 fibroblast cells. Cells were then grown in the 
presence of the selection antibiotic G418 at a concentration of 900µg/ml. 
Individual G418 resistant colonies were picked and expanded. When analysed 
by western blotting, none of the clones were expressing detectable levels of 
either WT or Ser228Ile His-tagged PCNA.  Advice was sought from Dr Atsuko 
Niimi who had carried out the PCNA p.Lys164Arg work. Dr Niimi had had 
similar difficulties obtaining sufficient levels of stably expressed His-tagged 
PCNA, and had found that using a higher concentration of G418 (1200µg/ml) in 
the cloning step was critical. Increasing the concentration of G418 as advised, 
we were able to produce MRC5 clones expressing siRNA-resistant His-tagged   
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Figure 15: MRC5 cell clones stably expressing His-PCNA 
MRC5 cell clones expressing (A) His-tagged siRNA resistant WT PCNA or (B) His-tagged siRNA resistant 
PCNA p.Ser228Ile were analysed by Western blot for PCNA. Similar expression levels of endogenous and 
His-tagged WT PCNA were seen. PCNA p.Ser228Ile was expressed, but only at much lower levels than 
the endogenous WT protein. Membrane exposures after 1sec and 8secs are shown. (C) Shows partial 
siRNA depletion of endogenous PCNA in MRC5 cells stably expressing His tagged siRNA resistant WT 
PCNA, levels were unaffected in cells either mock transfected or treated with non-specific control siRNA. 
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WT PCNA at levels similar to the levels of endogenous PCNA. However only 
very low levels of siRNA-resistant His-tagged Ser228Ile PCNA expression were 
seen after western blot analysis of large numbers of clones (Figure 15). 
Previously we had only sequenced verified successful Ser228Ile mutagenesis 
and the presence of the sequence alterations rendering the PCNA siRNA-
resistant. Consequently, a mutation elsewhere in the construct perhaps in the 
promotor region could be affecting His-tagged PCNA p.Ser228Ile expression. 
Sequencing primers were therefore designed and the integrity of the entire 
construct sequence was confirmed eliminating this as an explanation. However 
it remains a possibility, that although there were no detectable differences in 
trimer formation or stability between PCNA p.Ser228Ile and WT PCNA, there 
may be subtle variations, which might account for the poor expression levels of 
His-tagged PCNA p.Ser228Ile. The final amount (steady state) of PCNA 
p.Ser228Ile that is found in the cells of affected individuals appears to be 
approximately the same as the WT PCNA protein in WT individuals. However, 
the relative stability of the two PCNA proteins in heterozygotes is unknown. It 
remains a possibility that the p.Ser228Ile protein has a faster rate of synthesis 
and degradation than the WT equivalent. Thus, if it is absolute levels of PCNA 
protein that are monitored by the cell, the p.Ser228Ile protein might be at an 
expression disadvantage.  
In parallel to this attempts were made to optimise siRNA depletion of 
endogenous PCNA in an MRC5 cell clone stably expressing siRNA-resistant 
His-tagged WT PCNA. Cells were either mock-transfected, treated with 10nM 
non-specific control siRNA or 10nM PCNA-specific siRNA. The PCNA-specific 
siRNA did deplete the endogenous PCNA but not at levels that would be 
sufficient enough to enable us to assess whether UV-sensitivity is increased as 
a result of the Ser228Ile alteration. It would be possible to treat the cells with 
higher doses of the siRNA. However given that we were unable to generate 
clones expressing siRNA-resistant His-tagged PCNA p.Ser228Ile at levels 
approaching endogenous PCNA levels, we were unlikely to ever achieve 
experimental conditions suitable to assess whether the PCNA p.Ser228Ile was 
responsible for the abnormal responses to UV irradiation observed in cells from 
affected individuals. 
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In order to demonstrate that the PCNA p.Ser228Ile was responsible for the 
increased UV sensitivity observed, we next attempted to complement the 
defective recovery of RNA synthesis by lentiviral transduction of WT PCNA into 
primary cell lines from affected individuals. WT PCNA fully rescued the recovery 
of RNA synthesis deficiency in cells from affected individuals (Figure 14E), 
whereas such expression had only a minor effect on recovery of RNA synthesis 
in normal fibroblasts (Appendix Figure). This provides important conclusive 
verification that the deficient UV responses are caused by the p.Ser228Ile 
sequence alteration. 
3.4.3.6 The PCNA p.Ser228Ile alteration has no effect on DNA 
replication 
The most well recognised function of the DNA sliding clamp PCNA is the 
fundamental role that it plays in DNA replication, forming a homotrimeric ring 
that encircles DNA and can slide freely along it acting as a processivity factor 
for DNA polymerases. Given this and the generally poor growth exhibited by the 
affected individuals, parameters of DNA replication were next investigated. 
5-Bromo-2´-Deoxyuridine (BrdU) is an analogue of the DNA precursor 
thymidine and as such is incorporated into newly synthesized DNA by cells 
entering and progressing through the S-phase of the cell cycle. When coupled 
with a DNA stain such as propidium iodide (PI) or &-aminoactinomycin D (7-
AAD), BrdU staining permits enumeration and characterisation of cells that are 
actively synthesising DNA in terms of their cell cycle position (G0/1, S, G2/M 
phase). In order to assess the influence of the p.Ser228Ile alteration on DNA 
replication we incubated asynchronously growing primary fibroblast cells (at < 
passage 10) with BrdU for 30mins and analysed the incorporation (stained with 
anti-BrdU fluorescent antibodies) and DNA content by Fluorescence Activated 
Cell Sorting (FACS) (Figure 16). No apparent differences in cell cycle profile or 
progression through S-phase were observed when comparing the fibroblasts 
from affected individuals, with related heterozygote and unrelated WT controls.  
During S phase, PCNA is recruited to so called “DNA replication factories”, 
which are the sites of nucleotide incorporation and are visible as foci in the 
nuclei of replicating cells. Immunofluorescence analysis of endogenous PCNA 
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in fibroblasts from affected individuals revealed no abnormalities in these foci 
(Figure 17). In addition, no difference in replication fork rate was detected 
during unperturbed S phase using DNA fibre analysis (Figure 18). Taken 
together, these data suggest that the Ser228Ile variant does not dramatically 
interfere with the major replicative function of PCNA and that bulk DNA 
replication is not grossly perturbed. 
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Figure 16: Cells homozygous for PCNA p.Ser228Ile have normal replication parameters. 
(A) FACS analysis of S phase in primary cells. Cells at passage number 10 or less were labelled with 
BrdU for 30mins and BrdU incorporation and DNA content analysed by FACS. No significant differences 
were observed between cells from affected individuals (P1, P3) and related (Het1) or unrelated (WT) 
control cells. Representative scatter plots are shown, each line was independently analysed at least twice. 
(B) FACS analysis of DNA content in asynchronously growing primary cells. Cellular DNA was stained with 
7-AAD; accordingly, DNA content is represented by 7-AAD intensity. A G1 peak, representing cells with 2N 
DNA content, and a G2/M peak, representing cells that have undergone replication and therefore possess 
a 4N DNA content, are labelled. The area between these two peaks is representative of cells in S phase. 
Typically 60% of cells are seen to be in G1 and 20% in each of S and G2/M phases.  No significant 
differences were observed between the cell cycle profiles of affected individuals and WT controls, each 
line was independently analysed at least twice. 
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Figure 17: Cells homozygous for PCNA p.Ser228Ile have normal replication factories 
Immunofluorescence of primary control fibroblast cells (WT) and fibroblast cells from affected individuals 
homozygous for PCNA p.Ser228Ile (P2 and P3). Soluble proteins were removed by triton extraction prior 
to fixation, and cells were immunostained for PCNA (right hand panel). The centre panel shows sites of 
active DNA replication, visible as foci of incorporation of EdU (5-ethynyl-2´-deoxyuridine), a nucleoside 
analogue, into the DNA. Enlargement shows colocalisation between these signals and reveals no notable 
differences between the individuals investigated. DNA throughout the nucleus was counterstained with 
DAPI (left hand panel). Data courtesy of Dr Helen Chambers, University of Cambridge. 
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Figure 18: Cells homozygous for PCNA p.Ser228Ile have normal replication fork rates 
Analysis of replication fork progression. Primary control cells and Cockayne syndrome cells (WT and CS) 
and cells homozygous for PCNA p.Ser228Ile (P2 and P3) were incubated sequentially in medium 
supplemented with IdU (5-iodo-2’-deoxyuridine) and CldU (5-chloro-2’-deoxyuridine), and the length of the 
DNA fibre replicated during each pulse measured. Comparable lengths of DNA were replicated during 
each pulse (top panel, compare light grey [IdU] and dark grey [CldU] bars for each cell line). The frequency 
distribution of the ratio of IdU/CldU within each fibre was similar between cell lines (bottom panel). The 
error bars indicate SEM of two experiments. Data courtesy of Dr Catherine Green, University of Oxford.  
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3.4.3.7 Specific PCNA interactions are perturbed by the Ser228Ile 
mutation  
Serine 228 lies near the external face of PCNA and the mutation is therefore 
unlikely to affect its interaction with DNA (Figure 19). Interestingly however, the 
altered residue is close to the inter-domain connecting loop (IDCL) region which 
mediates the interaction of PCNA with many of its protein partners. PCNA 
partner proteins, including DNA polymerase delta (PolD), DNA Ligase 1 (Lig1) 
and Flap endonuclease 1 (Fen1), often contain a PCNA interacting protein 
(PIP) box, a sequence motif (Gln xx [Leu or Ile or Met] xx [Phe or Try][Phe or 
Try]) which mediates the inter-domain connecting loop interaction (Figure 20) 
(Warbrick, 1998). The crucial amino acids on PCNA that directly contact the PIP 
box residues are Met119 to Pro129, but other regions of PCNA either side of 
the inter-domain connecting loop are also implicated in binding events. In 
published crystal structures serine 228 does not directly contact the PIP box-
containing peptide (Gulbis et al., 1996, Bruning and Shamoo, 2004), although 
it’s close proximity to this crucial interaction region may generate subtle 
positional alterations within this crucial domain, with functional consequences. 
To determine whether specific protein interactions are perturbed by the 
p.Ser228Ile alteration, a SILAC (stable isotope labelling by amino acids in 
culture) affinity purification assay was performed. Extracts were made from 
HeLa cells grown in either normal medium, or SILAC medium containing 
“heavy” amino acids: [13C6/
15N2] lysine and [
13C6/
15N4] arginine. These extracts 
were individually exposed to affinity columns comprising recombinant PCNA, 
either WT or PCNA p.Ser228Ile. Proteins that bound to each column were 
eluted, the eluates combined, and the relative binding to each column was 
determined by mass spectrometry (for more detailed methodology please see 
Appendix). This identified clear perturbations in the interaction of PCNA 
p.Ser228Ile with a limited number of interacting partners, most strikingly with 
Fen1 and Lig1 (Figure 21A, Appendix Table). This experiment revealed 
relatively increased amounts of Fen1 and Lig1 in the 500mM eluates from the   
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Figure 19: The Ser228 residue of PCNA lies close to the Interdomain connector loop.  
The PCNA homotrimer from the front (left panel) and side (right panel), with Ser228 highlighted in magenta 
and the interdomain connector loop highlighted in cyan. Generated using POLYVIEW-3D (Porollo and 
Meller, 2007), based on the 1YM crystal structure, rendered using PyMol. 
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Figure 20: PCNA-binding proteins.  
PCNA interacts directly with a host of proteins involved in many different cellular processes. Listed are a selection of key PCNA-dependent activities and the corresponding PCNA-interacting 
proteins. Proteins in orange are known to contain PIP-box sequences, which bind to a groove in PCNA (orange) buried underneath the interdomain connector loop. Taken with permission from 
(Moldovan et al., 2007) 
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Figure 21: Perturbed PCNA interactions resulting from the p.Ser228Ile mutation. 
(A) The PCNA Graphical representation of SILAC-based comparative PCNA-interaction analyses. Lysine 
[
13
C6/
15
N2] and arginine [
13
C6/
15
N4] labelled (H), or unlabelled (L), cell extracts were purified over either wild 
type (WT) PCNA or p.Ser228Ile PCNA
 
affinity columns and eluted proteins were analysed by mass 
spectrometry. Each point represents a protein present in 3/3 experiments. X and Y axis positions are the 
H:L ratios of each protein in experiments performed in the forward or reverse directions, respectively. 
Highlighted in blue are known PCNA interacting proteins (Appendix Table). Proteins of particular interest 
are labelled by name. Data shown in A is courtesy of Dr Helen Chambers. (B) A pull down experiment in 
which recombinant His-PCNA (WT or p.Ser228Ile) was added to HeLa cell extracts and proteins bound to 
nickel-NTA. The resin was washed with up to 500mM NaCl and then proteins eluted at 1M NaCl or 
retained on the beads were analysed by western blot for Fen1. 
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PCNA p.Ser228Ile column, when compared to the WT column, suggesting that 
the mutant protein bound more tightly to these partner proteins. 
To investigate this unexpected finding further, the salt resistance of the PCNA-
Fen1 interaction was analysed. HeLa nuclear extract was incubated with His-
PCNA WT or p.Ser228Ile) beads, which were then washed with increasing NaCl 
up to 500mM. The material eluted at 1M NaCl and that which was retained on 
the beads was subsequently analysed by western blot for Fen1 (Figure 21B). 
This clearly demonstrates that the interaction between Fen1 and WT PCNA is 
much more resistant to high salt concentrations that the interaction between 
Fen1 and PCNA p.Ser228Ile. This leads us to conclude that in the SILAC 
experiments, Fen1 remained bound to the WT-PCNA column during the elution 
with 500mM NaCl, resulting in a dramatic reduction of this protein in the WT 
eluate. This conclusion, that the p.Ser228Ile change impairs the ability of PCNA 
to bind Fen1, was further validated by subsequent immunoprecipitation and 
GST pull down experiments (described below). 
3.4.3.8 Optimisation of an assay to assess the PCNA – Fen1 interaction 
In order to investigate the perturbed interaction between PCNA and Fen1 
further, attempts were made to examine the kinetics of this interaction using the 
phenomenon of surface plasmon resonance (SPR) via the Biacore system. 
Complete profiles of recognition, binding and dissociation can be generated in 
real time using this methodology. This allows data such as specificity, affinity, 
kinetic behaviour and sample concentration to be determined (Biacore, 1999) 
Recombinant His-tagged WT PCNA, PCNA p.Ser228Ile and PCNA IDCL* 
(PCNA interdomain connecting loop mutant, sequence alterations detailed in 
methods) were coupled to channels 2-4 of a CM5 chip. Recombinant N-
terminus His-tagged Fen1 (stock concentration 1.5mg/ml) was diluted 1/100 in 
HBS and run over the coupled PCNA, the binding in channel 1 was the same as 
the binding in the other channels. This was likely due to a problem with Fen1 
aggregation, given that precipitation of purified Fen1 protein solutions had been 
observed even at low concentrations, and as such a buffer that does not 
destabilise Fen1 was sought. The analysis was repeated diluting the Fen1 in 
PBS, with no improvement in the results. The next experiment used 
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recombinant Fen1 harbouring a sequence alterations that result in disruption of 
the Fen1 PIP box, completely abrogating it’s interaction with the interdomain 
connector loop of PCNA (Fen1 PIP*, sequence alterations detailed in methods). 
With this analysis, no binding of the Fen1 PIP* would be expected in any of the 
channels, however similar results were seen as with WT Fen1. 
The isolelectric point (pI) of Fen1 is unusually high at 8.7, which means that the 
protein is positively charged at a pH of <8.7. It was therefore highly likely that 
Fen1 was adhering non-specifically to the highly carboxymethyl dextran matrix 
on the chip as has been reported for other basic proteins (Myszka, 1999) 
However a further trial using TBS buffer pH8.5 did not result in any 
improvement.  
The only published SPR analysis of the PCNA – Fen1 interaction was carried 
out by Gomes and Burgers using recombinant yeast proteins (Gomes and 
Burgers, 2000). This analysis was carried out using recombinant yeast proteins 
as opposed to human. Interestingly, the authors had modified the standard SPR 
buffer by adding Inositol and MgCl2.  The Fen1 nuclease requires a divalent 
metal in its active site, absence of magnesium might destabilise protein folding. 
Inositol increases the hydrophobicity of the solution, so might stabilise proteins 
like Fen1 which have solvent exposed hydrophobic patches. Fen-1 was buffer 
exchanged into Gomes buffer, significant precipitation of Fen1 still occurred. 
Using the supernatant from this, the analysis was reattempted, however only 
non-specific binding of Fen1 to the chip was observed. 
The other modification made by Gomes and Burgers was to use a Pioneer chip 
B1 as opposed to the standard CM5 chip. The B1 chip has a lower charge 
density, and has been shown previously to profoundly reduce non-specific 
binding. The B1 chip is no longer manufactured, the Biacore representative 
suggested that the CM4 chip was similar to and had replaced the B1 chip. 
Using Gomes buffer and the CM4 chip, reduced non-specific binding in channel 
1 was observed, but this was still too high to permit any meaningful analysis. 
Despite additional attempts to optimise conditions including varying the salt 
concentration up to 300mM NaCl and digestion of any DNA that might be 
contaminating the Fen1, we were unable to produce conditions suitable for 
 135 
analysis of the PCNA-Fen1 interaction. At this stage, it was apparent that a 
result with Fen1 in flow was not going to be obtainable, leading to attempts to 
couple Fen1 to channels 2-4 on the chip. Fen1 would not dissociate from the 
chip surface even if it was not covalently coupled. This strongly suggests that 
the recombinant Fen1 protein was interacting in a non-physiological manner 
with the chip surface, probably unfolding and permanently precipitating on it, 
both when used as an anylate or ligand. These results rendered the experiment 
non-viable suggesting that the recombinant Fen1 being used was not amenable 
to invitro protein-protein interaction studies. 
Gomes and Burgers also used N-terminal tagged Fen1, however there are 
differences between the aminoacid sequences of yeast and human PCNA and 
perhaps C-terminal tagging of human Fen1 would produce better results. The 
N-terminus methionine of human Fen1 is likely to be internal and therefore 
adding a tag to this end of the protein may well destabilise the tertiary structure 
by exposing the hydrophobic centre of the protein leading it to unfold. 
The interaction of PCNA p.Ser228Ile with Fen1 was next assessed in a more 
physiological setting by immunoprecipitation from lymphoblastoid cell extracts. 
WT line L7 and homozygous PCNA p.Ser228Ile line L5 were initially used in 
attempts to optimise the assay. Whole cell extracts from each cell line were 
immunoprecipitated under standard conditions (NaCl final concentration 40mM) 
using anti-PCNA rabbit polyclonal antibody conjugated to Protein G Dynabeads. 
The resulting immunoprecipitates were separated by SDS-PAGE and probed 
with anti-PCNA mouse monoclonal antibody (PC10) and anti-Fen1 rabbit 
polyclonal antibody (ab17993). PCNA was clearly visualised but no Fen1 was 
co-immunoprecipitated. Given that co-precipitation of Fen1 with PCNA had 
been unsuccessful, an antibody that would immunoprecipitate Fen1 was 
sought. Anti-Fen1 mouse monoclonal antibody (4E7), which had previously 
been shown to immunoprecipitate Fen1 (Guo et al., 2010) was obtained along 
with and anti-Fen1 monoclonal rabbit antibody (EPR4459(2)), which was raised 
to a peptide taken from within the general region of amino acids 100-150 of the 
human Fen1 protein, away from the PCNA binding region (between amino acids 
252-371). Attempts made to precipitate Fen1 from the WT line L7 using either 
anti-Fen1 antibody gave further unsatisfactory results. 
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The PCNA protein interactions in the SILAC assay had been analysed in the 
presence of a lower salt concentration of 25mM NaCl. Given this and that the 
interaction of PCNA with another PIP box containing partner protein, CAF1, had 
been shown to be very salt sensitive with the optimal NaCl concentration being 
25mM (Hoek et al., 2011), whole cell extracts from lines L5 and L7 were buffer 
exchanged into an interaction buffer at that lower salt concentration, (see 
materials and methods section 2.7.4 for a detailed description).  Anti-Fen1 
mouse monoclonal antibody (4E7), and anti-Fen1 monoclonal rabbit antibody 
(EPR4459(2)) were each conjugated to a 50:50 mix of protein A and G 
Dynabeads. After separation of immunoprecipitates by SDS-PAGE and probing 
with anti-Fen1 and anti-PCNA antibodies, Fen1 was seen not to have 
precipitated with the mouse antibody. However, an interaction between Fen1 
and PCNA was clearly demonstrated in the WT line L7 when the rabbit antibody 
was used to precipitate Fen1, whereas the interaction was barely detectable in 
cell extract L5 which is homozygous for the Ser228Ile PCNA alteration. An IgG 
control was run in parallel which revealed that the Fen1 co-precipitates with 
PCNA and is not just adhering non-specifically to the Dynabeads (Figure 22). 
Precipitation of PCNA using the PCNA polyclonal antibody was also attempted 
to see if Fen1 would co-precipitate. Although PCNA was clearly seen to have 
precipitated using extracts from both WT and homozygous p.Ser228Ile lines, 
Fen1 did not co-precipitate (Figure 23). 
3.4.3.9 The PCNA p.Ser228Ile alteration perturbs the PCNA – Fen1 
interaction 
Having optimised the conditions for co-immunoprecipitation of PCNA with Fen1, 
The analysis was repeated including whole lymphoblastoid cell extracts from 
two WT lymphoblastoid cell lines (L7 and L9), two heterozygous lines (L8 and 
L10) and two lines homozygous for PCNA p.Ser228Ile (L5 and L6). Fen1 
protein was precipitated using the anti-Fen1 rabbit antibody (EPR4459(2)) and 
protein A/G Dynabeads. Proteins in the extracts and precipitates were analysed 
by western blot with anti-PCNA (PC10) or anti-Fen1 (4E7) antibodies. While an 
interaction between Fen1 and PCNA was clearly demonstrated in controls, an 
intermediate level of interaction was detected in heterozygote cell lines and the 
interaction was barely detectable in cells homozygous for the PCNA p.Ser228Ile 
alteration (Figure 24). These data provide unambiguous confirmation that   
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Figure 22:  Anti-Fen1rabbit monoclonal antibody (EPR4459(2)) is suitable for use in co-immuoprecipitation analyses of the PCNA-Fen1 interaction. 
Anti- Fen1 immunoprecipitates, from extracts made from lymphoblastoid lines derived from affected individuals or family members, were analysed by western blot for the presence of PCNA and 
Fen1. Endogenous PCNA was co-precipitated with Fen1 in cells from WT individuals, but was almost undetectable in the precipitation from cell extracts derived from affected individuals. No 
PCNA is seen in the IgG control.. I =input, L=load, FT=flow-through, B=beads. 
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Figure 23: PCNA rabbit polyclonal antibody is not suitable for use in co-
immuoprecipitation analyses of the PCNA-Fen1 interaction 
Anti-PCNA immunoprecipitates, from extracts made from lymphoblastoid lines derived from affected 
individuals or WT individuals, were analysed by western blot for the presence of PCNA and Fen1. 
Endogenous Fen1 was not co-precipitated with PCNA in cells from either affected or WT individuals. I 
=input, L=load, FT=flow-through, B=beads. 
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Figure 24:The PCNA-Fen1 interaction is perturbed by the p.Ser228Ile mutation 
Anti-Fen1 immunoprecipitates, from extracts made from lymphoblastoid lines derived from affected 
individuals or family members, were analysed by western blot for the presence of PCNA, Fen1 and actin. 
PCNA was almost undetectable in the precipitation from cell extracts derived from affected individuals. 
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interaction of Fen1 with PCNA is dramatically reduced by the p.Ser228Ile 
mutation and we postulated that interactions with other PCNA partner proteins 
would be similarly affected, providing a plausible explanation for the reduced 
nucleotide excision repair activity 
3.4.3.10 Optimisation of an assay to assess the PCNA – Lig1 interaction. 
We first attempted to assess the PCNA-Lig1 interaction using SPR. 6xHis-
tagged human Lig1 protein, Lig1 PIP* (Lig1 mutant that results in disruption of 
the Lig1 PIP box, completely abrogating it’s interaction with the interdomain 
connector loop of PCNA) and empty vector were expressed in E.coli. After 
transformation, overnight culture and induction of protein expression with 
Isopropyl β-D-1-thiogalactopyranoside (IPTG), the bacterial cells were 
harvested and lysates prepared under native conditions before protein 
purification using Ni-NTA affinity chromatography. Analysis by SDS-PAGE and 
Coomassie blue staining revealed that the Lig1 and Lig1 PIP* proteins were 
induced but the His-tag was not binding to the nickel, instead all of the protein 
was in the flow-through. 
PCNA (WT/p.Ser228Ile/IDCL*) were coupled to 3 flow cells of the CM5 chip as 
described above and given that the protein purification had failed, bacterial 
supernatant containing unpurified human Lig1 was run in flow. Although we 
knew that we would not obtain clean curves, we were hopeful that this analysis 
would provide us with some indication as to the likelihood that interpretable 
results would be possible if sufficient amounts of pure Lig1 could be produced. 
The concentration of Lig1 was unknown, thus it was not possible to generate 
absolute affinity values. However, binding of Lig1 to WT PCNA appeared to 
always be greater than to PCNA pSer228Ile. As expected given the complex 
nature of the mixture, the curves were not easy to interpret. However, 
equilibrium did appear to be reached quickly and dissociation was rapid and 
complete on the WT PCNA channel. The curves obtained from the PCNA 
p.Ser228Ile channel were of lower quality, but it was clear that equilibrium was 
not reached rapidly and dissociation was less rapid (Figure 25). 
It was concluded that large quantities of purified Lig1 protein would be required 
to be able to make an assessment of kinetics of the PCNA-Lig1 interaction. One  
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Figure 25: Surface plasmon resonance analysis of the PCNA-Lig1 interaction 
Recombinant PCNA WT, p.Ser228Ile and IDCL* were coupled to a biacore chip and unpurified human 
Lig1 present within bacterial supernatant was run in flow. (A) Steady state equilibrium binding curves for 
Lig1 on the three different PCNA surfaces. More Lig1 binds WT than S228I at equal Lig1 concentrations, 
suggesting a lower Kd for Lig1 and WT PCNA. Inspection of the sensorgrams for PCNA WT (B) and 
p.Ser228Ile (C) surfaces show that for WT PCNA the equilibrium is reached more rapidly and dissociation 
is also more rapid compared to p.Ser228Ile.  
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possible reason to explain why we had been unable to obtain purified Lig1 
using Ni-NTA affinity chromatography was because the 6xHis-tag on the protein 
was not available for binding. Hence, if bacterial lysate was prepared and 
protein purified under denaturing conditions, this should render the 6xHis tag 
available for binding. An important consideration was that it was not known 
whether once purified and renatured the Lig1 protein would behave normally. 
Purified Lig1 was obtained using this method, but the protein concentration was 
very low (Figure 26). Surface plasmon resonance analysis gave results similar 
to those obtained using the bacterial lysate, but there was insufficient protein to 
make any firm conclusions. It might be possible to produce sufficient Lig1 
protein by expressing in baculovirus as opposed to E.coli, however the facilities 
were not available to try this method. 
In an attempt to study the PCNA-Lig1 interaction by another method, E.coli 
lysates containing recombinant S-tagged PCNA (WT, p.Ser228Ile or IDCL*) 
were combined with HeLa nuclear extract. S-protein agarose beads were added 
and proteins were subsequently analysed by western blot with anti-PCNA, anti-
Lig1 or anti-actin antibodies. PCNA bound to the beads as expected, but no 
Lig1 was seen to precipitate even with WT PCNA (Figure 27). Given the earlier 
success with co-immunoprecipitation studies, immunoprecipitation of Lig1 from 
L7 (WT) or L5 (Homozygous PCNA p.Ser228Ile) lymphoblastoid extracts was 
attempted, using either Lig1 mouse monoclonal (10H5), Lig1 mouse 
monoclonal (10G12) or Lig1 rabbit polyclonal antibody and the same 
methodology as for the Fen1-PCNA studies described above. Lig1 precipitated 
with the rabbit polyclonal antibody, however there was no co-
immunoprecipitation of PCNA from either the WT or homozygous p.Ser228Ile 
extract. 
3.4.3.11 The PCNA p.Ser228Ile alteration perturbs the PCNA – Lig1 
interaction 
Given that no antibody against Lig1 that is effective for immunoprecipitation 
from lymphoblastoid extracts was commercially available, an invitro approach to 
study the PCNA-Lig1 interaction was used. Gary et al. published an assay 
utilising lysates from E.coli expressing a fusion protein consisting of glutathione  
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Figure 26: Recombinant human DNA Ligase 1 protein prepared under denaturing 
conditions 
His-tagged human Lig1 protein, Lig1 PIP* and empty vector were expressed in E.coli before protein 
purification using Ni-NTA affinity chromatography. Purified recombinant human Lig1 (A) and Lig1 PIP* (B) 
can be seen in eluates 2-4. U = total E.coli extract (uninduced), I = total E.coli extract (induced) Ex = Urea 
extracts (8M) FT = flow-through (unbound from Ni-NTA column in 8M urea) D1-D4 = column washes with 
D buffer (pH 5.9) E1-E4 column elutions with E buffer (pH 4.5). 
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Figure 27: S-tagged PCNA does not bind to endogenous Lig1 at detectable levels 
E.coli lysates containing recombinant S-tagged PCNA (WT, p.Ser228Ile or IDCL*) combined with HeLa 
nuclear extract. Inputs and S-agarose purified proteins were analysed by western blot for the presence of 
PCNA, Lig1 and actin. No detectable interaction of PCNA with Lig1 is seen under these conditions. 
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S-transferase (GST) and PIP box motifs of either Fen1 or XPG and then studied 
the interaction with PCNA (Gary et al., 1997).  
Plasmids that express a fusion protein of GST and the PIP boxes of Fen1 
(amino acids 328-355) or Lig1 (amino acids 1-21 with an 8 amino acid glycine-
serine spacer to maintain an equal distance between the GST and the PIP box) 
were generated. Lysates from E.coli harbouring GST, or the GST-fusion 
proteins were prepared. The lysates were mixed with lysate containing PCNA 
(WT, p.Ser228Ile or IDCL*) expressed from pET30a or pET30a as a control, in 
a buffer containing 100mM KH2PO4/K2HPO4. Glutathione beads were added 
and the proteins that associated with the beads were subsequently analysed by 
SDS-PAGE stained with Coomassie blue. This assay recapitulates the defective 
interaction between PCNA p.Ser228Ile and Fen1 (Figure 28A) and most 
significantly shows that the Ser228Ile protein also has a reduced affinity for the 
PIP box of Lig1 (Figure 28B). In both cases the defective interaction was similar 
to that seen with PCNA IDCL*, which has been specifically mutated to destroy 
the interaction of PCNA with partner proteins that bind to its interdomain 
connector loop. 
3.4.3.12 The PCNA p.Ser228Ile alteration perturbs the PCNA–XPG 
interaction 
Given that Fen1 and Lig1 are both implicated in the nucleotide excision 
pathways (Araujo et al., 2000, Wu et al., 2012), it is plausible that the cellular 
nucleotide excision repair defects observed in cells from affected individuals 
result from the compromised interactions of these proteins with p.Ser288Ile 
PCNA. It also seemed likely that the Ser228Ile alteration would perturb the 
PCNA interaction with other PIP box containing partners, and that this may 
contribute to the cellular phenotypes observed. A clear candidate known both to 
be required for nucleotide excision repair and to bind PCNA through a PIP box 
interaction is XPG. Peptides derived from XPG were not detected in the SILAC 
assay, however the PCNA-XPG interaction has previously been shown to 
require phosphate (Gary et al., 1997), which was not present in that assay. 
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Figure 28: Perturbed PCNA interactions resulting from the p.Ser228Ile mutation 
(A) E. coli lysates expressing empty vector (EV) or PCNA (WT, p.Ser228Ile or IDCL*) were mixed with 
lysates expressing GST or GST fused to the PIP box of Fen1. Inputs and glutathione-purified proteins 
were analysed by SDS-PAGE and Coomassie staining. (B) Similar to A, except GST fusions comprising 
the PIP box of Lig1 (left panel) and XPG (right panel) were used. Greatly reduced interaction of PCNA 
p.Ser228Ile or PCNA PIP* is seen with either the Fen1, Lig1 or XPG PIP boxes. Expression vectors were 
cloned by Dr Catherine Green. 
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Immunoprecipitation of XPG from whole cell lymphoblastoid extracts was 
attempted using either an XPG mouse monoclonal antibody (8H7) or an XPG 
rabbit polyclonal antibody known to be raised against the N-terminus of XPG 
away from the PIP box. PCNA did not co-immunoprecipitate in assays utilising 
either of these antibodies. In the absence of an XPG antibody suitable for 
immunoprecipitation of endogenous XPG, the GST assay was again used to 
assess the binding of WT PCNA and p.Ser228Ile to the PIP box of XPG (amino 
acids 981-1009). Crucially, although less WT PCNA was bound to the XPG PIP 
box when compared to its binding to the Fen1 PIP box, the p.Ser228Ile PCNA 
displayed greatly reduced interaction with the XPG PIP box (Figure 28B). Thus, 
it seems reasonable to suggest that a defective interaction with XPG is also 
likely to contribute to the defective nucleotide excision repair phenotype seen in 
cells homozygous for p.Ser228Ile PCNA. 
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3.5 Discussion 
The genetic and cellular data described here implicate PCNA in a new distinct 
neurodegenerative DNA repair disorder displaying some features in common 
with other conditions associated with deficient DNA metabolism including 
Cockayne syndrome, xeroderma pigmentosum and ataxia telangiectasia. The 
most notable similarities between Cockayne syndrome, the neurological form of 
xeroderma pigmentosum and the individuals with PCNA mutation described 
here include growth abnormalities, premature ageing, cognitive decline, 
photosensitivity and photophobia. The presence of a basal cell carcinoma in 
situ in one affected individual (VI:11) likely indicates a predisposition to sun-
induced malignancy in individuals homozygous for PCNA p.Ser228Ile mutation, 
and further clinical overlap with xeroderma pigmentosum. However the 
phenotype associated with p.Ser228Ile mutation of PCNA appears in general to 
be milder than that seen with either typical Cockayne syndrome or xeroderma 
pigmentosum, most noticeably the rate of premature ageing seems to be 
slower, with none of the ophthalmic manifestations associated with Cockayne 
syndrome reported and the effects of UV sensitivity less significant. 
Interestingly, although hearing loss is found in Cockayne syndrome and some 
xeroderma pigmentosum patients, the age of onset is typically later 
(DiGiovanna and Kraemer, 2012, Nance and Berry, 1992). Thus, prelingual 
sensorineural hearing loss may, in association with the other clinical features 
described, be a helpful diagnostic feature in patients with this condition. The 
ocular and cutaneous telangiectasia seen in patients with the PCNA 
p.Ser228Ile mutation are reminiscent of those seen in ataxia telangiectasia, as 
is the pattern and progression of neurological abnormalities, although as with 
Cockayne syndrome and xeroderma pigmentosum, PCNA p.Ser228Ile 
homozygotes generally appear to be less severely affected than typical ataxia 
telangiectasia patients. As with Cockayne syndrome and xeroderma 
pigmentosum, there are also striking differences between the phenotype 
associated with PCNA p.Ser228Ile and ataxia telangiectasia, including an 
absence of both the immunodeficiency and oculomotor apraxia commonly seen 
in ataxia telangiectasia affected individuals. 
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Complete disruption of PCNA in flies or yeast is lethal (Henderson et al., 1994, 
Waseem et al., 1992) an expected finding given its fundamental involvement in 
DNA replication. Until now, no pathological mutations in the PCNA gene have 
been reported in human populations. In other species however, some mutations 
of PCNA are compatible with life. For example, point mutations have been 
produced in the S. cerevisiae PCNA gene (POL30) that result in a wide variety 
of phenotypes, including DNA damage sensitivity, alterations in mutation rate 
and epigenetic silencing defects (Zhang et al., 2000). Similar phenotypes are 
seen in the various reported mutations in Drosophila PCNA (mus209) 
(Henderson et al., 1994). The only previously reported pathological mutation of 
PCNA in mammalian systems is a targeted missense mutation of lysine 164 to 
arginine (PCNAp.Lys164Arg) in mice, generated to assess the role of ubiquitination 
at this residue in somatic hypermutation in the immune system (Langerak et al., 
2007). Ubiquitination of PCNA at lysine 164 is essential for translesion 
synthesis, a DNA damage tolerance process (Kannouche et al., 2004). Mice 
homozygous for PCNAp.Lys164Arg are viable, but infertile and have an altered 
mutation spectrum of hypermutated immunoglobulin genes (Langerak et al., 
2009, Langerak et al., 2007). Thus a subtle mutation of PCNA that impinges 
upon a specific function can lead to characteristic loss of function effects on 
DNA metabolism. 
Consistent with this, our assays suggest that the PCNA p.Ser228Ile mutation 
described here is hypomorphic in nature. We did not detect any gross 
abnormalities of DNA replication associated with this mutation. Instead, we 
showed that the mutation has distinctive consequences for the cellular 
responses to UV, affecting both global genome and transcription coupled- 
nucleotide excision repair. The effects on recovery of RNA synthesis seen in 
Cockayne syndrome cell lines, and on unscheduled DNA synthesis in 
xeroderma pigmentosum cell lines, are typically more dramatic than those 
observed in homozygous PCNA p.Ser228Ile cells. This may in part explain why 
the phenotypic manifestations associated with these cellular abnormalities are 
not as profound in the individuals described here when compared to those seen 
in Cockayne syndrome and xeroderma pigmentosum. 
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Our studies define particular defective interactions of p.Ser228Ile PCNA which, 
together with others not yet recognised, are likely to be responsible for the 
specific alterations in cellular activities observed. The altered protein interaction 
capability of PCNA p.Ser228Ile is also likely to account for the clinical 
manifestations of this syndrome. Complete abrogation of the PCNA-Fen1 
interaction, mediated by a homozygous mutation of the Fen1 PIP box, is lethal 
in mice (Zheng et al., 2007). Hence, it seems likely that while the p.Ser228Ile 
alteration dramatically reduces the association between PCNA and Fen1 in cell 
extracts, it is unlikely to completely abrogate their functional partnership. 
Consistent with this, both our SILAC and interaction assays using recombinant 
proteins show that the p.Ser228Ile protein remains capable of interacting with 
Fen1, although with significantly altered affinity. It is not possible to conclude 
from our assays whether the defective interactions with XPG, Fen1 and Lig1 are 
solely responsible for the observed effects on nucleotide excision repair, 
although it is important to note that all these proteins are reported to be involved 
in this repair pathway (Araujo et al., 2000, Cleaver et al., 2009, Wu et al., 2012). 
Thus, the perturbation of their interactions with PCNA could well be a major 
contributor to this abnormal cellular phenotype.  
Mutations in XPG are rare, and can be divided into two categories: missense 
mutations in the nuclease domains abrogate nucleotide excision repair but 
result in relatively mild xeroderma pigmentosum phenotypes, while truncating 
mutations cause a very severe xeroderma pigmentosum/Cockayne syndrome 
complex disorder (Clarkson, 2003, Scharer, 2008). The xpg-/- mouse is barely 
viable (Harada et al., 1999). These varying phenotypes are thought to result 
because, in addition to its function in nucleotide excision repair, XPG is involved 
in other processes (Scharer, 2008). In particular, it associates with the 
transcription factor TFIIH, and RNA polymerase II, and has a role in 
transcription (Clarkson, 2003, Sarker et al., 2005, Ito et al., 2007). It is the 
disruption of these other functions of XPG that is thought to be responsible for 
the more severe features of truncation mutations. As an example, patient 
XPCS1RO, (94RD27), had severe early-onset Cockayne syndrome and died 
aged 7 months. He was homozygous for a frame-shift mutation at codon 926 of 
XPG. This mutation leaves the nuclease domains intact, but truncates the 
protein before the PIP-box and nuclear localisation signal (Nouspikel et al., 
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1997). Thus, the C-terminal region of XPG, including the motif responsible for 
interacting with PCNA, is very important for XPG function. These observations 
lead us to suggest that perturbation of PCNA’s interaction with XPG may 
contribute to the neurological features associated with PCNA p.Ser228Ile. 
In contrast to the homozygous state, mice heterozygous for the Fen1 PIP box 
mutant are viable, though they show predisposition to malignancy (Zheng et al., 
2011). Although specific PIP box mutations of Lig1 have not been generated in 
mammals, loss of function mutations in LIG1 have been reported in a single 
individual and result in a complex human phenotype comprising growth 
restriction, immunodeficiency and photosensitivity (Barnes et al., 1992), 
features reminiscent of those seen in p.Ser228Ile homozygotes. It is possible 
that Lig1 deficiency and PCNA p.Ser228Ile homozygosity together represent a 
group of conditions that are the result of disruption to multiple different DNA 
repair pathways. In addition, while the observed cellular defects correlate with 
the Cockayne syndrome and xeroderma pigmentosum like features of the 
syndrome, the clinical overlap with ataxia telangiectasia will require further 
investigation.  
As well as being crucial to the maintenance of genomic integrity and prevention 
of neoplastic changes, DNA repair is known to be fundamentally important both 
during the rapid proliferative phase characteristic of early neurogenesis, and in 
the prevention of early cell death. The affected individuals with PCNA mutation 
described in this study display signs of neurodegeneration, a recognised feature 
of Cockayne syndrome, ataxia telangiectasia as well as neurological forms of 
xeroderma pigmentosum, although the pathological patterns seen in each are 
distinct. More detailed investigation of the altered biological processes resulting 
from the p.Ser228Ile PCNA alteration will thus provide invaluable insight into the 
biological basis of this novel human disorder, as well as the neurodegenerative 
disease mechanism(s) involved in DNA damage tolerance and repair disorders. 
Further, while mutations resulting in complete loss of function of PCNA in 
humans may be incompatible with life, it remains an intriguing possibility that 
additional sequence variants in this gene, affecting other distinct aspects of 
PCNA function, might be viable and result in a phenotype more or indeed less 
severe than that associated with the p.Ser228Ile alteration described here.
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4 MUTATIONS IN KPTN CAUSE A 
NEURODEVELOPMENTAL DISORDER ASSOCIATED 
WITH MACROCEPHALY AND SEIZURES 
4.1 Summary 
The proper development of neuronal circuits during neuromorphogenesis and 
neuronal-network formation is critically dependent on a coordinated and 
intricate series of molecular and cellular cues and responses. Although the 
cortical actin cytoskeleton is known to play a key role in neuromorphogenesis, 
relatively little is known about the specific molecules important for this process. 
We identified nine affected individuals from four Ohio Amish families affected by 
an inherited variable neurodevelopmental disorder. The most consistent 
features were global developmental delay/intellectual disability, macrocephaly, 
anxiety, and some features suggestive of a pervasive developmental disorder. 
A primary seizure disorder was described in three cases. Using a combination 
of autozygosity mapping, linkage analysis and whole-exome sequencing, we 
demonstrated that two founder mutations in KPTN, encoding kaptin, can result 
in this phenotype. Our immunofluorescence analyses in primary neuronal cell 
cultures showed that endogenous and GFP-tagged kaptin associates with 
dynamic actin cytoskeletal structures and that this association is lost upon 
introduction of the identified mutations. Histopathological assessment of kaptin 
deficient mice revealed megalencephaly. Additionally mutant mice displayed 
cognitive deficits mirroring the human phenotype. Taken together, our studies 
have identified kaptin alterations responsible for both the human and mouse 
disorder and define kaptin as a molecule crucial for normal human and mouse 
neuromorphogenesis. 
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4.2 Introduction 
Extremes of brain growth have frequently been associated with impaired 
neurodevelopment and cognition. Occipitofrontal circumference (OFC) is an 
indirect measure of brain growth and the one most widely accepted in clinical 
practice with microcephaly (greater than or equal to 3 standard deviations/SDS 
below the mean) signifying significant brain undergrowth, and macrocephaly 
(greater than or equal to 3 SDS above the mean) indicative of brain 
overgrowth/megalencephaly in the absence of hydrocephalus and cranial 
thickening (Stevenson et al., 1997). The differential diagnosis relates to the 
underlying presence or absence of structural brain anomalies. Known 
pathologies associated with megalencephaly include generalised overgrowth 
syndromes, metabolic syndromes including storage disorders and Fragile X 
syndrome. The strong association between macrocephaly with 
neurodevelopmental disability, autism and other pervasive developmental 
disorders is well recognised (Kanner, 1968, Klein et al., 2013, Nevo et al., 
2002). Where macrocephaly is associated with developmental disability, there is 
a significantly increased risk of seizures (Nevo et al., 2002). 
Over recent years family studies have begun to identify genes which may be 
mutated to cause inherited forms of developmental disability. These studies 
have shed important new light into the molecular and cellular processes which 
orchestrate the human neuronal circuitry, and which may malfunction in 
neurological disorders. The establishment of the incredibly intricate human 
neural circuitry is critically dependent upon a complex and tightly regulated 
myriad of cellular processes and migrational cues. The actin cytoskeleton is 
known to play an important role in the formation, propagation and steering of 
cell motility and migration during brain development. This in turn leads to the 
astonishing morphological intricacy that neurons acquire during neuronal 
differentiation that is required for the formation of the complex functional 
neuronal networks underlying human higher brain functions. Mutations in genes 
encoding molecules important for normal function of the actin cytoskeleton have 
previously been implicated in inherited forms of human developmental disability 
and brain development, (Drevillon et al., 2013, Riviere et al., 2012, Ropers et 
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al., 2011), highlighting the important role of the actin cytoskeleton in 
neuromorphogenesis. 
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4.3 Methods 
4.3.1 Exome sequencing  
Coding regions were captured using SureSelect Target Enrichment System 
(50Mb) with sequencing on a HiSeq (Illumina) with 76bp paired end reads. 
Duplicates were marked by Picard (v1.46) and were excluded before mapping 
to the human genome reference sequence (GRCh37). GATK (v1.0.5777) was 
used to realign reads near potential insertion-deletion (indel) sites and to 
recalibrate base qualities, and single nucleotide variants were called using 
GATK and SamTools (v0.1.16) whilst indels were called using GATK and Dindel 
(v1.01). All variants were annotated using dbSNP (134) and the 1000 genomes 
pilot study (May 2011) for minor allele frequency. The variant consequences on 
protein structure were predicted by SNP Effect Predictor (VEP v2.1) based on 
Ensembl (version 63). Variants were filtered out if the read depth <4x or 
>1200x, if the consensus quality <20 or if the SNP quality <25 (this work was 
undertaken by Dr Saeed Al-Turki). 
The VCF file obtained was further custom filtered using EVA (exome variant 
analysis suite now know as FEVA, family based exome variant analysis suite), a 
desktop application from the Wellcome Trust Sanger Institute which can handle 
VCF files and permits the application of customised filters to select a subset of 
variants.  Insilico analysis of variants was performed using PROVEAN, Sift, 
Mutation Taster and VEP (variant effect predictor) online software 
4.3.2 Functional studies  
Functional studies were undertaken to understand the impact of the two 
variants identified in this study on kaptin function in collaboration with Dr 
Michael Kessels, Professor Britta Quamann and Ms Maryam Izadi based at the 
Research Institute of the FSU Jena, Germany. Methodology for these studies is 
included in the appendix. 
Sequence analyses of kaptin was performed using online protein domain 
retrieval tools BLAST and SMART. 
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4.3.3 Mouse studies 
The construct used to generate the Kptn -/- (KptnTm1a/Tm1a) mice is shown in the 
appendix. The main insertion cassette is placed between exons 4 and 5, with a 
further LoxP between exons 8 and 9. This allele is known as the Tm1a allele, 
given that none of the endogenous allele is actually removed, only disrupted as 
the insertion generates a frame shift followed by a premature stop codon. Any 
shortened mutant mRNAs transcribed from the Tm1a allele should be targeted 
for destruction. Wellcome Trust Sanger Institute in house data suggests that 
gene expression is completed ablated by the insertion, at least in adipose and 
liver tissues. 
Mouse studies were designed by Dr Darren Logan and Dr Chris Lelliott based 
at the Wellcome Trust Sanger Institute after discussion of the human phenotype 
with myself and Professor Crosby .The analysis was performed by Ms Maria 
Levitin, I observed this work. 
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4.4 Results 
4.4.1 Identification of a potentially pathogenic mutation in KPTN 
identified by autozygosity mapping and whole exome sequence 
analysis  
Autozygosity mapping studies were initially undertaken in a single nuclear 
Mennonite family. Three boys had a history of early onset of seizures refractory 
to treatment, global developmental delay, significant intellectual impairment and 
macrocephaly (Figure 29A, family 1). Only one of the brothers was alive at the 
time of recruitment to the study. A detailed history was taken for each of the 
affected boys from their mother. Individual IX:3 was examined. We obtained 
consent to review the existing medical records for all three affected individuals. 
Unfortunately although neuroimaging had been undertaken, the films had been 
destroyed. Clinicians who had reviewed the siblings previously, had suspected 
Fragile X syndrome, but this had subsequently been excluded. 
Assuming that this was an autosomal recessive condition and that a founder 
mutation was responsible, a genome-wide screen was undertaken in order to 
map the chromosomal location of the pathogenic variant. Samples from 
individuals IX:3 and IX:4 were genotyped using Illumina Human Cyto12 
Beadchip arrays which revealed a large 8.74Mb homozygous region on 
chromosome 19q13.13-19q13.33 containing 394 genes. Comparison of the 
haplotype across that region with that of another individual with notable 
phenotypic similarities (Figure 29A, family 2, individual IX:6) revealed an 
overlapping 2.59Mb region on 19q13.33 and shared heterozygous haplotype 
extending beyond the homozygous segment. The homozygous region identified 
in families 1 and 2, considered likely to correspond to the disease locus in these 
families, is delimited by recombinant SNP markers rs2253022 and rs7246244 
and contains 149 genes (Figure 29B). Autozygosity across this interval was 
corroborated by microsatellite marker analysis in all family members. 
In order to identify the causative mutation, whole exome sequence analysis was 
undertaken. A single affected individual (Figure 29A, IX:9,) was sequenced to 
generate a novel variant profile. We obtained 7.6G bases of which 93% have a 
quality >= Q30. Approximately 8% of the reads were marked as duplicates by 
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Picard (v1.46) and were excluded before mapping to the human genome 
reference sequence (GRCh37). The VCF file obtained was then further filtered 
using EVA to select all the novel homozygous variants within the critical region 
on chromosome 19. After filtering, we were left with only a single likely 
deleterious variant, in exon 8 of the KPTN gene encoding the 436 amino acid 
protein kaptin (chromosomal variant: g.47983131G>T[NC_000019.9]; 
NM_007059.2:c.776C>A;NP_008990.2: p.S259*). The presence of the variant 
was confirmed by dideoxy sequencing which also confirmed its cosegregation 
within families 1 and 2 (Figure 29A). The KPTN c.776C>A nonsense variant 
destroys an EagI restriction site. Restriction digest was performed and 7 
heterozygous carriers were identified in 560 control chromosomes examined, 
indicating an allele frequency of approximately 0.012 in this community. The 
variant was also listed in the Exome Variant Server (NHLBI GO Exome 
Sequencing Project (ESP), Seattle, WA; http://evs.gs.washington.edu/EVS/), 
with 1 heterozygote being reported in 8285 European American chromosomes. 
4.4.2 Identification of a second potentially pathogenic mutation in KPTN 
within the same Anabaptist community 
It was interesting that no notable homozygous regions were detected in affected 
members of families 3 and 4 despite them showing significant phenotypic 
overlap with the affected individuals from families 1 and 2. We next investigated 
these and 18 other families with individuals affected by developmental delay 
and features suggestive of a pervasive developmental disorder, but without 
macrocephaly. All five affected individuals from families 3 and 4 were found to 
be heterozygous for KPTN c.776C>A. This prompted evaluation of KPTN for a 
second mutation which may be acting in conjunction with the c.776C>A 
alteration in these families. Subsequent dideoxy sequence analysis of all coding 
regions and associated splice junctions of KPTN (primer sequences Appendix) 
in these families revealed that all affected children were indeed compound 
heterozygous for the c.776C>A variant, as well as an in-frame 18bp duplication 
(NC_000019.9:g.47983179_47983196dup;NM_007059.2:c.711_728dup) 
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Figure 29: Family Pedigree and Gene Mapping 
(A). Pedigree diagram showing all 4 (families 1-4) nuclear families investigated, which interlink into a single extended family. Segregation of the two mutations identified (X denotes p.S259*, and 
Dup denotes p.M241_Q246dup) is shown (all genotypings were validated by dideoxy sequence analysis). (B). Pictorial representation of the SNP genotype data encompassing the chromosome 
19 homozygous (solid box) and compound heterozygous (dashed box) regions in affected individuals, with the disease locus being demarcated by SNPs rs2253022 and rs7246244 (2.59Mb; 
families 3 and 4). Support with SNP mapping data analysis was provided by Mr Reza Maroofian, University of Exeter. 
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in exon 8, predicted to result in the duplication of amino acids 241-246  
(NP_008990.2:p.M241_Q246dup), the presence of this variant was confirmed 
in the transcript. Both the c.776C>A and c.711_728dup sequence alterations 
completely cosegregate with the disease phenotype as would be expected of 
causative compound heterozygous mutations (Figure 29A, Figure 30), a 
LODMAX=10.33 was calculated using Simwalk2 (Sobel and Lange, 1996). The 
c.711_728dup sequence duplication is not listed in genomic sequence 
databases and one heterozygote was detected in 560 Amish control 
chromosomes analysed by PAGE. 
4.4.3 Phenotype of individuals homozygous or compound 
heterozygous for mutations in KPTN 
In total 9 family members present in 4 nuclear families were included in the 
original study. All are affected by an inherited variable form of 
neurodevelopmental disorder. The most consistent features were global 
developmental delay, macrocephaly with frontal bossing, high levels of anxiety, 
a characteristic pattern of speech with little alteration in tone and some features 
suggestive of a pervasive developmental disorder. Neuroimaging was 
performed in 4 cases with no significant intracranial abnormalities reported. A 
primary seizure disorder was described in 3/9 cases. The clinical features are 
summarised in Table 13. Dysmorphic features were subtle and appeared to 
evolve with age. The facial phenotype included frontal bossing, a broad nasal 
tip, scaphocephaly, hooded eyelids with small downslanting palpebral fissures 
and a prominent chin (Figure 31). 
4.4.4 KPTN is a stringently conserved but relatively uncharacterised 
protein 
The KPTN gene encodes a largely uncharacterised protein kaptin. Sequence 
and predicted structural conservation of both the N-terminal and C-terminal half 
of kaptin are very high even between evolutionarily-distant mammalian species 
(Figure 32). Our sequence analyses of kaptin using online protein domain 
retrieval tools identified no protein domains, or homologous human proteins, 
which might provide clues to the functional basis of the neurological deficits 
associated with its mutation (Figure 30). 
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Figure 30: In silico analysis of the predicted effects of the KPTN sequence variants on the KPTN protein  
(A) Genomic organisation of the KPTN and position of the two exon 8 KPTN mutations (c.776C>A; c.714-731dup) identified and translated outcomes (p.Ser259*; p.Met241_Gln246dup) in the 
corresponding polypeptide products (B, C). Red boxes denote beta-sheets and blue ellipsoids denote alpha-helices.  
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Table 13: A comparison of the clinical findings of individuals homozygous or compound heterozygous for KPTN mutations 
 IX:3 IX:4 IX:5 IX:6 IX:8 IX:9 IX:10 X:1 X:2 
Genotype p.Ser259*/p.Ser259* p.Ser259*/p.Ser259* p.Ser259*/ p.Ser259* p.Ser259*/ p.Ser259* p.Ser259*/ 
p.Met241_Gln246dup 
p.Ser259*/ 
p.Met241_Gln246dup 
p.Ser259*/ 
p.Met241_Gln246dup 
p.Ser259*/ 
p.Met241_Gln246dup 
p.Ser259*/ 
p.Met241_Gln246dup 
Gender M M M M M F F M F 
Age at evaluation 
(years) 
28.2 Deceased age 29 
yrs (head injury) 
Deceased age 30 
yrs(pneumonia 
16.5 13.2 22.7 24.9 1.4 7.8 
          
Growth parameters          
Birth weight kg (SDS) 2.95(0.7) 2.92 (0) 3.46 (1.3) 1.59 (-0.2) 3.35(-0.4) 2.89 (-1.2) 3.16 (-0.5) 3.2 (2.0) 2.75 (1.1) 
Birth OFC cm (SDS)  40.6 cm at 6 wks 
(2.9) 
35.6 cm (1.75)  51cm at 10mo (3.9)   “macrocephaly” “macrocephaly” 
Height cm (SDS) 166.7cm (-1.6) N/K 165.1 (-1.8)  at 
19.1yrs 
169 (-0.7) 161.6 (0.6) 156.2 (-1.3) 160 (-0.6) NK 123.5 (-0.4) 
Weight kg (SDS) 121.2 (3.4) N/K 66.5 (-0.2) at 
19.1yrs 
63.1 (0.1) 51.5 (0.8) 107.9 (3.6) 82 (2.2) NK 23.1 (-0.5) 
OFC cm (SDS) 62 (3.0)  63.5(3.6) at 19.1yrs 62.5 (3.4) 61 (3.3) 63 (5.4) 60 (3.2) 52.5 (3.0) 55.4 (2.1) 
Parental OFC cm (SDS) Mother 55.5 (0.1) 
Father 60 (1.7) 
Mother 58 (1.9) 
Father 59 (1.2) 
 Mother 58.5 (2.3)  Mother 57 (1.2) 
Father 59.5 (1.5) 
Development          
Walked (years) 1 1  1.33 1.9 4 3.8 2.4 >2.2  2.2 
Expressive & receptive 
language deficit 
         
Intellectual disability Moderate Mild/Moderate Severe Moderate Moderate Moderate 
IQ 45 
Moderate/Severe 
IQ 42 
Mild Mild 
Neurology          
Childhood hypotonia - - -       
Seizures onset age   3 mo 
AS and GTCS 
onset age  7 yrs 
AS and GTCS 
onset age 7 yrs 
GTCS - - - - - - 
Neuroimaging MRI - normal
a
 N/A CT mild 
ventriculomegaly
a
 
N/P N/A N/P N/P CT– widening of 
the metopic suture 
CT normal 
Behavioural characteristics Repetitive speech 
Anxiety 
 
 Stereotypies Stereotypies  
Hyperactivity 
Anxiety 
Stereotypies 
Repetitive speech 
Anxiety 
Stereotypies 
Repetitive speech 
Anxiety 
Stereotypies 
Repetitive speech 
Anxiety 
Phobias 
Anxiety 
Anxiety 
Physical anomalies          
Head shape Frontal bossing 
Prominent chin 
Frontal bossing 
    Prominent chin 
 
Frontal bossing 
Prominent chin 
   Frontal bossing 
Scaphocephaly 
Prominent chin 
Hypertelorism 
Scaphocephaly 
Sagittal synostosis-
operated age 10mo 
Frontal bossing 
Frontal bossing 
 
Scaphocephaly 
Frontal bossing 
 
Plagiocephaly 
Frontal Bossing 
Frontal bossing 
Prominent chin 
 
Other physical findings 5th finger 
clinodactyly 
5th finger 
clinodactyly 
5th finger 
clinodactyly 
   Hepatosplenomegally 
Liver cirrhosis 
Recurrent pneumonia 
in childhood 
 
Splenomegally 
Anaemia 
Recurrent 
pneumonia 
Fetal finger pads 
Fetal finger pads 
Abbreviations: F, female; M, male; OFC, occipitofrontal circumference; SDS, standard deviation scores; N/P, not performed; N/
subject; IQ, Intelligence quotient (Wechsler Adult Intelligence Scale); AS, absence seizures; GTC, Generalised tonic clonic seizures; CT, computerised tomography; a, original imaging no longer available. 
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Figure 31: Clinical features of KPTN 
Panels (A-C) show the facial features of individuals homozygous for the KPTN p.Ser259* mutation. Dysmorphic features are subtle and include macrocephaly, scaphocephaly, frontal bossing 
with a high frontal hairline, long face with a prominent chin, down-slanting and small palpebral fissures, hooded eye lids and broad nasal tip. 
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Human           MMGEAAVAAGPCPLREDSFTRFSSQSNVYGLAGGAGGRGELLAATLKGKVLGFRYQDLRQ 60 
Armadillo       -MGEAAVAAGPCPLREDSFTRFSSQSNVYGLAGGAGGRGELLAATLKGKVLGFRYQDLRQ 59 
Dolphin         -MGEAAVAAGPCPLREDSFTRFSSQSNVYGLAGGAGGRGELLAATLKGKVLGFRYQDLRQ 59 
Mouse           -MGEAAVAEGPCPLLEDSFTRFSSQSNVYGLAGGADGRGELLAATLKGKVLGFRYQDLRQ 59 
                 ******* ***** ********************.************************ 
 
Human           KIRPVAKELQFNYIPVDAEIVSIDTFNKSPPKRGLVVGITFIKDSGDKGSPFLNIYCDYE 120 
Armadillo       KIRPVAKELQFNYIPVDAEIVSIDTFNKSPPKRGLVVGITFIKDSGDKGSPFLNIYCDYE 119 
Dolphin         KIRPVAKELQFNYIPVDAEIVSIDTFNKSPPKQGLVVGITFIKDSGDKGSPFLNIYCDYE 119 
Mouse           KIRPVAKELQFNYIPVDAEIVSIDTFNKSPPKRGLVVGITFIKDSGDKGSPFLNIYCDYE 119 
                ********************************:*************************** 
 
Human           PGSEYNLDSIAQSCLNLELQFTPFQLCHAEVQVGDQLETVFLLSGNDPAIHLYKENEGLH 180 
Armadillo       PGSEYNLDSIAQSCLNLELQFTPFQLCHAEVQVGDQLETVFLLSGNNPAIHLYKENEGLH 179 
Dolphin         PGSEYNLDSIAQSCLNLELQFTPFQLCHAEVQVGDQLETVFLLSGNDPAIHLYKENEGLH 179 
Mouse           PGSEYNLDSIAESCLNLELQFTPFQLCHAEVQVGDQLETVFLLSGNDPAIHLYKENEGLH 179 
                ***********:**********************************:************* 
 
Human           QFEEQPVENLFPELTNLTSSVLWLDVHNFPGTSRRLSALGCQSGYVRVAHVDQRSREVLQ 240 
Armadillo       QFEEQPVENLFPELTHLTSSVLWLHVHNLPGTSRRLSALGCQSGYVRVAHVDQRSREVLQ 239 
Dolphin         QFEEQPVENLFPELTNLTSSVLWLDVHNLPGTSRRLSALGCQSGYVRVAHVDQQSREVLQ 239 
Mouse           QFEEQPVENLFPELTNLTSSVLWLDVHNLPGSSQRLSALGCQSGYVRVAHVDQKNQEILQ 239 
                ***************:********.***:**:*:*******************:.:*:** 
 
Human           MWSVLQDGPISRVIVFSLSAAKETKDRPLQDEYSVLVASMLEPAVVYRDLLNRGLEDQLL 300 
Armadillo       TWTVLQDAPISRVTVFNLAAPEESTERPQQEEYSVLVASMLEPAVVYRDLLRRGLEDQLL 299 
Dolphin         TWTILQDGPISRVIVFSLSAPEETEDRPQREEYSVLVASMLEPAVVYRDLLSRGLEDQLL 299 
Mouse           TWTIQQDGPISRVIVFSLSASEATQDSPQQEGYSLLVASMLEPAVVYWDLLNKGLDDQLL 299 
                 *:: **.***** **.*:*.: : : * :: **:************ *** :**:**** 
           
Human           LPGSDQFDSVLCSLVTDVDLDGRPEVLVATYGQELLCYKYRGPESGLPEAQHGFHLLWQR 360 
Armadillo       LPGSDQFDSVLCGLVTDVDLDGRPEVLVATYGQELLCYKYCA-------AGQGFRLLWRR 352 
Dolphin         LPGSDQFDSVLCGLVTDIDLDGRPEVLVATYGQELLCYKYCSPGRGLPGAQRGFRLLWQR 359 
Mouse           LPGSDQFDSVLCGLVTDVDLDGQPEVLVATYGQELLCYKYRG----LPEDSRGFRLLWRR 355 
                ************.****:****:***************** .         :**:***:* 
 
Human           SFSSPLLAMAHVDLTGDGLQELAVVSLKGVHILQHSLIQASELVLTRLRHQVEQRRRRLQ 420 
Armadillo       SFSSPLLAMADVDLTGDGLRELAVVSLKGMHILQHSLVQASELALTRLRRQVEQRRRRPP 412 
Dolphin         SFSSPLLAMAHVDLTGDGLRELAVVSLKGVHILQHSLIQASELVLTRLRHQVEQRRRQPQ 419 
Mouse           SFASPLLAMAHVDLTGDGLRELAVISLKGVHILQHSLIQASELVLTRLRHQVEQRK-HQQ 414 
                **:*******.********:****:****:*******:*****.*****:*****: :   
 
Human           GLEDGAGAGPAENAAS 436 
Armadillo       GLGARAGPGAAENPAS 428 
Dolphin         RLGDRVGAGPAETPAS 435 
Mouse           GLGDRVGPRPVEHPAS 430 
                 *   .*. ..* .** 
 
Figure 32: Alignment of kaptin proteins  
The KPTN aminoacid sequence from diverse mammalian species including human 
(gi|108936022|sp|Q9Y664.2), armadillo (gi|488582075|ref|XP_004476450), dolphin 
(gi|470599504|ref|XP_004311953) and mouse (gi|148710164|gb|EDL42110.1) were aligned, revealing an 
almost complete sequence conservation of the N-terminal half of kaptin and an also very high conservation 
of the C-terminal half. Residues corresponding to kaptin amino acids 1-258 are shaded in grey, residues 
duplicated in the p.Met241_Gln246dup mutant are highlighted in yellow. 
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Kaptin was originally isolated from human blood platelets but subsequently 
found to be expressed in fibroblasts as well as intestinal and sensory epithelia 
(Bearer and Abraham, 1999). A previous study of this molecule suggested a 
role at stereocilia tips, and so KPTN was proposed as a candidate gene for 
hearing loss (Bearer et al., 2000). However, although no formal hearing 
assessments have been undertaken the information available for the affected 
individuals described in this study contains no evidence of hearing deficits. 
Bearer and Abraham showed that kaptin binds to filamentous F-actin by F-actin 
affinity chromatography and that it could be eluted from F-actin affinity columns 
(Bearer and Abraham, 1999). Given this evidence, and the importance of the 
actin cytoskeleton to neuromorphogenesis, we hypothesised that the likely 
underlying cause of this neurodevelopmental disorder was a disruption of the 
interaction between KPTN and F-actin and a consequential reduction in 
dendritic arborisation. 
4.4.5 Kaptin colocalises with F-actin rich sites in primary neuronal cells 
As no cellular material from affected individuals was initially available, the 
majority of the functional studies were undertaken in a primary rat hippocampal 
neuronal cell line. Initial investigations involved the expression and localisation 
of kaptin in neurons. In order to do so, human kaptin was first cloned from 
HEK293 cell cDNA. Primary rat hippocampal neurons, identifiable by anti-MAP2 
immunostaining (Sigma, Abcam), were transfected with wild type Flag-tagged 
kaptin (Flag-kaptin) at DIV3 and imaged two days later. Wild type Flag-kaptin 
was observed to be localised at F-actin-rich foci in close proximity to the cell 
bodies as well as in growth cones (Figure 33A and B, arrow heads). At later 
stages of development, when neurons established synapses (DIV14), wild type 
Flag-kaptin again colocalised with F-actin-rich sites. Along dendrites, these sites 
appeared mainly to represent F-actin-rich postsynapses, as almost all kaptin-
enriched puncta were contacted by bassoon (a marker for presynaptic active 
zones) containing presynaptic structures (Figure 33C). To be able to undertake 
immunolabeling experiments of endogenous kaptin, polyclonal rabbit anti-kaptin 
antibodies (Sigma) first were first characterized in COS-7 cells. Cells expressing 
wild type Flag-kaptin were highlighted by anti-kaptin immunolabelling (Figure 
34A). Co-immunostaining of primary rat hippocampal neurons at DIV24 with 
anti-kaptin and anti-ProSAP1/Shank2 (Neuromab) antibodies demonstrated that 
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the dendritic accumulations of tagged kaptin at F-actin-rich puncta are indeed of 
physiological relevance and reflect the localisation of endogenous kaptin at 
postsynapses. The vast majority of anti-kaptin immunolabeled puncta were not 
only enriched for F-actin, but additionally were immunopositive for 
ProSAP1/Shank2, a postsynaptic scaffold protein interacting with F-actin 
binding proteins (Hering and Sheng, 2001, Qualmann et al., 2004); (Figure 
33D). Kaptin thus appears to be associated with dynamic actin cytoskeletal 
structures of neuronal cells. Consistent with this, wild type Flag-kaptin 
accumulated at lamellipodia of COS-7 cells (Figure 34B), the subcellular 
regions of mobile fibroblastic cells marked by dense arrays of dynamic actin 
filaments. In neurons, the cortical actin cytoskeleton is known to be important 
for proper neuronal network formation during development. Our observations 
thus support our hypothesis of a significant role of kaptin in 
neuromorphogenesis.  
4.4.6 KPTN c.776C>A and c.714_731dup likely result in kaptin loss of 
function 
The c.776C>A sequence variant is predicted by to introduce a premature stop 
codon and result in loss of function due to degradation of the mutated transcript 
by mRNA surveillance cell mechanisms, although due to lack of patient material 
we have been unable to confirm whether a truncated protein (lacking the C-
terminal amino acids 257 to 436) is produced. In contrast, the in-frame 
c.711_728dup mutation is likely to result in the insertion of 6 amino acids (Met-
Trp-Ser-Val-Leu-Gln) into full-length kaptin. In order to investigate the functional 
outcome of this mutation, an in silico analysis of the secondary structural 
elements of wild type and mutant kaptin, was undertaken. This revealed that the 
N-terminal half of kaptin is likely to comprise a series of relatively densely 
organized -sheets, interspersed by only three -helices, and becomes more -
helical starting with helix 4 (spanning amino acids 234 to 245; Figure 35A). 
Strikingly, duplication of the 6 amino acids, Met-Trp-Ser-Val-Leu-Gln (241-246) 
is predicted to disrupt the -helix 4 and result in its conversion into an extended 
-sheet (Figure 35C), and so is likely to have a profound effect on kaptin 
function.
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Figure 33: Kaptin immunolocalisation studies in neuronal cell lines 
(A and B) Flag-kaptin colocalised with F-actin-rich foci at the cell body and in growth cones (examples of both are marked by arrow heads in A) in DIV5 rat hippocampal neurons transfected at 
DIV3. For clarity, the anti-MAP2 immunostaining was omitted from the merged images. Scale bars represent 10 mm. (C and D) Endogenous kaptin immunostained together with the presynaptic 
marker bassoon at DIV14 (C) and with the postsynaptic marker Shank2 at DIV24 (D). Puncta enriched with anti-kaptin immunoreactivity (marked by arrow heads) were rich in F-actin, as shown 
by fluorescently labelled phalloidin. (C) Furthermore, they were usually contacted by presynapses. The scale bar represents 5 mm. (D) Postsynapses marked by Shank2 were largely positive for 
both F-actin and anti-kaptin immunolabelling (arrow heads). For clarity, the anti-F-actin staining was omitted from the merged image in (D). High-magnification images are shown. The scale bar 
represents 2.5 mm. Postsynapses marked by ProSAP1/Shank2 to a large extend are positive for both F-actin and anti-kaptin immunolabelling (arrow heads). For clarity, the anti-F-actin staining 
has been omitted from the merge in D.High magnification images, Bar, 2.5 µm. Data courtesy of Dr Michael Kessels. 
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Figure 34: Kaptin immunolocalisation studies in COS-7 cells 
(A) Flag-kaptin (green in merge) in COS-7 cells is enriched in F-actin-rich lamellipodia (red in merge) and additionally shows a cytoplasmic localisation. (B), Anti-kaptin antibody characterisation 
using Flag-kaptin overexpression in COS-7 cells. Note that transfected cells were recognised by anti-kaptin antibodies, that untransfected cells showed no significant immunolabelling and that 
there was a good spatial overlap of Flag-kaptin and anti-kaptin detection. Bars, 10 µm. Data courtesy of Dr Michael Kessels. 
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Figure 35: Schematic representation of wild-type human kaptin 
(A), the truncation mutant S259* (c.1240>T; GFP-kaptin
1-258
) (B) and the duplication mutant (GFP-kaptin
Met241_Gln246dup
). (C). On the left is a graphic overview of secondary structures with beta-
sheets as red boxes and alpha-helices as blue ellipsoids. On the right are amino acids and secondary structure elements around amino acid 230. α-helix 4 is predicted to be converted into a β-
sheet by the insertion of amino acids 241-246, as shown in yellow.
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4.4.7 Mutant KPTN p.Ser259* and p.Met241_Gln246dup do not associate 
with F-actin 
In order to explore experimentally the functionality of any protein arising from 
translated mutant transcripts, both disease-associated GFP-tagged mutants 
were generated. Whereas wild type GFP-tagged kaptin (GFP-kaptin) was found 
to localise at F-actin-rich lamellipodia of COS-7 cells, both kaptin mutants 
displayed no F-actin association but instead accumulated at irregular 
perinuclear sites (Figure 36A-C). GFP-Kaptin1-258 showed a more pronounced 
tendency to form such accumulations with almost all cells being marked with 
little additional cytoplasmic staining outside of these foci, while GFP-
kaptinp.Met241_Gln246dup typically displayed fewer and slightly smaller 
accumulations with slightly higher levels of cytoplasmatic staining outside of 
these foci (Figure 36A-C). This indicates that both proteins are likely to be non-
functional, although it is not possible to exclude the possibility that misfolded 
mutant protein may accumulate in neurons of affected individuals leading to 
dominant-negative effects on other neuronal proteins or cell processes. 
Finally, as KPTN mutations result primarily in a form of neurodevelopmental 
disease, we also analysed the behaviour of the kaptin mutants in primary 
hippocampal neurons during early development. Whereas wild type GFP-kaptin 
was again found to colocalise with dynamic F-actin in growth cones and foci at 
the cell body, both GFP-kaptin1-258 and GFP-kaptinp.Met241-Gln246dup were found to 
accumulate in a manner reminiscent of the COS-7 studies in the cell body or at 
perinuclear sites (Figure 37A-C). 
4.4.8 KPTN -/- mice are macrocephalic and exhibit impaired cognition 
A Kptn knockout mouse model (Kptntm1a(EUCOMM)Wtsi) was identified on the  
Wellcome Trust Sanger Institute mouse resources portal. The preliminary Kptn-/- 
mouse phenotype described was primarily a metabolic phenotype. Female 
homozygotes had a significantly increased body weight related to an increase in 
adipose tissue when compared to WT control mice. In addition they exhibited 
impaired glucose tolerance following a high fat diet. Although the cohort of 
affected individuals from Ohio was small, no significant differences in weight 
between the sexes had been observed. 
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Figure 36:Immunolocalisation studies of altered kaptin in COS-7 cells 
Localisations of GFP-kaptin, GFP-kaptin
1-258
 and GFP-kaptin
Met241-Gln246dup
 (green in merges) in COS-7 
cells counterstained with phalloidin (red in merged images). Note that whereas wild-type kaptin is 
distributed in the cytosol and accumulated at F-actin-rich lamellipodia (A), both mutants show 
accumulations at perinuclear regions (B and C). Data courtesy of Dr Michael Kessels. 
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Figure 37: Immunolocallisation studies of altered kaptin in rat hippocampal neurones 
Transfection of DIV3 rat hippocampal neurons with wild-type kaptin and mutants thereof fixed and imaged at DIV5. Wild-type kaptin is found throughout the cell with accumulations at growth 
cones and at F-actin rich sites of the cell body (A; arrow heads). In contrast, both mutants accumulate in areas of the cell body (B and C; arrows). Merged images show WT kaptin and altered 
kaptin in green, MAP2 in red and phalloidin in blue. Scale bar represents, 10 µm. Data courtesy of Dr Michael Kessels. 
 
 In order to explore the correlation between the human and mouse phenotypes 
further, the Kptn-/- mouse was re-examined. KPTN-/- mice had an increased 
skull circumference when compared to WT mice.  Analysis of brain pathology 
revealed megalencephaly but otherwise unremarkable brain histopathology 
(Figure 38). 
The social recognition assay which tests long term memory, was used to make 
an assessment of cognition in Kptn-/- mice. Female Kptn-/- mice were presented 
with an anaesthetised stimulus animal over 4 trials. After 24hrs, the mice were 
presented with two anaesthetised animals: 1) a novel anaesthetised mouse, 
and 2) the stimulus animal from the previous day. As expected the WT but not 
the Kptn-/- mice investigated the novel animal more than the stimulus (Figure 
39). 
 181 
 
Figure 38: The kptn
-/-
 mouse is megalencephalic.  
Shown in the left panel is a half coronal section of Kptn -/- mouse (M00663346) Nissl stained. On the right 
is a half coronal section of a matched control mouse (M00526682) stained with Luxol Nissl. Data courtesy 
of Dr Christopher Lelliott, Wellcome Trust Sanger Institute. 
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Figure 39: Long term memory impairment in Kptn-/- female mice 
(A) Habituation-dishabituation test. Both Kptn-/- (n=9) and Kptn+/+ (Kptn WT, n=9) mice recognise a 
stimulus animal (mouse A) repetitively presented to them over the course of four trials, as shown by a 
decline in the investigation time over trials 1-4. Both mutant and WT mice display an increase in the 
investigation time on trial 5 when presented with a novel stimulus animal (mouse B) (trial 4 vs trial 5, 
*p,0.05, post-hoc analysis after 2 way ANOVA). (B) Discrimination test (24hrs after the habituation-
dishabituation test). The WT (+/+, n=9), but not the mutant mice (-/-), show a significant increase in time 
spent investigating the unfamiliar stimulus (mouse C) versus the familiar (mouse A), suggesting that Kptn
-/- 
mice do not retain the memory of a familiar animal over 24hrs (P value = 0.0340*, t=2.348, df=16, two-
tailed Student’s t-test). The error bars represent the standard error of the mean. Experimental design was 
discussed with the author and analysis was observed. Data courtesy of Dr Darren Logan and Ms Maria 
Levitin, Wellcome Trust Sanger Institute. 
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4.5 Discussion 
We investigated a number of families from the Anabaptist communities of Ohio, 
USA, with multiple individuals aged 1-30 years affected by a novel syndrome in 
which the cardinal features include macrocephaly, developmental delay, 
behavioural abnormalities and seizures. Our molecular studies determined that 
two distinct founder mutations affecting the same gene (KPTN, encoding kaptin) 
are responsible, both of which have become entrapped within the community. 
Those individuals found to be homozygous for the p.S259* nonsense mutation 
appeared to be more severely affected with a higher degree of intellectual 
impairment, compared with individuals found to be compound heterozygous for 
this as well as the p.Met241_Gln246dup mutation. This may indicate that the 
p.M241_Q246dup mutation retains a limited functionality in vivo, and perhaps 
consistent with this we observed that the p.Met241_Gln246dup mutation 
showed a slightly lesser tendency to form perinuclear accumulations in our 
transfection studies compared with the pS259X mutation. However, the sample 
cohort is currently too small to confidently determine any genotype-phenotype 
correlation.  
Relatively little was known about kaptin other than a potential role at stereocilia 
tips, leading to the historical suggestion that KPTN may be a candidate gene for 
hearing loss (Bearer et al., 2000), not a feature seen in the affected individuals 
described here. The actin cytoskeleton plays a pivotal role in neuronal cell 
morphology and migration during development including the generation, 
protrusion and steering of growth cones as well as the formation of postsynapse 
and dendritic spines (Dent et al., 2011, Kessels et al., 2011, Svitkina et al., 
2010). Our studies confirm kaptin expression in neuronal (MAP2-positive) cells. 
Since kaptin was found to localise to F-actin-rich structures, it is conceivable 
that loss of kaptin function may either directly, or indirectly, lead to impairment 
of the neuronal actin cytoskeleton required for dendritic arborisation and/or 
spine formation and result in the disease phenotype described. Support for this 
is provided by studies of Rab39B, a small GTPase associated with the Golgi 
apparatus (Chen et al., 2003), in which mutations lead to down regulation of 
Rab39B protein and a concomitant reduction in dendritic arborisation and 
synapse formation. This was associated with a disease phenotype comprising 
 184 
intellectual disability, epilepsy and macrocephaly (Giannandrea et al., 2010, 
Tarpey et al., 2009), features which overlap with those described here arising 
from kaptin mutation. Similarly, deficiencies of Rho GTPases, which regulate 
the actin cytoskeleton by a growing variety of effector proteins, have been 
associated with spine structure defects and impaired cognition (Ba et al., 2013, 
Kasri et al., 2008, Nakayama and Luo, 2000, von Bohlen Und Halbach, 2010). 
Several other actin-associated proteins including drebrin A, Cortactin, and Abp1 
have also been found to decrease spine density or formation (Haeckel et al., 
2008, Tada and Sheng, 2006, Takahashi et al., 2003), and a growing body of 
evidence supports a role for the Arp2/3 complex and directly and indirectly 
associated proteins in postsynapse formation and proper development of 
neuronal morphology (Ahuja et al., 2007, Djagaeva and Doronkin, 2009, Irie 
and Yamaguchi, 2002, Kim et al., 2013, Koch et al., 2012, Martinez-Quiles et 
al., 2004, Michaelsen et al., 2010, Nakamura et al., 2011, Pinyol et al., 2007, 
Soderling et al., 2007, Tada and Sheng, 2006, Weed et al., 2000, Wegner et al., 
2008).  
Our analyses reveal that wild type kaptin is enriched in neuronal growth cones 
and at discrete cortical sites of neurons at early developmental stages. 
Furthermore, wild type kaptin was found to accumulate at postsynapses of 
neurons undergoing synaptogenesis (DIV14), as indicated by spatial correlation 
along dendrites of kaptin accumulations with phalloidin and synaptic marker 
immunostaining. Consistent with this, kaptin also was found to be present in the 
postsynapses of mature neurons. The sites demarcated by kaptin localisation 
represent areas of high F-actin content and high actin dynamics. An association 
of kaptin with dynamic F-actin was also indicated by the observed 
accumulations of tagged-kaptin at the dynamic lamellipodia, as opposed to the 
more static stress fibers in COS-7 cells. These observations are consistent with 
the suggestion of a lamellipodial localisation of kaptin in chicken embryonic 
fibroblasts as well as with the original isolation of kaptin from blood cells using 
F-actin columns (Bearer and Abraham, 1999). 
The genetic and functional studies presented in this chapter indicate that both 
of the KPTN mutations identified are likely to result in loss of function of kaptin, 
either by degradation of the mutant transcript via mRNA surveillance 
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mechanisms (c.776C>A) or by the production of mislocalised and/or non-
functional protein products. These KPTN mutations result in a distinctive clinical 
syndrome, and the presence of macrocephaly combined with global 
developmental delay/intellectual disability should prompt the diagnostic analysis 
of the KPTN gene in patients from Anabaptist communities. The benefits of 
early diagnosis in this condition is suggested by the improvement in 
developmental markers in the two youngest affected individuals in this study, 
both of whom received early and intensive developmental interventions, 
although the lack of seizures in these individuals may also have been 
beneficial. Finally our identification of two KPTN founder mutations within this 
Anabaptist population parallels the situation seen for a number of other genes 
with multiple mutations already known in the community which also commonly 
cause inherited diseases globally (e.g. connexin-26 mutations in inherited 
hearing loss, and ATM mutations in ataxia telangiectasia), indicating that the 
kaptin neurodevelopmental disorder may be similarly widespread.  
Assessment of the phenotype in Kptn-/- mice demonstrated that these animals 
are macrocephalic and have impaired long term memory which aligns well the 
clinical characteristics of the human disorder. It is interesting that none of the 
mice have developed seizures, although the numbers assessed have been 
small and it is not a consistent feature of the human disorder. Taken together, 
these results show that kaptin plays a crucial role in normal neurodevelopment 
in humans and in mice and that its disruption leads to a syndrome characterised 
by megalencephaly and impaired cognitive ability. 
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5 
CHAPTER FIVE 
AUTOSOMAL RECESSIVE MUTATIONS IN CLOSELY 
LINKED WDR73 AND WHAMM GENES UNDERLIE A 
NOVEL COMPOSITE NEPHROCEREBELLAR 
SYNDROME PHENOTYPE  
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5  AUTOSOMAL RECESSIVE MUTATIONS IN 
CLOSELY LINKED WDR73 AND WHAMM GENES 
UNDERLIE A NOVEL COMPOSITE 
NEPHROCEREBELLAR SYNDROME PHENOTYPE 
5.1 Introduction 
5.1.1 The Swartzentruber church 
There are four main separate Amish affiliations in the Holmes County 
settlement (Figure 40A). The most conservative Amish subgroup, the 
“ultraconservative” Swartzentruber group has its origins in Holmes County. The 
Swartzentruber church group arose between 1913 -1920 following a particular 
interpretation of church discipline. Unlike other Amish affiliations the name does 
not originate from the surname of the original leader, Bishop Samuel E Yoder 
(1872-1932), instead it comes from the surname of the two bishops who’s views 
shaped the group’s formation following Yoder’s death.  
Shunning ex-members of the church is common to all Amish affiliations. 
Traditionally anyone who left the Amish church or who was excommunicated 
(Bann) for a major sin would be shunned until they repented. For those who did 
not, the shunning (Meidung) was life-long. Around 1900, many of the Old Order 
Amish Bishops wanted to relax these rules such that those who left the church 
to become a faithful member of a different Anabaptist church group would no 
longer be shunned. However, Samuel Yoder, felt strongly that strict shunning 
should persist no matter what the offence and opposed what he saw as any 
potential loopholes. His church district broke fellowship with the other nearby 
Amish church groups and mediators were unable to mend the schism, leading 
to the formation of the Swartzentruber group.  
The Swartzentruber church are now known for their resistance to any innovation 
in household or farm technology and practices, such as indoor plumbing, 
milking machines and community phone booths (Figure 40B). Unlike other 
Amish groups who are permitted to travel in cars so long as they are not the 
drivers, the Swartzentruber group may only use this mode of transport in 
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“emergency” situations. The group has also refused to adopt what they call 
“fast-time” (daylight saving time). Despite efforts from law enforcement bodies in 
the USA, they have resisted the use of the orange “slow-moving vehicle” 
triangle sported on the rear of the buggies of Amish from other groups. The 
buggies of the Swartzentruber group are recognisable by their windowless and 
plain appearance and are only dimly lit at night by kerosene lanterns, as 
opposed to more modern and powerful electric lights which have been accepted 
by other Amish church groups. Whereas small business ownership is now 
common amongst the Amish, farming is still the main form of occupation for 
Swartzentruber men. The group have their own distinctive style of dress and 
worship rituals and remain very much separate from other Amish affiliations 
(Hurst and McConnell, 2010, Kraybill et al., 2013). Importantly, the 
Swartzentruber church districts in Holmes County do not contribute to the “Ohio 
crippled children fund”, meaning that any medical investigations or treatment 
needed by Swartzentruber children affected by an inherited disorder must be 
funded by their family. Consequently, affected individuals typically undergo only 
very limited clinical investigations and treatment (personal communication). 
5.1.2 Genetic studies in the Swartzentruber church 
In 2012 Swartzentruber settlements could be found in a total of thirteen states 
and the group comprised around 7% of the total Amish population (Kraybill et 
al., 2013). Currently due to the particularly large numbers of children typical of 
families in this group, they remain the fastest growing affiliation. Parents in this 
group also tend to be more closely related than the 7-9 generation common 
ancestor typically seen in other groups. This is a significant figure to bear in 
mind given that the original founder population of this group was made up 107 
already related individuals from two church districts. Consequently 
Swatrzentruber individuals typically harbour larger and more numerous 
autozygous genomic regions. While this may add an extra layer of complexity to 
genetic mapping studies of inherited disease amongst this group, this is offset 
at least in part by the beneficial effects of a larger family size. 
As may be expected the structure and ancestry of these “ultraconservative” 
Amish has led to the expected enrichment of certain founder mutations within 
this group and an absence of other mutations commonly seen amongst the rest 
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of the Ohio Amish community. In 1967 the WOH co-founder, Professor Harold 
Cross published with his PhD supervisor Professor Victor Mckusick, a report 
describing three distinct and unique neurological conditions best classified as 
complex hereditary spastic paraplegias that he had identified amongst the 
Holmes County Amish. The syndromes were each named after the surname of 
the original nuclear family in which they were described (Cross and McKusick, 
1967). Professors Cross and Crosby identified the molecular causes of two of 
these disorders, “Troyer syndrome” and “Mast Syndrome” in 2002 and 2003 
respectively (Patel et al., 2002, Simpson et al., 2003b). The third condition 
named “Hershberger syndrome” appeared to be particularly prevalent amongst 
the Swartzentruber Amish in Holmes County. The syndrome had proven more 
difficult to study given the added clinical, genetic and social difficulties to 
investigating inherited disease amongst this ultraconservative church group. 
The affected children from the original family described by Cross and Mckusick 
exhibited profound developmental delay, spasticity and irritability evident from 5 
months of age. However, Hershberger syndrome appeared to be neurologically 
complex displaying significant phenotypic variability. This chapter describes the 
results of our clinical and molecular study of Hershberger syndrome. Many of 
the families recruited were directly related to the original family from the 1967 
publication.  
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Figure 40: The Swartzentruber Amish church group  
(A) Amish church group affiliations in the Holmes County settlement. The Swatrzentruber Amish affiliation 
in Holmes County, Ohio was formed after the earliest of the three main schisms from  the Old Order Amish 
Church Group, adapted from (Hurst and McConnell, 2010). (B) Swartzentruber Amish barn raising in 2013. 
The men are wearing the typical wide brimmed hat sported by this church group. At the base of the barn 
the women of the family were quilting. 
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5.2 Methods 
5.2.1 Exome sequencing 
Kings College London 
Sequencing of the consensus coding sequence (CCDS) defined exome was 
undertaken using the Agilent Sure Select All Exome Hybrid Capture kit and 
sequencing on the Illumina platform with 76bp paired end reads, in 
collaboration with Professor Richard Trembath and Dr Michael Simpson based 
at King's College London (KCL). Briefly, genomic DNA from was fragmented 
and enriched for exomic sequences with the Agilent SureSelect Whole Exome 
hybrid capture. The resulting enriched sequence library was sequenced across 
one lane of the Illumina GaIIx flowcell (v4 chemistry). The sequence reads were 
aligned to the reference genome (hg18) with the Novoalign aligner. Duplicate 
reads, resulting from PCR clonality or optical duplicates, and reads mapping to 
multiple locations were excluded from downstream analysis. Single nucleotide 
substitutions and small insertion deletions were identified and quality filtered 
within the SamTools software package. Filtering of variants for novelty was 
performed by comparison to dbSNP131, 1000 Genomes SNP calls (March 
2010) and variants previously seen in the KCL cohort. The exome sequencing 
was performed by Dr Michael Simpson who also provided guidance and support 
with the analysis of the data. 
Wellcome Trust Sanger Institute 
Genomic DNA from venous blood was obtained and captured by SureSelect 
Target Enrichment V3 (Agilent).GA-II (Illumina, USA).was used to sequence the 
sample. Reads were mapped to the reference genome via BWA, duplicates 
where marked and removed using Picard (v1.27). Single nucleotide variants 
were called using GATK (v1.0.4269M) and Samtools (v0.1.7) while indels were 
called using Dindel (1.01) and Samtools. All variants were reported within bait 
regions +/- 100bp and the results merged in a single VCF file. The variant 
consequences on the protein structure was predicted using Ensembl (58) and 
annotated with dbSNP 130 and the minor allele frequencies from the 1000 
genomes project to filter common variants (MAF >1%), to generate a profile of 
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rare sequence variants and variants not present in publically available 
databases. The exome sequencing was performed by Dr Saeed Al-Turki who 
also provided guidance and support with the analysis of the data. 
5.2.2 Functional studies 
Functional studies undertaken to understand the impact of the WHAMM variant 
identified in this study were carried out in collaboration with Dr Kenneth 
Campellone. 
5.2.3 Genetic and clinical studies of other patient cohorts 
Dr Erik Puffenberger planned and undertook the genetic studies for the Clinic 
for Special Children patient cohort. Exome sequencing was performed at the 
Broad Institute. 
Dr Kevin Strauss and Dr Heng Wang phenotyped affected patients seen at the 
Lancaster Clinic for Special Children and DDC clinic, Geagua County 
respectively. 
Analysis of the neuropathology was performed by Dr Brian Harding, Department 
of Neuropathology, University of Pennsylvania. The renal pathology is courtesy 
of Dr Kevin Strauss, Clinic for Special Children, Pennsylvania. 
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5.3 Results section A 
5.3.1 Identification of a pathogenic Amish founder mutation in SAMHD1  
5.3.1.1 Autozygosity mapping reveals a single notable autozygous 
region on chromosome 20q11.22-23 in affected individuals 
A single nuclear Swartzentruber Amish family (Figure 41, family 1) were 
recruited through the WOH project and were originally seen by Dr Christos 
Proukakis (Consultant Neurologist, University College Hospital) and Professor 
Harold Cross in 2007. Three siblings were affected by what was felt likely to be 
a novel condition and to consist of significant short stature (greater than -2.5 
SDS), hoarse voice, and skin sensitivity (the clinical phenotype is described in 
detail below). A further individual (VIII:X) from a closely related family (Figure 
41, family 2), thought likely to be affected by the same condition, was 
ascertained through the maternal grandmother. Family 2 lived in a different 
region of the USA and so the information pertaining to that individual was 
obtained through his maternal great aunt. The family pedigree is illustrated in 
Figure 41. 
Assuming that a founder mutation was responsible for this condition, 
autozygosity mapping studies were initially carried out for family 1. A genome 
wide microarray scan using Illumina Human CytoSNP-12v2.1 330K arrays was 
undertaken using DNA from the three affected brothers (VIII:I, VIII:III and 
VIII:IV) and one unaffected sibling (VIII:VIII). This identified a 5.4Mb region of 
chromosome 20q11.22-23 as the likely disease locus. The locus was delimited 
by markers rs2747539 and rs2009579 and contained 113 candidate genes.  
5.3.1.2 Exome sequencing identifies a novel intronic variant in SAMHD1 
within the splice-acceptor site of intron 12 
In parallel with the mapping studies, given that the vast majority of disease 
causing mutations occur within coding regions and intronic splice junctions, 
whole exome second generation sequencing was undertaken. Sequencing of 
the consensus coding sequence (CCDS) defined exome was undertaken in a 
single affected individual (VIII:IV, Figure 41, family 1). The efficiency of the 
hybrid capture was 71.4% with 45576342 of the 63847126 uniquely mapped 
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sequence reads originating from the targeted exomic regions (74.6% to the 
targeted regions +150bp). This level of capture efficiency and sequence 
generation resulted in a mean coverage of the CCDS defined exome of 85.6%, 
with 91.6% of CCDS bases covered by at least 10 reads. 
A single novel variant located within the essential splice site sequence of intron 
12 of the SAMHD1 gene (NM_015474.3 c.1411-2 A>G) was identified within the 
putative disease locus. The variant was analysed using the Alamut mutation 
interpretation software package (Interactive Biosoftware) which predicted the 
highly conserved splice acceptor site to be abolished. Primers were designed to 
flank the SAMHD1 variant for further investigation (see Appendix for primer 
sequences). PCR amplification and automated Sanger sequencing of the 3 
affected siblings, their mother and 5 unaffected siblings revealed that the 
mutation co-segregated with the disease phenotype (Figure 41). Homozygous 
loss of function mutations in SAMHD1 have previously been found to cause 
Aicardi-Goutières syndrome associated with an intracerebral aneurysmal and 
occlusive intracerebral arteriopathy (Ramesh et al., 2010, Xin et al., 2011). 
The SAMHD1 c.1411-2 A>G variant identified in this Amish family introduces a 
novel MspI restriction site. This permits visualisation of the mutation by MspI 
digestion of the 400bp PCR product, producing fragment sizes of 209bp and 
191bp. SAMHD1 PCR products generated from 112 control chromosomes from 
unaffected individuals from the same Ohio Amish community and 106 from 
unaffected individuals of European descent were digested with MspI restriction 
endonuclease and subsequently visualised on agarose gels. While no carriers 
of the mutation were identified in European controls, 3 out of 56 healthy 
individuals from the same Ohio Amish community were found to be 
heterozygous for the sequence variant, indicating that this is a founder mutation 
with a relatively high carrier frequency within the community. No homozygotes 
for the mutation were identified. 
5.3.2 SAMHD1 c.1411-2 A>G results in skipping of exon 13 
In order to establish the effect of the variant at the level of transcription, RNA 
was extracted from peripheral blood lymphocytes derived from the 3 affected 
siblings, their mother and a healthy control. RT-PCR was carried out.  
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Figure 41: Simplified pedigree of the Amish family initially investigated 
All affected individuals were subsequently shown to be homozygous for the SAMHD1 (NM_015474.3 
c.1411-2 A>G) variant (indicated). The parental sample was heterozygous and unaffected siblings were 
either wild type or heterozygous carriers. The genotype is shown in red under individuals in generations VII 
and VIII, with (+) denoting mutant and (-) wild type. 
  
Family 1             Family 2 
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Forward and reverse primers were designed specific for sequences in exon 11 
and 14 respectively; primers were designed to produce a product of size 356bp 
using wild type DNA. In accordance with this, amplification of control DNA 
produced a single product of expected size, whilst products from the affected 
individuals produced a 263bp fragment, consistent with the omission of exon 
13. The mothers sample produced bands of both sizes 263bp and 356bp 
consistent with her carrier status, (Figure 42A). 
The RT-PCR products from the healthy control, the mother and one affected 
individual were subsequently sequenced confirming the skipping of exon 13, 
that was predicted to result in an in-frame deletion of 31 amino acids (SAMHD1 
p.Glu471_Asp501del), (Figure 42B). 
5.3.3 Clinical findings of individuals homozygous SAMHD1 c.1411-2 
A>G  
The identification of the Amish SAMHD1 founder mutation permitted a more 
direct comparison of the affected Amish cases with previous reports of 
individuals homozygous for mutations in SAMHD1. Aicardi-Goutières syndrome, 
was initially described as a progressive familial early onset encephalopathy 
associated with intracranial calcifications and CSF lymphocytosis (Aicardi and 
Goutieres, 1984). The characteristic clinical picture associated with the 
condition is one of early onset subacute severe encephalopathy associated with 
intermittent sterile pyrexias, developmental regression and acquired 
microcephaly (Aicardi and Goutieres, 1984, Aicardi, 2002). The majority of 
affected individuals have abnormal neuroimaging findings include cerebral 
atrophy, intracranial calcification classically of the basal ganglia, and white 
matter changes most commonly affecting the frontotemporal region. In the early 
stages of the condition in addition to leukocytosis, raised levels of interferon 
alpha and neopterin are found in the CSF. Around 40% of affected individuals 
have been found to suffer chilblain lesions of the extremities (Depienne et al., 
2007). Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C SAMHD1, 
ADAR1 and most recently IFIH1 (Crow et al., 2006a, Crow et al., 2006b, Rice et 
al., 2009, Rice et al., 2012, Rice et al., 2014), account for around 90% of cases 
with a classical presentation. Since the initial description of Aicardi-Goutières 
syndrome significant phenotypic variability has been recognised. In some   
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Figure 42: SAMHD1 RT-PCR products 
(A) A single product of expected size 356bp (red arrow) is seen in the healthy control, the affected 
individual has a single product of size 263bp consistent with deletion of exon 13. The parent has two 
products, one of each size consistent with her carrier status. Positive control, mouse Beta-actin (500bp). 
(B) Electropherograms showing the sequence of SAMHD1 RT-PCR products in a wild-type control (above) 
and a homozygous affected individual (below). Exon 13 has been spliced out in the affected individual. 
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individuals the condition is almost indistinguishable from congenital infection 
(Crow and Livingston, 2008) whereas others have a later onset of disease and 
very mild neurological manifestations (Depienne et al., 2007). Clinical overlap 
with systemic lupus erythematosus is also widely recognised (Lee-Kirsch et al., 
2007, Ramantani et al., 2010), moreover heterozygous TREX1 mutations have 
been identified in a subset of patients with systemic lupus erythematosus (Lee-
Kirsch et al., 2007). 
In light of the genetic results, further history was gathered and the family were 
re-examined, the case histories and clinical findings are summarised below. We 
were subsequently informed by the family that following the identification of the 
SAMHD1 mutation as causative of the phenotype, the fourth affected child ( 
Figure 41, family 2) was tested locally and as expected, found to be 
homozygous for the SAMHD1 variant. 
Individual VIII:I: An 18 year old man was born at term weighing 2608g (-2 
SDS) after an uncomplicated pregnancy. He grew appropriately until 3 months 
of age, when weight gain slowed. There was no history of regression or 
unexplained fever, although he was described to be more lethargic from the age 
of 6 months. He has a mild hearing loss, development was otherwise normal 
and he works on the family farm, neurological examination was unremarkable. 
From the age of 1 year he developed unexplained pruritic inflammatory lesions 
at extremities in the cold weather, particularly on the helices of his ears, nose, 
cheeks, hands and feet, resolution of the lesions left significant scaring. His 
cutaneous features had previously been unclassified but the appearance and 
history is consistent with chilblains. The lesions have become less frequent over 
the last 5 years. He experiences joint stiffness that worsens in winter making it 
difficult to climb up onto the buggy (the main Amish form of transport). A long 
history of recurrent severe mouth ulcers necessitating ENT investigation was 
reported and direct laryngoscopy demonstrated laryngeal oedema. Since the 
age of 5 years he has developed a progressively hoarse voice. At the age of 18 
years he suffered a subarachnoid haemorrhage secondary to a ruptured middle 
cerebral artery aneurysm. Follow-up angiography detected a further berry 
aneurysm that was subsequently clipped. CT brain imaging revealed multiple 
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areas of hypoatenuation within the deep white matter of both cerebral 
hemispheres, but no intracranial calcification was reported. 
Notable findings on examination included short stature (156.8cm, -2.9 SDS), 
OFC was within normal limits (56cm, -0.7 SDS). There was marked swelling of 
the interphalyngeal joints. Neurological examination was unremarkable. At age 
18 he had no facial hair, genitalia were reportedly underdeveloped but 
understandably formal examination to establish pubertal status was refused. 
Additional findings included a left preauricular pit, said to also be present in 
other members of the family. 
Individual VIII:III: A 13 year old boy born at term weighing 2920g (-1.3 SDS). 
He had short stature measuring 137cm at 13 years (-3 SDS), OFC was within 
normal limits (54.5cm, -0.8 SDS). Developmental progress was similar to his 
older brother with no reported problems at school. Oral ulceration had been less 
severe and the hoarseness of his voice was less pronounced. He also suffered 
with joint stiffness which worsened in the winter months. Examination revealed 
similar cutaneous lesions to individual VIII:I. 
Individual VIII:IV: Is one of dizygotic twins aged 12 years. He weighed 2466g 
at birth (-2.3 SDS). He was short for his age at 122.5 cm (-3.8 SDS), OFC 
measured 52.5cm (-1.68 SDS). Development was essentially normal and he 
has no learning difficulties. He had joint stiffness, worst in cold weather and the 
most significant problems with oral ulceration. His voice was extremely hoarse. 
He had the same skin manifestations as his older brothers, although less 
severe. 
Patient VIII:X: An 8 year old boy born at term, previously diagnosed with 
cerebral palsy. He suffers from chilblain lesions on his buttocks that worsen in 
severity during cold weather. This child was not available for review and no 
medical records were available. 
Individual VII:I: The father of the 3 boys was reported to have had a hoarse 
voice and suffered with cutaneous lesions similar to his sons although much 
more mildly. He died at the age of 37 years from a presumed myocardial 
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infarction, no autopsy was performed as it is against Swartzentruber Amish 
beliefs. No DNA sample was available for molecular analysis, however one of 
his healthy children was homozygous for the wild-type SAMHD1 sequence 
indicating that he was likely heterozygous for the c.1411-2 A>G sequence 
variant. Consequently it remains a possibility that the cause of death may be 
related to his SAMHD1 carrier status. 
The diagnosis of Aicardi-Goutières syndrome in this family was only considered 
in the light of the whole exome sequencing data, and subsequent thorough 
clinical evaluation that resulted in recognition of the cutaneous manifestations 
as chilblain lesions. Oral ulceration is commonly found in patients with systemic 
lupus erythematosus and is now a recognised feature of Aicardi-Goutières 
syndrome (Ramantani et al., 2010, Dale et al., 2010). In Aicardi-Goutières 
syndrome the ulcerative lesions are usually limited to the buccal mucosa 
although pharyngeal ulceration has been reported (Ramantani et al., 2010). 
Interestingly, laryngeal ulceration and oedema resulting in a hoarse voice have 
also been described in systemic lupus erythematosus (Teitel et al., 1992). 
A specific association between Aicardi-Goutières syndrome caused by 
mutations in SAMHD1 and features of arthritis has been reported (Ramantani et 
al., 2010, Dale et al., 2010), this combined with the inflammatory vascular 
features reported is strongly supportive of an underlying abnormal immune 
response. In patients affected with Aicardi-Goutières syndrome of known 
molecular cause higher expression of genes induced by type I interferon is seen 
leading to a sustained interferon signature (Crow et al., 2014) and (Dale et al., 
2010, Rice et al., 2009). 
While a manuscript reporting this work was in preparation by our group Xin et al 
published a paper entitled "Homozygous mutation in SAMHD1 gene causes 
cerebral vasculopathy and early onset stroke" (Xin et al., 2011) in which they 
describe identifying the founder mutation in SAMHD1 in 14 Old Order Amish 
individuals. Despite this report the work presented in this thesis is novel, and at 
the time of discovery had not previously been reported. 
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5.3.4 Hershberger syndrome is genetically heterogeneous, with 
SAMHD1 Aicardi-Goutières syndrome accounting for the clinical 
presentation in some families 
The phenotype of the affected Amish individuals reported by Xin et al varied 
from the more severe classical Aicardi-Goutières syndrome to milder 
presentations much like the family described here. The variability in clinical 
presentation of Aicardi-Goutières syndrome led to a review of the medical 
records of other individuals recruited to the WOH project and Sanger 
sequencing for the SAMHD1 founder mutation in those with a phenotype 
suggestive of the condition. This molecular analysis revealed that SAMHD1 
likely accounted for the clinical presentation of four individuals from two nuclear 
Swartzentruber Amish families, all of whom were homozygous for the SAMHD1 
founder mutation. Interestingly, all four affected individuals had previously been 
diagnosed with Hershberger syndrome. Both families had moved from the 
Holmes County area since 2007 and so were unavailable for further clinical 
evaluation. However, all had been documented to have an Aicardi-Goutières 
syndrome compatible phenotype comprising of pre and post-natal growth 
failure, profound global developmental delay, spasticity, contractures, 
hyperreflexia and microcephaly. 
Over the last four years through the WOH project, we have subsequently 
identified an increasing number of additional Amish children and adults affected 
with Aicardi-Goutières syndrome in Holmes County who are homozygous for 
SAMHD1 c.1411-2 A>G, all are from the Swartzentruber church group. 
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5.4 Results section B 
5.4.1 Hershberger syndrome is comprised of two phenotypically 
distinct groups 
All the individuals from Holmes County originally described as having 
Hershberger syndrome that were WT for SAMHD1 were subsequently 
reviewed. In total we identified and obtained DNA samples from 12 children 
from 6 interlinking nuclear families (Figure 43, families 3-5 and 7-9) all of whom 
were said to have Hershberger syndrome. In 5 of the families, there were 
additional children now deceased who had a history consistent with the same 
disorder. Although all were profoundly neurologically impaired and most were 
microcephalic, it was clear that the phenotype of these individuals was distinct 
from those that were homozygous for SAMHD1. Given the distinctive features 
of the condition described below, it was renamed nephrocerebellar syndrome. 
All of the children with nephrocerebellar syndrome recruited to the WOH project 
were from the Swartzentruber church group, consequently only limited medical 
investigations had been performed. 
More detailed phenotyping revealed that at birth, affected children usually 
appeared normal. By 6 weeks of age, their parents report extreme irritability, 
poor feeding, and congenital roving nystagmus. Head size was normal at birth 
but brain growth was slow thereafter (Figure 44A). Psychomotor development 
was stagnant in all areas; affected children were non-communicative, had 
minimal purposeful hand use, and did not learn to sit or crawl.  The only notable 
physical features were coarse facial features more evident with increasing age, 
microcephaly, receding forehead, fine slow growing hair and hypoplastic yellow 
teeth that were prone to decay (Figure 44B). All affected children had axial and 
limb hypotonia with preservation of deep tendon reflexes. Some developed a 
movement disorder in late infancy that manifested as a combination of axial 
dystonia, limb chorea, and restlessness. Abnormal movements were especially 
evident during agitation or emotional excitement. Brief, multifocal seizures were 
common and in some cases medically intractable. All affected children suffered 
from severe visual impairment that was attributed primarily to abnormal cortical 
processing, but some patients also had evidence of mild or moderate optic 
atrophy. The majority of patients had irregular sleep patterns and reversal of the  
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Figure 43: Nephrocerebellar syndrome family pedigree and gene mapping 
Pedigree showing all of the Ohio families investigated, which interlink into a single extended family. Beneath is a pictorial representation of the SNP genotype data encompassing the 
chromosome 15 homozygous (red box) region in affected individual, healthy siblings investigated are heterozygous across this region. 
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normal sleep-wake cycle. Survival beyond teenage years was rare. The clinical 
presentations of individuals from Homes County affected with nephrocerebellar 
syndrome are summarised in Table 14. 
In parallel with our studies in Holmes County, the Clinic for Special Children 
(CSC; Lancaster Pennsylvania) and the DDC Clinic (Geagua County) were 
studying a clinically similar condition to that under investigation by ourselves. 
Through discussions at the “Genomic Medicine and the Plain Populations of 
North America” conference (July 2013 at Franklin and Marshall College, 
Pennsylvania), it became clear that the same condition was likely under 
investigation by all groups. The Clinic for Special Children and DDC cohort 
included individuals from Ohio, Wisconsin, Virginia and Indiana, but most 
patients were primarily of Big Valley, Pennsylvania origin. All of these children 
were from a less conservative Amish background than the Swartzentruber 
church, which permitted more detailed clinical investigation allowing more 
detailed collaborative clinical studies. 
Although the majority of the Holmes County Swartzentruber families underwent 
only minimal interactions with the modern medical system, a history of oedema 
with intercurrent illness was consistently given. All of the nephrocerebellar 
syndrome affected individuals who had had their renal function evaluated 
developed nephrotic syndrome during early childhood, which invariably 
progressed to fatal renal failure (Figure 45A). Proteinuria fluctuated over time 
from mild to heavy (mean urine protein:creatinine ratio 12.0 mg:mg, range 3.5 - 
20.0 mg:mg; normal reference range 0.0-0.2 mg:mg) and did not appear to be 
steroid-responsive. 
Neuroimaging revealed a spectrum of brain phenotypes. In some affected 
children, the myelination pattern appeared immature for age but the brain was 
otherwise morphologically normal (Figure 46A). In others, evidence of diffuse 
cerebral atrophy (most notably involving the frontal lobes), ex vacuo 
ventriculomegaly, hypomyelination, thin corpus callosum, and 
underdevelopment of the cerebellar vermis and hemispheres was identified 
(Figure 46B). At this stage, sufficient imaging data was not available to 
determine if this variability was age-dependent; i.e. if there was progressive 
 207 
atrophy over time. Electroencephalograms were characterised by a slow and 
disorganized background, absent posterior (occipital) rhythm, poor wake-sleep 
transition, multifocal spikes and sharp waves, and rarely, high-voltage modified 
hypsarrhythmia. 
5.4.2 Renal pathology 
Two affected children had renal biopsies (Figure 45B-D), which showed 
enlarged and hypercellular glomeruli, narrowing of capillary lumina, lobulation of 
glomerular tufts, disorganised segmental sclerosis with endocapillary 
proliferation, and duplication of the glomerular basement membrane, producing 
a characteristic “tram-track” configuration. While components of both 
membranoproliferative glomerulonephritis type I and IgA nephropathy were 
present, the abundant number of glomeruli with disorganised segmental 
sclerosis and endocapillary proliferation were reflective of the rapid and 
intractable course of kidney disease observed in patients. 
5.4.3 Neuropathology 
An affected girl died at age 9.3 years and her brain was fixed for examination 
27 hours post-mortem. Brain weight was 681grams (expected weight for age, 
1100-1300 grams). The cerebral hemispheres were symmetric and showed no 
softening, atrophy, or mass effect. The leptomeninges were clear and 
transparent, there was no internal herniation, and the basal vessels and cranial 
nerves appeared normal. Gross coronal sections showed no malformation of 
the cortex, white matter, ventricular system or basal grey nuclei. Histological 
sections from the hexalaminar cortex, hippocampus, lentiform and caudate 
nuclei, internal capsule, hypothalamic nuclei, mammillary body, and the 
ependymal lining of the third ventricle were normal, and horizontal sections of 
midbrain and pons were unremarkable (the medulla was unavailable for 
examination). The white matter had scattered spongy changes but no cellular 
reaction; myelin was well preserved with no gliosis. 
The cerebellum was markedly abnormal. Macroscopically the cerebellar vermis 
and hemispheres were firm and sclerotic (Figure 47A). Histologically the 
cerebellar hemispheres had sufficient branching, but folia were short and 
stubby and granule cells were markedly decreased (Figure 47B).  
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Figure 44: Clinical Features of nephrocerebellar Syndrome 
(A) Children affected with nephrocerebellar syndrome (NCS) were typically born with a low-normal head 
circumference, but head growth decelerated by 6 months of age, reflecting decreased postnatal brain 
growth (gray shaded area = normal head circumference for age, mean ± 2SD; red circles = head 
circumference of patients, mean ± SD), data courtesy of Dr Kevin Strauss. (B)  Primary and secondary 
dentition appeared hypoplastic and were prone to decay. 
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Table 14: Clinical findings of individuals with nephrocerebellar syndrome 
  
Pedigree reference X:1 X:9 X:11 X:16 X:17 X:18 X:19 X:25 X:33 X:44 X:55 X:56 X:59 X:62
Gender
Age at evaluation (years) † 5.9 0.8 9.8 † 6.4 2.9 † 10.3 2.1 11 8.29 1.3 X:7.8
Age of Death 13.7 3.3 3.2 2.7 12.3
WDR73 Genotype M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M
WHAMM Genotype M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M M/M
Development
No independent sitting 1 1 1 1 1 1 1 1 1 1 1 1 1 1
No purposeful hand use 1 1 1 1 1 1 1 1 1
Neurology
OFC SDS N/K -4 -3.3 -2.2 N/K -2.2 -3.5 N/K N/K -6 -2.4 -3.1 -5 N/K
Non-communicative 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Central hypotonia 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Restless limb movements 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Roving eye movements 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Neuroimaging
CT-cerebellar 
hypoplasia
CT-cerebellar 
hypoplasia
CT-NAD CT-NAD
Epilepsy 1 1 1 1 1 Febrile 1 1
Renal 
Nephrotic syndrome
Severe 
Oedema prior 
to death
1 Unknown Unknown
Symptomatic  
no evaluation
Unknown Unknown
Oedema prior 
to death
1
Symptomatic 
no evaluation
Symptomatic  
no evaluation
1
Renal insufficiency/failure
Severe 
Oedema prior 
to death
N/K
Severe 
generalised 
oedema prior 
to death
N/K N/K
Severe 
generalised 
oedema prior 
to death
1 N/K N/K
Physical anomalies
Dental caries 1 1 1 1 1 1 1 1
†, Deceased; M, denotes the presence of the variant;  1, indicates the presence of a feature; OFC, occipitofrontal circumference; SDS, standard deviation scores; N/K, not known
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Figure 45: Nephrocerebellar syndrome renal pathology 
(A) The pace of nephron loss varies among individual patients (indicated by blue, orange, and green symbols), and is punctuated by episodes of acute, reversible renal failure (red asterisks). 
Renal failure was the primary cause of mortality across all three cohorts (red arrow indicates time of death). Gray shaded area = normal serum creatinine for age, mean ± 2SD. (B) Glomeruli of 
affected patients are enlarged and hypercellular with narrowing of capillary lumina and lobulation of glomerular tufts. (H&E stain 40x magnification). (C) There is disorganised segmental sclerosis 
with endocapillary proliferation (H&E stain 20x magnification), and (D) duplication of the glomerular basement membrane produces the characteristic “tram-track “ configuration (yellow 
arrowhead; Jones stain, 40x magnification). 
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Figure 46: Neuroradiology findings in nephrocerebellar syndrome 
(A) Some patients had small but apparently structurally normal brains (affected female, age 3 months). (B) Commonly observed abnormalities among other patients include enlarged, irregular 
ventricles (asterisks), indicating ex vacuo cerebral atrophy, hypoplastic frontal lobes (red arrow), underdevelopment and/or atrophy of the cerebellar vermis and hemispheres (red arrowheads), 
and thin corpus callosum (yellow arrow) (affected male, age 19 months; from left to right, coronal T2, transverse T2, coronal T2, sagittal T1). We did not have sufficient historical imaging to 
determine if this variability was age-dependent; i.e. reflective of postnatal degeneration or atrophy of brain tissue. Data courtesy of Dr Kevin Strauss, Clinic for Special Children, Pennsylvania 
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Purkinje cells were better preserved by comparison, but still decreased in 
number, crowded together, and surrounded by rich Bergman gliosis. Purkinje 
cells were overlaid by a thin molecular layer that was hypercellular: some of 
these cells were Bergman glia but others were misplaced Neu-N positive 
granule cells. Rare Purkinje cells were also present in the molecular layer. 
Globose swellings of Purkinje cell dendrites (‘asteroid bodies’) were covered in 
fine spikes, and dysmorphic Purkinje dendritic trees formed ‘weeping willow’ 
arrangements throughout the narrow molecular layer (Figure 47C and D).  
Synaptophysin staining was strong throughout the molecular layer and present 
around Purkinje cell somata while punctate glomerular immunoreactivity was 
also present in the depleted granule layer. A neurofilament 211 stain 
demonstrated preservation of basket cells, fibers, and pericellular baskets, as 
well as occasional. Purkinje axonal swellings (“torpedos”) (Figure 47C). The 
dentate nucleus was well formed, properly convoluted, and had a normal 
complement of neurons.  Myelin of the amiculum was well preserved but there 
was a subtle decrease of myelin in the hilum where gliosis was visible with 
GFAP stain. No axon terminal swellings were detected in or around the dentate 
nuclei. 
5.4.4 Disease gene mapping identifies a 2.95Mb homozygous region on 
chromosome 15q25.2-q25.3  
Assuming that autosomal recessive inheritance of a founder mutation was likely 
causative of nephrocerebellar syndrome, we isolated DNA from the 
blood/buccal samples of 7 affected individuals, 9 healthy siblings and their 
parents (Figure 43). A genome wide microarray scan was performed using 
Illumina Human CytoSNP-12v2.1 330K arrays. Homozygosity analysis identified 
a single autozygous region shared by all affected individuals of 2.95Mb on 
chromosome 15q25.2-q25.3, delimited by markers rs872332 and rs8027118, 
chr15:82320166-85268752, likely to correspond to the disease locus and 
refining the locus above defined by our collaborators. No other notable regions 
of autozygosity were observed giving an estimated LODmax of >15. The putative 
disease locus was predicted to contain 30 genes, 2 of which are hypothetical, 
and 2 of which are predicted pseudogenes. 
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Figure 47: Nephrocerebellar syndrome neuropathology. 
(A) Medial surface of the brain shows atrophy and sclerosis of cerebellar folia (yellow arrowhead), 
especially anteriorly.  (B) Folia of the cerebellar cortex are short and stubby with severe loss of granule 
cells, crowded Purkinje neurons, and a hypercellular molecular layer (H&E, bar=500 µm).  (C) 
Neurofilament stain shows disoriented Purkinje cell dendrites with irregular globose swellings, called 
asteroid bodies (inset, bar=100 µm), Purkinje torpedo axonal swellings (yellow arrow), and preservation of 
basket fibers with  empty baskets. (D) Calbindin stain shows the fine structure of Purkinje neurons, which 
are decreased in number, crowded together, and surrounded by rich Bergman gliosis. The Purkinje cell 
layer is overlaid by a thin, hypercellular molecular layer composed of Bergman glia, some misplaced Neu-
N positive granule cells, and rare Purkinje neurons. Dysmorphic Purkinje dendritic trees formed ‘weeping 
willow’ arrangements throughout the narrow molecular layer; abnormal, fine spikes were observed on the 
surface of some Purkinje cells within the molecular layer (asterisks;  inset, bar=50 µm). The histological 
appearance suggests disruption of external granule layer development and survival.  
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5.4.5 Whole exome sequencing identifies two likely deleterious 
frameshift variants within the 15q25.2-q25.3 critical region 
To identify the causative mutation, whole exome sequence analysis of a single 
affected individual was undertaken at the Wellcome Trust Sanger Institute, the 
sample generated 11.1Gb with a mean depth of 119. After appropriate filtering, 
two likely deleterious variants in two closely linked genes were identified within 
the 15q25.2-q25.3 critical region, both predicted to be novel homozygous 
frameshift mutations. The first was a seven base pair deletion 
(NM_001080435.2:c.1264_1270del) in exon 5 of the 10 exon WHAMM (WAS 
protein homolog associated with actin, golgi membranes and microtubules) 
gene. The proximal end of the WHAMM gene containing the putative mutation 
is highly repeated throughout the genome with multiple highly similar copies of 
the gene positioned throughout chromosome 15q, rendering sequence analysis 
problematical. The second mutation identified entailed a single base pair 
deletion (NM_032856.2:c.888del) in the final exon of WDR73 (WD Repeat 
Domain 73) gene, which is not duplicated facilitating sequence analysis. Neither 
variant was listed in online sequencing project databases. Sanger sequencing 
confirmed the presence of the WDR73 frameshift variant (Figure 48A-B), which 
co-segregated perfectly with disease status, affected individuals were 
homozygous with respect to the mutation, all of the parents were carriers of the 
variant, and available unaffected siblings were either homozygous wild-type or 
heterozygous carriers (Appendix). 
5.4.6 Optimising a strategy for confirming the WHAMM c.1264_1270del 
variant 
The repeated nature of the WHAMM gene required the development of a 
sequencing strategy to confirm the presence of the c.1264_1270del putative 
mutation identified by exome sequencing. The Integrative Genomics Viewer 
(IGV, Broad Institute) plot for the variant did not indicate that the variant might 
be artifactual (Figure 49). 
Given this, alignments were generated for WHAMM exon 5 containing the 
c.1264_1270del variant, and surrounding sequences. Primers were then 
manually positioned in regions in which at least a single nucleotide specific to 
the WHAMM gene was present. 
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Figure 48: WDR73 c.888del  
(A) Electropherograms showing the WDR73 c.888del sequence alteration in a WT control and (B) a 
homozygous affected individual. (C) Diagrams of the wild type (wt) WDR73 protein and frameshift 
p.Phe296LeuFs*26 (fs) variant are shown. The frameshift protein includes the N-terminal 295 amino acids 
followed by 26 aberrant residues, and lacks half of the second WD repeat domain and all of the third. 
C 
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Figure 49: WHAMM Integrative Genomics Viewer plot  
(A) Integrative Genomics (IGV) plot showing alignments of reads around the WHAMM 
c.1264_1270delATAAAAG variant called in an individual affected with nephrocerebellar syndrome. The 
variant is shown as present in all reads correctly aligned. (B) IGV plots of an affected individual and 
healthy unrelated control sequences are compared in parallel. The WHAMM variant is not seen in aligned 
reads derived from the control individual.  
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Using this approach PCR product corresponding specifically to the WHAMM 
gene was ultimately obtained, suitable for Sanger sequencing (Figure 50). This 
confirmed the presence of the variant which was found to cosegregate with the 
disease phenotype. All patients were thus confirmed to be doubly homozygous 
for both WHAMM and WDR73 sequence variants, with all the parents carrying 
both variants and the available siblings either heterozygous or WT for both 
(Appendix). Sanger sequencing of 144 Holmes County, Ohio controls, identified 
13 individuals who were heterozygous for both the WDR73 and WHAMM 
variants, and a single individual who was heterozygous for WDR73 while being 
wild type for WHAMM. 
In parallel with our studies the Clinic for Special Children (CSC) and DDC clinic 
had SNP genotyped nephrocerebellar syndrome patients from Pennsylvania, 
Michigan and Ohio. A 3.96Mb homozygous region on 15q25.1-25.3 
(chr15:81427307-85369577), was shared by all the affected individuals. The 
2.95Mb locus identified by our studies fell within and refined this locus. 
Previously the CSC had performed sanger sequencing for the coding regions of 
26 validated genes within the shared homozygous block including WHAMM and 
had identified no likely pathogenic variants. Exome sequencing and analysis of 
seven affected patients was undertaken by the CSC at the Broad Institute, 
USA, which identified only the WDR73 variant. We shared our WHAMM 
sequencing strategy with the CSC, who confirmed the presence of this mutation 
in their cohort. 
5.4.7 Nephrocerebellar syndrome is likely to comprise a composite 
phenotype arising from both WHAMM and WDR73 mutations 
The WHAMM c.1264_1270del variant was subsequently shown to cosegregate 
with the disease phenotype in a total of 29 patients. A three year old child 
proved to be the only exception. Given her Amish heritage and the lack of a 
unifying diagnosis, this child had been discussed with Dr Kevin Strauss, CSC. 
The neurological features described appeared consistent with nephrocerebellar 
syndrome and so DNA was sent to Dr Strauss for further investigation. The 
child was homozygous for the WDR73 variant, but found to be only 
heterozygous for the WHAMM variant. Consistent with this, one parent was 
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heterozygous for both variants while the other was heterozygous for WDR73 
while being WT for WHAMM. 
In light of the genetic findings described above, this child was subsequently 
reviewed at the CSC, at the age of three years her neurological features were 
entirely consistent with those of other nephrocerebellar syndrome affected 
children. She had notable microcephaly of -5 SDS, irritability, hypotonia, cortical 
visual impairment and a seizure disorder. Serial neuroimaging by MRI revealed 
cerebellar atrophy and degeneration. Significantly however, she had no 
evidence of renal disease. The age of onset of proteinuria and renal impairment 
is variable in nephrocerebellar syndrome (Figure 45A), thus a number of 
plausible possibilities remain; (i) The WHAMM variant underlies the renal 
phenotype of nephrocerebellar syndrome and WDR73 the neurological 
component, (ii) WDR73 is the sole cause of the nephrocerebellar syndrome 
phenotype and the child is yet to develop renal disease, (iii) the phenotype 
attributable to loss of function of WHAMM is unrecognisable beneath that of the 
more profoundly debilitating WDR73 phenotype or (iv) the child is compound 
heterozygous for WHAMM. 
In order to investigate the fourth possibility further, the coding sequence and 
associated splice junctions of WHAMM was sequenced and primers checked 
against alignments of similar sequences to ensure unique amplification of 
WHAMM alone (primer sequences in Appendix). No potentially pathogenic 
second variant was identified. Amplification of the transcript from lymphocyte 
derived cDNA has proved problematical. 
5.4.8 In silico modelling of the WHAMM and WDR73 variants 
Alamut and mutation taster insilico variant prediction software were used to 
predict the effects of the WHAMM and WDR73 variants .The nature and 
position of the WHAMM variant lead to complexity in accurately predicting the 
effect. The canonical WHAMM gene encodes a “wild type” protein of 809 amino 
acids that consists of an N-terminal WHAMM membrane-interaction domain 
(WMD), a central coiled-coil (CC) domain that binds microtubules, and a   
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BC1117556       TTGTAGATGAATTAGAAATGCAATTTTATGAAATTCAGTTAGAACTATATGAAGTTAAAT 5381 
segment4        TTGTAGATGAATTAGAAATGCAATTTTATGAAATTCAGTTAGAACTATATGAAGTTAAAT 5373 
whamml2         TTGTAGATGAATTAGAAATACAATTTTATGAAATTCAGTTAGAACTATATGAAGTTAAAT 5590 
whamml1         TTGTAGATGAATTAGCAATACAATTTTATGAAATTCAGTTAGAACTATATGAAGTTAAAT 5512 
WHAMM           TTGTAGATGAATTAGAAATACAATTTTATGAAATTCAATTAGAACTATATGAAGTTAAAT 5110 
                *************** *** ***************** ********************** 
 
BC1117556       TTGAGATATTAAAAAACGAAGAAATACTGCTTACTACACAGTTGGACTCTCTTAAAAGAC 5441 
segment4        TTGAGATATTAAAAAACGAAGAAATACTGCTTACTACACAGTTGGACTCTCTTAAAAGAC 5433 
whamml2         TTGAGATATTAAAAAACAAAGAAATACTGCTTACTACACAGTTGGACTCTCTTGAAAGAC 5650 
whamml1         TTGAGATATTAAAAAACAAAGAAATACTGCTTACTACACAGTTGGACTCTCTTGAAAGAC 5572 
WHAMM           TTGAGATATTAAAAAACGAAGAAATACTGCTTACTACACAGTTGGACTCTCTTAAAAGAC 5170 
                ***************** *********************************** ****** 
 
BC1117556       TTATAAAAGGTAAAGTTTATATTTAAGTATATAGATAACAATGTTTA-----TAAATTTA 5496 
segment4        TTATAAAAAGTAAAGTTTATATTTAAGTATATAGATTACAATGTTTA-----TAAATTTA 5488 
whamml2         TTATAAAAGGTAAAGTTTTTATTTAAGTATATAGATTACAATGTTTA-----TAAATTTA 5705 
whamml1         TTATAAAAGGTAAAGTTTTTATTTAAGTATATAGATTACAATGTTTA-----TAAATTTA 5627 
WHAMM           TTATAAAAGGTAAA------ATTTAAGTATATAGATTGCAATGTTTAAATTATAAATTTA 5224 
                ******** *****      ****************  *********     ******** 
 
BC1117556       AGGAAATACAGACCATATTATCAATTACTTTTTGTAAACTGTAACATCTGAAAATTTCCT 5556 
segment4        AGGAAATACAGACCATATTATCAATTACTTTTTGTAAACTGTAACATCTGAAAATTTCCT 5548 
whamml2         AGGAAATACAGACCATATTATCAATTACTTTTTGTAAACTGTAACATCTGAAAATTTCCT 5765 
whamml1         AGGAAATACAGACCATATTATCAATTACTTTTTGTAAACTGTAACATCTGAAAATTTCCT 5687 
WHAMM           AGGAAATACAGACCATATTATCAATTACTTTTTGTAAATTATAACATCTGAAAATTTCCT 5284 
                ************************************** * ******************* 
 
BC1117556       AAAGTTTTCCTTCAGTAGTTTATTATTCAAATAATATATTCATTGTTAGCACATAGCAAA 5616 
segment4        AAAGTTTTCCTTCAGTAGTTTATTATTCAAATAATATATTCATTGTTAGCACATAGCAAA 5608 
whamml2         AAAGTTTTCCTTCAGTGGTTTATTATTCAAATAATATATTCATTGTTAGCACATAGCAAA 5825 
whamml1         AAAGTTTTCCTTCAGTGGTTTATTATTCAAATAATATATTCATTGTTAGCACATAGCAAA 5747 
WHAMM           AAAGTTTTCCTTCAGTGGTTTATTATTCAAATAATATATTCATTGTTAACACATAGCAAA 5344 
                **************** ******************************* *********** 
 
Figure 50 WHAMM c.1264_1270del variant 
Alignment of WHAMM genomic sequence surrounding the c.1264_1270del variant (highlighted in red) is 
shown above. Primers sequences are highlighted in yellow with bases specific to the WHAMM sequence 
in bold and underlined. Electropherograms obtained using these primers show the DNA sequence at the 
position of the WHAMM variant in a WT control and a homozygous individual affected with 
nephrocerebellar syndrome. 
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C-terminal polyproline-WH2-connector-acidic domain that interacts with actin 
and Arp2/3 to promote actin nucleation (WHAMM WT;Figure 51A) (Campellone 
et al., 2008). The 7 nucleotide (ATAAAAG) deletion is predicted to potentially 
result in a translational frameshift, leading to premature termination. This 
WHAMM variant encodes a protein predicted to contain the first 421 amino 
acids of WHAMM followed by 34 aberrant residues after the frameshift mutation 
(WHAMM c.1264_1270del; WHAMM p.Ile422Lysfs*35 Figure 50A). Thus, any 
polypeptide produced from the mutated WHAMM allele would be predicted to 
retain its entire membrane-binding domain, half of its microtubule-binding 
domain, and completely lack the domain responsible for actin nucleation. The 
deleted bases c.1264_1270 of WHAMM comprise the last 7 base pairs of exon 
5 of the gene. The last three bases of an exon form part of the donor splice 
junction consensus sequence. While the position of the variant would predict 
that the donor splice site would be disrupted, it is difficult to be certain what the 
specific outcome of this may be. A suitable cryptic splice donor site could be 
used, and exon loss or retention are other possibilities, with nonsense mediated 
mRNA decay seeming overall to be the most probable outcome resulting from 
this variant. It remains a possibility that any splicing defect would be incomplete 
and that some transcripts would be spliced normally resulting in production of 
the mutant protein. 
Little is known about WDR73 and the protein function remains essentially 
uncharacterised. The WDR gene family encodes a series of proteins with WD 
(Trp-Asp) repeat domains that fold to form a tertiary structural beta-propeller 
conformation, which consist of 4 to 8 blade-like structures arranged in a circle. 
These act as a stable platform for the transient interplay among other proteins 
(van Nocker and Ludwig, 2003) and the assembly and disassembly of large 
protein complexes (Haack et al., 2012, Hayflick et al., 2013). WDR proteins 
participate in an array of cellular functions, including cell division, autophagy, 
signal transduction, vesicle trafficking, and cystoskeletal dynamics (van Nocker 
and Ludwig, 2003, Cohen-Katsenelson et al., 2011, Gregory and Hayflick, 
1993, Gross et al., 2001, Saitsu et al., 2013). A number of WDR proteins are 
expressed in mammalian brain (Cohen-Katsenelson et al., 2011, Traka et al., 
2013, Castets et al., 1996) and recently, mutations of WDR45 (Haack et al., 
2012, Saitsu et al., 2013) WDR62 (Bilguvar et al., 2010, Memon et al., 2013), 
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and WDR81 (Gulsuner et al., 2011, Tan, 2006), have been associated with 
severe neurodevelopmental disability in humans. The single nucleotide deletion 
(T) is within the last exon of the gene and is expected to result in a translational 
frameshift leading to premature termination, the WDR73 c.888del variant 
encodes a protein which is predicted to contain the first 295 aminoacids of the 
protein followed by 27 aberrant residues after the frameshift (Figure 48C).The 
position of the variant within the last exon of the gene, may indicate that mutant 
transcript could escape nonsense mediated mRNA decay surveillance 
mechanisms. 
To confirm whether WHAMM and WDR73 protein expression are altered by the 
mutations, skin fibroblasts were collected and cultured from two individuals with 
nephrocerebellar syndrome, both of whom were homozygous for both the 
WHAMM and WDR73 variants, as well as from healthy individuals in the same 
community. In contrast to the two healthy controls, the fibroblasts from the two 
nephrocerebellar syndrome affected individuals were difficult to maintain in 
culture growing very slowly, halting proliferation after only a few cell divisions. 
Thus far, we have been able to maintain cultures from only one affected 
individual for several months. Similarly lymphoblastoid cell lines were 
established from nephrocerebellar syndrome affected individuals, heterozygous 
carriers of both the WHAMM and WDR73 variants and related wild type 
individuals. No significant difference in growth rates between lymphoblastoid 
cell lines was observed.  
Investigation of the functional consequences of the WDR73 variant are primarily 
being undertaken by the CSC and the results of these studies are not yet 
available. However functional assessments of the WHAMM mutation were 
undertaken in collaboration with Dr Ken Campellone. 
5.4.9 Nephrocerebellar syndrome fibroblasts express a truncated 
WHAMM protein 
WHAMM expression was examined by immunoblotting using extracts from 
nephrocerebellar syndrome primary fibroblasts and a rabbit polyclonal antibody 
raised to the whole protein, but preferentially recognising the C-terminal WCA 
domain of WHAMM previously generated by Dr Campellone   
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Figure 51: Nephrocerebellar syndrome fibroblasts do not express full length WHAMM 
protein 
(A) Diagrams of the wild type (WT) WHAMM protein and frameshift p.Ile422Lysfs*35 (fs) variant. The 809-
residue WT protein includes an N-terminal WHAMM membrane-interacting domain (WMD) that binds 
phospholipids, a central coiled-coil (CC) domain that binds microtubules, and a C-terminal polyproline-
WH2-WH2-connector-acidic (PWWCA) segment promotes actin nucleation. The frameshift variant 
includes the N-terminal 421 residues of WHAMM followed by 34 aberrant residues after the frameshift 
mutation, and lacks half of the CC domain and all of the PWWCA segment. (B) Primary skin fibroblasts 
from WT, or homozygous mutant (NCS) individuals were subjected to immunoblotting with anti-WHAMM or 
anti-tubulin antibodies. Relative levels of the WT WHAMM protein were determined by densitometry. Data 
in B is courtesy of Dr Ken Campellone, University of Connecticut. 
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Figure 52: Nephrocerebellar syndrome fibroblast cells express a truncated WHAMM 
variant with an altered localisation pattern 
WT or nephrocerebellar syndrome (NCS) fibroblasts were fixed and stained with antibodies to visualise 
WHAMM (green) or microtubules (red), and with DAPI to label DNA (blue). In contrast to the compact 
perinuclear WHAMM staining of in WT cells, the nephrocerebellar syndrome cells exhibited a more 
reticular WHAMM localisation pattern. The mean fluorescence intensity of WHAMM staining was quantified 
and found to be lower in nephrocerebellar syndrome cells. Data shown is courtesy of Dr Ken Campellone. 
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(Campellone et al., 2008). As expected, full-length WHAMM was found not to 
be expressed in fibroblasts (Figure 51B). However, utilising a guinea pig 
monoclonal antibody raised against the coil-coil domain of WHAMM detected a 
WHAMM protein with an abnormal and unusual intracellular localisation pattern 
in primary fibroblast cell lines from nephrocerebellar syndrome affected 
individuals (Figure 52). 
5.4.10 Nephrocerebellar syndrome fibroblasts have reduced F-actin 
staining and altered organelle morphology 
Among WASP-family proteins, WHAMM is the only molecule whose main 
function is known to lie in remodelling membranes of the secretory system as 
RNA interference approaches have demonstrated that WHAMM organises the 
Golgi apparatus near the centrosome promoting tubulation of endoplasmic 
reticulum (ER)-Golgi intermediate compartment (ERGIC) membranes 
(Campellone et al., 2008). WHAMM is also the only WASP-family member 
known to physically interact with microtubules (Shen et al., 2012), and its 
membrane tubulation function has been shown to require both its microtubule-
binding and actin nucleation activities (Campellone et al., 2008). To determine if 
nephrocerebellar syndrome fibroblasts have altered cytoskeletal or membrane 
organisation, we stained cultured fibroblasts with probes to visualise the 
microtubule and actin cytoskeletons and with antibodies to organelles of the 
traditional secretory pathway, including the ER (GRP94), ER-exit sites (Sec16), 
ERGIC (ERGIC-53), cis-Golgi (GM130), and trans-Golgi (TGN46). 
Nephrocerebellar syndrome fibroblasts were found not to contain any gross 
alterations in microtubule organisation or in ER morphology. However, 
nephrocerebellar syndrome fibroblasts were shown to contain fewer punctate F-
actin structures in their cytoplasm when compared with control cells, unusual 
orthogonal bundles of stress fibres and F-Actin aggregates were also seen 
(Figure 53). Given that the nephrocerebellar syndrome affected individual from 
whom these cells originate is homozygous for both the WHAMM and WDR73 
sequence variants, it is not possible to attribute these intracellular abnormalities 
to either (or both) mutations. However, these observations would be consistent 
with a lack of WHAMM actin nucleation function in cells, moreover, again in 
accordance with a known role for WHAMM in organising membranes of the 
intermediate compartment and Golgi apparatus, the ER-Golgi Intermediate   
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Figure 53: NCS fibroblasts have abnormalities in their actin cytoskeleton 
(A) WT or nephrocerebellar syndrome (NCS) fibroblasts were fixed and stained with phalloidin to visualise 
F-actin (green) and DAPI to label DNA (blue). NCS cells contained unusual orthogonal bundles of stress 
fibers and F-actin aggregates. A lack cytoplasmic F-actin puncta in NCS cells is highlighted in the 
magnified images. (B) The % of cells with cytoplasmic F-actin puncta in the perinuclear region was 
quantified. Each bar represents the mean (+/- SEM) from analyses of 350 cells. The number of F-actin 
puncta per cell was also quantified. Each bar represents the mean (+/- SEM) from analyses of 11 cells. ***, 
p<0.001. (C) The % of cells with aberrant (orthogonal or aggregated) F-actin stress fibers was quantified. 
Each bar represents the mean (+/- SEM) from analyses of 350 cells. ***, p<0.001. Data shown is courtesy 
of Dr Ken Campellone. 
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compartment (ERCIG), cis-Golgi, and trans-Golgi were larger in 
nephrocerebellar syndrome fibroblasts when compared to control fibroblasts 
(Figure 54). 
5.4.11 Nephrocerebellar syndrome fibroblasts exhibit defective 
autophagosome biogenesis 
Other aspects of membrane remodelling beyond secretory organelle 
morphology might be also altered in nephrocerebellar syndrome fibroblasts. 
One such aspect of cell function that requires dramatic changes in membrane 
shape is macroautophagy, the endogenous degradation of the intracellular 
components by the cell (hereafter called autophagy). Since the ER is one major 
source of autophagosomal membranes (Hayashi-Nishino et al., 2009, Zoppino 
et al., 2010), patient fibroblasts were investigated to determine whether they 
contained normal autophagosomes by staining them with an antibody to LC3A, 
a general marker of these organelles. Interestingly, while fibroblasts from 
healthy individuals contained a consistent basal of LC3A-positive structures and 
circular autophagosomes under normal growth conditions, nephrocerebellar 
syndrome fibroblasts were found to be devoid of LC3A-associated membrane 
structures (Figure 55). 
To test whether fibroblasts from nephrocerebellar syndrome affected individuals 
are able to form autophagosomes under conditions in which autophagic flux 
was disrupted, cells were treated with chloroquine, a drug which increases 
lysosomal pH and causes autophagosomes to accumulate in the cytoplasm. 
Strikingly, while control fibroblasts exhibited a buildup of LC3A-positive 
autophagosomes under these conditions (Figure 55), chloroquine treatment 
caused a significant amount of detachment (and presumably death) of 
nephrocerebellar syndrome fibroblasts. The remaining adherent cells showed a 
disorganised and diffuse LC3A staining pattern and notably their cytoplasm was 
filled with vacuoles (Figure 55). Importantly, re-introduction of WT WHAMM 
rescues the autophagy defects (Figure 56). Collectively, these results indicate 
that WHAMM plays a previously-unrecognised role in cell survival and 
autophagy, and that an essential role of WHAMM in human development is 
likely. 
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Figure 54: Nephrocerebellar syndrome fibroblasts have abnormalities in their ER-Golgi 
intermediate compartment (ERGIC). 
(A) WT or nephrocerebellar syndrome (NCS) fibroblasts were fixed and stained with antibodies to detect 
ERGIC-53 (red) and with DAPI to label DNA (blue). The ERGIC appeared to be enlarged, elongated, or 
more dispersed in NCS cells. A similar phenotype was observed when cells were stained with antibodies 
to GM130, a marker of the cis-Golgi (data not shown). (B-C). The area occupied by the entire cell 
(determined by F-actin staining), the ERGIC (detected using antibodies to ERGIC-53), and the nucleus 
(identified by DAPI staining) were calculated using ImageJ and converted to a ratio of organelle area/cell 
area. Each bar represents the mean (+/- SEM) from analyses of 25 cells. ***, p<0.001. Data shown is 
courtesy of Dr Ken Campellone. 
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Figure 55: Nephrocerebellar syndrome fibroblasts have severe defects in 
autophagosome biogenesis 
(A) WT or Nephrocerebellar syndrome (NCS) fibroblasts were grown in the absence or presence of 
chloroquine, fixed, and stained with antibodies to detect LC3A (red) and with DAPI to label DNA (blue). 
Compared to WT cells, NCS cells were virtually devoid of LC3A-positive (pre-) autophagosomal structures 
at steady-state (top row). When cells were grown in the presence of chloroquine to block autophagosome 
flux (bottom row), WT fibroblasts accumulated large numbers of mature autophagosomes (as expected), 
whereas NCS fibroblasts became filled with large vacuoles that did not stain for autophagosomal or 
lysosomal markers. (B) The number of LC3A puncta per cell, and the relative area within each cell that 
contained autophagosomes was quantified. The areas occupied by the entire cell (determined by F-actin 
staining) and autophagosomes (identified by LC3A staining) were calculated using ImageJ and converted 
to a ratio. Each bar represents the mean (+/- SEM) from analyses of 11 cells. ***, p<0.001. (C). The % of 
cells with large cytoplasmic vacuoles was quantified. Each bar represents the mean (+/- SEM) from 
analyses of 250 cells. ***, p<0.001. Data shown is courtesy of Dr Ken Campellone. 
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Figure 56: Re-introduction of wild type WHAMM into nephrocerebellar syndrome 
fibroblasts rescues the defects in autophagy 
(A) Nephrocerebellar syndrome (NCS) fibroblasts were grown in the absence or presence of chloroquine, 
transfected with plasmids encoding GFP-WHAMM, fixed, and stained with antibodies to detect LC3A (red) 
and with DAPI to label DNA (blue). GFP-WHAMM localised to cytoplasmic membranes and rescued the 
defects in autophagosome biogenesis. (B) NCS fibroblasts were transfected with a plasmid encoding 
GFP-WHAMM, fixed, and stained as in part A. Individual autophagosome structures are highlighted in 
these composites. GFP-WHAMM localised to regions of autophagosomal membrane growth or curvature 
due to its ability to remodel membranes during a variety of intracellular trafficking processes. Data shown 
is courtesy of Dr Ken Campellone. 
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5.5 Discussion 
A large number of interlinking families from the Swartzentruber Amish 
community in Ohio were investigated. Multiple individuals aged 9 months-12 
years were found to be affected by a novel complex disorder associated with 
abnormal brain development and progressive renal failure that we termed 
nephrocerebellar syndrome. The cardinal features of this condition include 
progressive microcephaly of post-natal onset, profound global developmental 
delay, irritability, central hypotonia, episodic dystonic movements, roving 
nystagmus, cortical visual impairment, predisposition to develop multifocal 
seizures, poorly formed caries prone dentition and nephrotic syndrome. In 
parallel with our studies, others had independently identified the same condition 
amongst Amish communities throughout the USA. A collaborative approach 
was taken to identify the underlying molecular cause of this disorder. 
Collectively our molecular studies determined that two distinct founder 
mutations affecting two closely linked genes (WHAMM and WDR73) both of 
which have become entrapped within the community and act in autosomal 
recessive fashion, cosegregate with the disease phenotype in all but a single 
individual. However, this child lacks the renal aspect of the phenotype, leading 
to the intriguing possibility that this is a composite phenotype and that the 
WHAMM variant might underlie the nephrotic syndrome in this condition and the 
WDR73 variant the neurological component. Although, as shown in Figure 45A 
the onset of renal disease in the other nephrocerebellar syndrome affected 
children shows significant variability, and lack of proteinuria or evidence of renal 
impairment at age 3 years, does not preclude later development of these. 
The analysis of the cellular functions in nephrocerebellar syndrome fibroblasts 
revealed a defect in autophagy which was rescued by ectopic expression of 
WHAMM protein. Autophagy is an essential catabolic process in which 
organelles and soluble and aggregated cellular components are enveloped in 
double membrane structures called autophagosomes which eventually fuse 
with lysosomes, leading to the degradation and recycling of the autophagosome 
contents (Settembre and Ballabio, 2014). It is difficult to see how such a 
fundamental cellular defect could not result in a clinical outcome. However, little 
is known about the level of redundancy of this process cells can tolerate and it 
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is plausible that there would be no detectable adverse consequences of this 
defect. 
The actin cytoskeleton controls membrane organisation, remodelling, and 
trafficking. To polymerise actin monomers into filaments, human cells rely on 
the activities of molecules called nucleators. Several classes of nucleator 
proteins promote actin assembly into linear unbranched filaments, including 15 
formins (Chesarone et al., 2010) and multiple monomer clustering proteins 
(Dominguez, 2009). But only one nucleator, the Arp2/3 complex, is known to 
create branched filament networks (Campellone and Welch, 2010). At the 
molecular level, the Arp2/3 complex nucleates actin while bound to existing 
filaments and engaged by proteins called nucleation factors from the WASP 
family [Rottner, 2010]. The founding member, WASP, gained its name because 
the gene that encodes it is mutated in patients with Wiskott-Aldrich Syndrome, 
an X-linked immune disorder (Derry et al., 1994). WHAMM is a member of the 
WASP-family of proteins. These 8 WASP-family nucleation factors are each 
thought to assemble actin during a distinct cellular function. While WASP 
controls actin dynamics and signalling in cells of the immune system, N-WASP 
remodels the plasma membrane during receptor-mediated endocytosis 
[Benesch, 2005; Bu, 2009; Innocenti, 2005] and some types of protrusion 
[Yamaguchi, 2005; Legg, 2007]. The WAVE proteins also drive extensions of 
the plasma membrane, but in the lamellipodia and ruffles that accompany cell 
migration (Innocenti et al., 2005, Suetsugu et al., 2003, Ide et al., 2003). 
Similarly, JMY can be recruited to the plasma membrane to enhance epithelial 
cell motility (Zuchero et al., 2009). In contrast, WASH localises to several 
endosome populations where it controls membrane shape and receptor 
trafficking (Derivery et al., 2009, Duleh and Welch, 2010, Gomez and Billadeau, 
2009, Zech et al., 2011). Finally, WHAMM is found at organelles of the 
secretory pathway where it promotes membrane tubulation and transport 
(Campellone et al., 2008, Shen et al., 2012). 
WASP is expressed only in hematopoietic cells, whereas the subsequently 
described family members N-WASP (Miki et al., 1996), WAVE1-3 (Miki et al., 
1998), WASH (Linardopoulou et al., 2007), WHAMM (Campellone et al., 2008), 
and JMY (Zuchero et al., 2009) are expressed broadly, but highest in neuronal 
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tissue. Due to their central role in important cellular processes, this protein 
family are also thought play a key role in mammalian development. Genetic 
studies have revealed that WASP knockout mice (Snapper et al., 1998) share 
many features with WASP-deficient humans, including defective T-cell 
signalling (Thrasher, 2009). Moreover, targeted disruptions of the murine genes 
encoding N-WASP (Lommel et al., 2001, Snapper et al., 2001), WAVE2 
(Yamazaki et al., 2003, Yan et al., 2003), and WASH (Gomez et al., 2012) are 
embryonic lethal, and WAVE1-null mice have reduced viability (Dahl et al., 
2003). These ubiquitously-expressed family members appear to be essential for 
neurological and cardiovascular development. However, it remains to be 
determined if the other newly-discovered nucleation factors also contribute to 
neurological and cardiovascular function. Surprisingly, aside from a variety of 
human mutations in WASP that result in Wiskott-Aldrich syndrome, 
thrombocytopenia, and neutropenia, mutations in other WASP-family members 
have not been implicated in human disease. 
The genetic evidence for WDR73 involvement in the neurological component of 
nephrocerebellar syndrome is strong and suggestive of a fundamental role for 
this molecule in the survival and activity of cortical neurons and development of 
the cerebellar external granule layer. In the absence of additional mutations in 
WDR73 associated with a similar phenotype to nephrocerebellar syndrome, 
functional evaluation of the effects of the Amish founder mutation in WDR73 are 
important to conclusively establish pathogenicity of the variant. It also remains 
to be seen whether it is simply a lack of WT protein, or loss of function of the 
mutant protein, that causes the neurological phenotype of nephrocerebellar 
syndrome and neuropathological abnormalities observed. Aggregates of 
abnormally folded protein might also be a contributing factor, as has been 
suggested for a number of other neurological diseases, such as Alzheimer’s 
disease, Huntington’s disease and Amyotrophic lateral sclerosis (Kesidou et al., 
2013). Much is left to learn about the largely uncharacterised WDR73 protein 
and the potential role played in human development. The human brain 
transcriptome (http://hbatlas.org) shows globally high levels of WDR73 gene 
expression in the brain with the highest levels early in embryonic development 
but persisting throughout adult life. The Amish nephrocerebellar syndrome 
provides a unique and unparalleled opportunity to study this critically important 
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molecule. Protein localisation, expression and interaction studies currently 
being undertaken by the CSC should give some indication of likely protein 
function. 
The Amish nephrocerebellar syndrome study also highlights one of the 
difficulties associated with the investigation of inherited diseases which occur 
within founder populations such as the Amish, and the importance of 
sequencing all of the coding regions within a putative disease locus. Prior to the 
advent of next generation sequencing technologies, the identification of a 
homozygous frameshift variant cosegregating with the phenotype, absent in the 
homozygous state in regional controls and predicted to significantly impair 
protein function such as is the case for both the WHAMM  and WDR73 
alterations described here, was commonly considered acceptable evidence of 
pathogenicity. Therefore it is probable that a number of gene variants previously 
thought to be causal of autosomal recessive conditions (identified through 
mapping studies in endogamous communities and consanguineous unions) will 
turn out to be innocent passengers in linkage disequilibrium with an unidentified 
causative variant located elsewhere in the disease locus. 
The FORGE Canada project, a large scale collaborative whole exome 
sequencing project seeking to identify the cause of rare paediatric onset single 
gene disorders, highlighted the potential confusion that composite phenotypes 
can cause in such studies. One of the conditions investigated by this group was 
the eponymously named Fitzsimmons syndrome (OMIM 270710), associated 
with a combination of spastic parapalegia and brachydactyly. All available 
cases of Fitzsimmons syndrome that were analysed were found to be 
composite phenotypes, a combination of two or more rare genetic disorders 
inherited in parallel (Beaulieu et al., 2014). This also seems to be the most 
plausible explanation for the Amish nephrocerebellar syndrome described in 
this chapter. 
Regardless of the role of WDR73 in nephrocerebellar syndrome, in the light of 
the results of our cellular studies it is impossible to discount any involvement of 
the WHAMM mutation in this condition, which in the very least is likely to have a 
role in modifying the phenotypical outcome of the more severe WDR73 
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mutation. Taken together with the genetic data and well established role of 
WHAMM in cellular function these results are highly suggestive of WHAMM 
involvement in the nephrocerebellar syndrome phenotype. Reduced F-actin 
staining and altered organelle morphology which would both be compatible with 
absence of WHAMM induced actin nucleation, was observed in cells from 
individuals homozygous for both the WDR73 and WHAMM variants. 
Additionally, our studies revealed previously-unrecognised roles for WHAMM in 
autophagy, a fundamental intracellular process. Also as of yet, no individual has 
been identified that is homozygous for the Amish WHAMM variant alone and it 
is difficult to predict the nature of the phenotype that might be expected and 
hence what patient population to look in. 
Finally, further understanding of the basis of the Amish nephrocerebellar 
syndrome will shed important new light on the function of the nephron and 
development of the cerebellum, potentially leading to the identification of novel 
therapeutic targets that might benefit those affected by this devastating 
disorder.  
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6 FINAL DISCUSSION AND FUTURE WORK 
In this thesis I describe three new disorders affecting brain growth and 
development identified amongst the Ohio Amish community. Individuals 
recruited to the Windows of Hope Amish inherited disease developmental delay 
and intellectual disability subproject underwent detailed clinical phenotyping, 
leading to the recognition and clinical delineation of novel syndromes. Mapping, 
traditional and next generation sequencing technologies were used to identify 
the genes and mutations responsible for these conditions. The causative 
mutations were verified by cosegregation and regional/non-regional (non-
Amish) control analysis. Following identification of the causative genetic 
variants, tissue distribution analysis, protein localisation studies and pathway 
analysis were used to investigate the molecular processes perturbed by these 
aberrations. The functional biology techniques used included western blotting 
for assessment of protein levels and stability, fluorescence activated cell 
sorting, surface plasmon resonance, immunoprecipitation and in vitro assays to 
assess protein interactions. Rescue of abnormal cellular phenotypes by 
endogenous expression of the native protein was used to provide definitive 
proof of involvement of the defective molecule. The results of this work 
underscore the power of new genotyping technologies combined with 
population-specific genetic knowledge and robust clinical phenotyping. 
This section provides an overview of the main findings in each chapter and 
relates these to the current literature. Further areas of future research are also 
highlighted. 
6.1 Chapter 3: Hypomorphic PCNA mutation underlies a novel 
human DNA repair disorder 
The identification of an Amish founder mutation in PCNA associated with a new 
neurodegenerative phenotype described in chapter 3 has provided important 
new insights into DNA repair and replication processes, including the definition 
of a novel human disease that may arise due to abnormalities in these cellular 
functions. 
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Orchestrating the multiple enzymatic activities that are required at the 
eukaryotic replication fork would appear to be a complex task. The proliferating 
cell nuclear antigen (PCNA) protein has long been recognised as a key 
contributor to this, binding a large diversity of partner proteins and recruiting 
them to their sites of action (Mailand et al., 2013). PCNA partners recruited to 
replication forks include DNA polymerases, DNA processing enzymes, DNA 
methyltransferases, cell cycle regulators, and chromatin assembly and 
modifying enzymes, each required at difference stages of chromosomal 
replication. The importance of PCNA for this most crucial of cellular functions is 
underlined by the fact that, until recently, no disease causing mutation in the 
PCNA protein had been reported in humans, suggesting that most sequence 
alterations that profoundly affect PCNA function would be incompatible with life. 
Through the work of the Windows of Hope project, a novel neurodegenerative 
condition was identified amongst the Ohio Amish community. Affected 
individuals exhibited features similar to, but distinct from, known disorders of 
DNA repair. All of the affected individuals were found to be homozygous for a 
c.683G>T Amish founder mutation in PCNA, which results in the substitution of 
a stringently conserved serine residue to isoleucine at position 228 
(p.Ser228Ile) of the protein. As individuals who are homozygous for the amino 
acid substitution survive, it may be predicted that this substitution does not 
completely destroy the function of the mutant PCNA molecule. Consistent with 
this, our studies did not detect any changes in DNA replication in cells from 
affected individuals. However altered parameters of DNA repair were identified, 
specifically within the nucleotide excision repair pathway which deals with 
damage to DNA generated by sunlight exposure (DiGiovanna and Kraemer, 
2012). As PCNA is known to be important for reconstitution of nucleotide 
excision repair in vitro, this finding provides a clear molecular link between the 
disease causing genetic alteration and the cellular phenotypes observed.  
While we were able to detect altered interaction between PCNA and three of its 
known binding partners (Fen1, Lig1 and XPG), these are unlikely to be 
represent the only outcomes of the sequence alteration. A systematic approach 
will be needed to assess the effect of the mutation on the binding to each 
known binding partner to ascertain whether other altered interactions may 
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contribute to the clinical manifestations of the disease. While the interactions 
between PCNA and XPG, Lig1 and Fen1 are mediated by ‘PCNA interacting 
protein’ (PIP)-boxes (Lehmann, 2011), the SILAC data suggests that not all PIP 
box containing proteins show altered affinity for PCNA p.Ser228Ile. For example 
the DNA methyltransferase DNMT1 binds both WT and PCNA p.Ser228Ile 
equivalently. Further work is needed to understand the structural changes 
triggered by the Ser228Ile amino acid alteration that result in such differential 
binding of some PCNA partners, but not others.  
The separation of function outcome caused by this mutation is, at first sight, 
remarkable. PCNA’s main role is during chromosomal replication, and yet the 
Amish individuals affected with this syndrome reach adulthood, and 
lymphoblastoid and primary fibroblast cells proliferate normally in culture with no 
apparent checkpoint activation or genomic instability. Thus the defective 
interactions observed, which are with key components of the DNA replication 
fork, appear not sufficient to significantly perturb replication while they do 
appear to significantly impair DNA repair. This presents a conundrum as the 
part of the nucleotide excision repair process that is presumed to be PCNA-
dependent, DNA synthesis, is enzymatically the same in both situations. How 
can this be reconciled? This may possibly be explained by the nuclear 
organisation of the two processes (replication and repair). Nucleotide excision 
repair is performed independently at each damage site, which are distributed 
randomly across the genome. In contrast, DNA replication processes occur 
within “replication factories”, transiently forming structures in the nucleus 
containing high local concentrations of DNA replication components, including 
Fen1 and Lig1 (Warbrick, 1998). A single factory can contain multiple replication 
forks, and at each fork there are likely more than two PCNA trimers, as PCNA is 
retained for some time on newly synthesised DNA (Sporbert et al., 2005). Such 
a high local concentration of PCNA at replication factories may serve to allow 
PCNA’s efficient interaction with partner proteins even if the affinity of such 
interactions is reduced, as with the p.Ser228Ile alteration (Figure 57). In 
contrast, during nucleotide excision repair there is no process that results in 
local concentration of PCNA, and as such the very same interactions may 
become sensitive to Ser228Ile mediated changes in interaction affinity. This   
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Figure 57: Hypomorphic effects of the PCNA p.Ser228Ile mutation 
Top: Schematic of DNA replication and repair sites in vivo. Replication factories processing Okazaki 
fragments generate high local concentrations of PCNA, not seen at repair sites. Bottom: The Ser228Ile 
alteration in PCNA destabilises its interaction with PIP-box containing partner proteins, increasing the Kd 
for crucial binding reactions. This will have a greater biological effect when PCNA concentrations are low, 
i.e. at repair sites. 
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raises the intriguing possibility that the organisation of replication into these 
factory structures may contribute to the stability of the replicative process, as 
the locally induced high concentrations of factors induced by such a physical 
organisation make the system inherently robust against any temporary stresses. 
This could be predicted to be a useful property for a process in which accuracy 
is ultimately required to ensure the stability of the genome. PCNA has many 
known cellular functions, and thus the PCNA p.Ser228Ile mutation could affect 
a diverse set of cellular activities. PCNA is implicated in many aspects of 
chromosomal replication and also other types of DNA repair. It will be important 
to assess the sensitivity of cells from affected individuals to DNA damage 
inducers other than UV such as hydrogen peroxide, and replication fork stalling 
agents such as aphidocolin. A suitable approach would be to use a clonogenic 
survival assay similar to those shown in Figure 14B. 
The cellular defects in nucleotide excision repair provide some explanation for 
the clinical overlap observed between individuals homozygous for PCNA 
p.Ser228Ile and those seen in Cockayne syndrome and xeroderma 
pigmentosa. The overlap with ataxia telangiectasia is more difficult to explain. 
The ocular and cutaneous telangiectasia and cerebellar atrophy seen in the 
affected individuals are remarkably reminiscent of ataxia telangiectasia. The 
defective molecule in ataxia telangiectasia is ATM, which is a crucial part of the 
DNA double strand break repair pathway (Perlman et al., 2003) as are other 
molecules implicated in the so called “ataxia telangiectasia – like disorders” 
such as MRE11 (Stewart et al., 1999). The hallmark of ataxia telangiectasia is 
profound radiosensitivity (Perlman et al., 2003). Although we did not find a 
cellular defect in the DNA double strand break repair pathway, the assays used 
were probably not sensitive enough to detect subtle abnormalities in this 
pathway. As with other specialised metabolic pathways for DNA repair, 
including nucleotide excision repair, base excision repair and mismatch repair, 
the repair synthesis step of this pathway is fundamentally dependent on PCNA 
and more sensitive assays such as those suggested below may well identify 
abnormalities in this pathway. 
It seems reasonable to hypothesise that the clinical presentation of affected 
individuals, and the cellular phenotypes, arise because the mutated PCNA is 
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specifically deficient in particular protein interactions while others are 
maintained normally. To evaluate this further analysis of which PCNA partner 
proteins fail to bind normally to PCNA p.Ser228Ile under a selection of relevant 
conditions is required. 
Analysing the effect of PCNA mutations on partner protein interactions is 
complicated by the trimeric nature of PCNA. Exogenously-expressed mutated 
PCNA will always form mixed trimers with endogenous WT PCNA, making it 
impossible to use standard purification strategies to identify interactions altered 
by the mutation. To overcome this the SILAC method was used to identify 
defective interactions of PCNA p.Ser228Ile partner proteins. This assay was 
used to quantitatively compare the full “interactome” of human PCNA, WT and 
p.Ser228Ile (Figure 21A). This experiment forms the foundation for a body of 
work, for which we were recently awarded MRC funding, to try to more fully 
explain why the p.Ser228Ile alteration causes the abnormal cellular phenotypes 
identified. This experiment has provided a candidate list of putatively altered 
interactions that are likely to be at least partially responsible for the cellular 
phenotypes seen in affected individuals, and in particular highlighted Fen1 and 
Lig1 as being potentially relevant. Each of the candidates identified by this 
approach now needs to be validated, and the extent of any defective interaction 
(either too tight or too weak) determined. Analysis of these PCNA interactions in 
a more physiological setting could be done by co-immunoprecipitation using 
extracts from PCNAp.Ser228Ile/p.Ser228Ile cells and control (WT or complemented) 
cells as was successfully done with Fen1. Alternatively if no suitable antibody 
can be identified, expression of tagged proteins via lentiviral transduction would 
be an alternative option. Binding assays using E. coli- or baculovirus-produced 
recombinant proteins by pull downs at different salt stringencies and by surface 
plasmon resonance will allow the kinetics of the binding reactions to be 
evaluated. Assessment of protein mislocalisation in PCNAp.Ser228Ile/p.Ser228Ile cells 
could also be examined by immunofluorescence. Once the defective nature of a 
partner interaction is verified, cell-based assays can be utilised to determine if 
that protein’s functionality is compromised in the PCNAp.Ser228Ile/p.Ser228Ile cells. 
It is known that some biologically important interactions on PCNA only occur 
after DNA damage or replication fork stalling (Lehmann et al., 2007). These 
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interactions would not have been recapitulated in the SILAC analysis to date. 
For example the PCNA–interacting proteins XPG and XPA were not identified 
by this analysis, although they may well be potentially responsible for some of 
the defective UV responses that were observed in PCNAp.Ser228Ile/p.Ser228Ile cells, 
and some of the phenotypic manifestations observed in affected individuals. 
The GST assay seen in Figure 28 which demonstrated no detectable interaction 
between PCNA p.Ser228Ile and the XPG PIP box provides preliminary 
evidence of this. The SILAC based procedure could be repeated using extracts 
from UV-irradiated cells, which should recapitulate the defective interaction 
observed between PCNA p.Ser228Ile and XPG and may well reveal such a 
defective interaction with XPA.  
The identification of additional cellular processes that are perturbed by the 
PCNA p.Ser228Ile mutation, would also inform protein interaction studies. For 
example if cellular sensitivity to a particular agent such as gamma radiation 
were to be identified, the SILAC-assay could be used to determine the PCNA 
p.Ser228Ile interactions that are defective after this treatment. This strategy 
should lead to the identification of the PCNA partners that fail to interact 
normally with PCNA p.Ser228Ile after relevant damage or stress. An assay 
such as this can only identify relatively stable interactions and relatively 
abundant proteins. A candidate approach to assess the binding of known PCNA 
interactors (including XPA, p21, and others that are potentially involved in the 
cellular pathways) implicated by the results of cellular sensitivity assays, should 
reveal defective interactions in the case that they are not found in the SILAC 
screens.  
Proteins that fail to bind properly to the mutated PCNA p.Ser228Ile are likely to 
be required for the PCNA functions that are perturbed in cells from affected 
individuals. It is therefore necessary to connect specific interaction defects to 
specific cellular effects. The Okazaki fragment processing proteins Fen1 and 
Lig1 are implicated by the SILAC analysis and subsequent validation studies. 
Therefore, the next step is to determine whether the PCNA p.Ser228Ile cells 
show normal Okazaki fragment maturation. Although gross parameters of DNA 
replication are unperturbed in PCNAp.Ser228Ile/p.Ser228Ile cells, recently published 
work suggests that even substantial disruption to Okazaki fragment maturation 
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does not in fact dramatically alter gross DNA synthesis parameters, but more 
subtly impacts on genome stability (Duxin et al., 2012). Comparing 
PCNAp.Ser228Ile/p.Ser228Ile cells and WT control cells for the parameters below 
would establish the effects of the PCNA p.Ser228Ile sequence alteration on 
Okazaki fragment maturation. Okazaki fragment size and quantity can be 
assessed utilising alkaline sucrose gradients and alkaline agarose gels. RNA 
persistence in the genome due to failure to remove primers would be a feature 
of perturbed Okazaki fragment maturation. This could be assessed by alkaline 
lysis and/or RNaseHII sensitivity of genomic DNA. If detected this phenotype 
could also be caused by a defective interaction between PCNA p.Ser228Ile and 
RNaseH, which interestingly was also suggested by the original SILAC analysis. 
Fen1 and Lig1 are both required for the last stages of nucleotide excision 
repair: the reconstitution of complete DNA strands after excision of damage and 
re-synthesis. Thus these defective interactions could also be responsible for the 
UV damage sensitivities seen in the PCNAp.Ser228Ile/p.Ser228Ile cells. Analysis of 
nucleotide excision repair in more detail, by measuring the kinetics of UV lesion 
removal, repair protein recruitment and RNA polymerase stalling should 
determine if direct effects on the final stages of nucleotide excision repair can 
be identified. Evidence that these cellular defects are a direct result of altered 
protein interactions could be shown by engineering the partner proteins to 
restore normal binding to PCNA p.Ser228Ile, complementing 
PCNAp.Ser228Ile/p.Ser228Ile cells with these engineered proteins by lentiviral 
transduction, and assessing if the cellular phenotypes are suppressed. 
Although much is known about the function of PCNA, there is unquestionably a 
great deal to learn about this fundamentally important molecule as well as the 
processes of DNA synthesis and repair. The further work detailed here would 
build upon the knowledge provided by the first disorder associated with PCNA 
dysfunction to enhance understanding about the role of PCNA in DNA synthesis 
and repair, and provide a molecular explanation for the intriguing clinical 
features of the novel syndrome that results. Such a complete understanding of 
the cellular defects associated with PCNA p.Ser228Ile will permit a more 
detailed investigation of the aberrant developmental and neurodegenerative 
processes associated with this disease. 
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It will be interesting to see if any additional pathogenic mutations in PCNA are 
detected in humans. Choosing a cohort of individuals in whom to screen for 
such mutations is somewhat difficult given that it is likely that mutation of only a 
very few residues of the molecule might be compatible with life and result in a 
similar or indeed dissimilar phenotype to that which was described in chapter 3. 
Individuals with an intermediate defect in recovery of RNA synthesis have been 
screened but none harboured any potentially pathogenic mutations in PCNA. 
Perhaps the next most likely place to look is in patients with clinical features 
suggestive of ataxia telangiectasia and minimal or complete absence of 
radiosensitivity. There are relatively few individuals who present in this way and 
collaborative screening for PCNA mutations in this cohort is planned. 
I was awarded an MRC Centenary fund early career award to generate a 
mouse model of the PCNA p.Ser228Ile mutation. This work is being undertaken 
in collaboration with the Wellcome Trust Human Genetics unit in Oxford, using 
the TALEN approach. The first step will be to see in the homozygous mutant 
mouse recapitulates the human phenotype and if so neuronal cell lines from 
these animals can be used for downstream analyses similar to those described 
above. This animal model has the potential to illuminate the neurodegenerative 
processeses seen in the Amish PCNA disorder as well as other DNA repair 
disorders. 
6.2 Chapter 4: Mutations in KPTN cause a neurodevelopmental 
disorder associated with macrocephaly and seizures 
Chapter four describes the identification of two founder mutations in the Amish 
KPTN, a gene never previously associated with human disease. All of the 
affected individuals identified displayed intellectual disability and were 
macrocephalic. Most of the individuals who were phenotyped during the course 
of this study had a neurobehavioral phenotype with features suggestive of a 
pervasive developmental disorder. This clinical aspect due to KPTN loss of 
function will require focussed study with further formal intelligence quotient 
testing and diagnostic testing for autistic spectrum disorder. Although only 
limited neuroimaging data from three affected individuals was available, brain 
size was increased, but appeared to be morphologically grossly normal, 
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additional cases will be needed to firmly establish the absence of structural 
brain abnormalities in association with KPTN mutations.  
At the time of the original study cellular material from affected individuals was 
not available, as such a primary rat neuronal cell line was used to model the 
effects of the Amish KPTN founder mutations. Cell studies revealed dynamic 
interactions between KPTN and components of the actin cytoskeleton which 
were lost upon introduction of the mutations. By their nature over expression 
studies have limited sensitivity and cannot be considered to be exhaustive. To 
gain further insight into KPTN function, recapitulation of the results of these 
studies in cell lines where the effect on endogenous KPTN can be examined 
are necessary. Primary fibroblasts and EBV transformed lymphoblastoid cell 
lines have been established from individuals homozygous for the KPTN 
c.776C>A nonsense mutation and compound heterozygotes for this and the 
18bp duplication (c.714_731dup) as well as heterozygous and WT family 
members.  
In silico analysis tools predict that the KPTN c.776C>A mutant transcript may 
well be degraded via mRNA-surveillance mechanisms. It will now be possible to 
carry out quantitative reverse transcription PCR to assess transcript levels in 
affected individuals homozygous and heterozygous for the mutation versus 
those of WT controls. Endogenous protein expression and localisation studies 
can also be performed to further confirm the likely outcome of both the KPTN 
variants identified in this study.  
Given how little is known about the function of KPTN in vivo any comments on a 
potential mechanism of disease pathogenesis are largely speculative. A better 
understanding of the physiological role of KPTN in neurodevelopment will hinge 
on the further characterisation of the function of KPTN. The initial phenotyping 
of the recently generated Kptn knockout mouse, produced in collaboration with 
our collaborators at the Wellcome Trust Sanger Institute, revealed clinical 
features overlapping with those of humans including, megalencephaly and 
cognitive impairment. Once the mouse colony has been re-established, further 
studies are planned to fully characterise the phenotype of Kptn deficient mice. It 
will be particularly interesting to study the effects of Kptn deficiency on the 
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brain, firstly by more detailed phenotype comparisons between humans and 
mice, and secondly by establishing neuronal cell lines for protein localisation 
and downstream functional analyses. The planned MRI and micro-CT 
neuroimaging of these mice will help to further characterise the brain pathology. 
Gene expression analysis in brain tissue will be facilitated by the LacZ gene 
encoding β-galactosidase inserted into the targeted allele when the mice were 
generated, which will permit visualisation of the neurons that express Kptn 
through hydrolysis of X-Gal producing a blue precipitate that can be easily 
visualised under a microscope. Transcriptome analysis of the mouse brain 
tissues should help indicate downstream molecules whose expression is 
affected by KPTN loss of function, suggesting these as useful candidates for 
down-stream analysis. An alternative approach to this would be the SILAC 
assay used to study deficient PCNA interactions which could be used similarly 
to study the KPTN “interactome”. In this way it may be possible to gain further 
insight into whether KPTN is involved in actin biology or whether 
neurodevelopment is affected through a distinct mechanism as yet unidentified. 
Despite a relatively similar genome, the human neocortex has undergone 
enormous evolutionary modification with a threefold increase in size occurring 
over the last 3 million years. The complex gyrification of the human brain has 
resulted in a brain surface area 1000 x that of a mouse. The relative complexity 
of the human brain complicates animal modelling of disorders of human brain 
development. Mouse models of primary microcephaly have not always 
recapitulated the human phenotype. More recently a human pluripotent stem 
cell-derived 3D organoid culture system has been used to recapitulate human 
cortical organisation and successfully model primary microcephaly (Lancaster et 
al., 2013). Although this is still an imperfect system, it would be interesting to 
utilise this to model KPTN deficiency, which appears to be a pure global 
megalencephaly.  
Human haploinsuffuiciency of the mTOR inhibitor PTEN is also associated with 
a global increase in brain size and high incidence of autistic features. The Pten 
haploinsufficient mouse is megalencephalic and shows impaired social 
behaviour (Clipperton-Allen and Page, 2014). Kptn-/- female mice showed 
evidence of impaired cognition, although the numbers in this preliminary 
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analysis were small. Further studies are planned to see if this result is 
recapitulated in a larger cohort of mice of both sexes and to establish whether 
or not social behavioural abnormalities are seen. 
Splenomegaly and an apparent increased susceptibility to infection had been 
observed in a number of affected Amish individuals. It was notable that the 
primary phenotyping of Kptn-/- mice revealed a reduced level of IgD-positive 
mature B-cells and an increased susceptibility to salmonella infection. The 
youngest affected Amish individual in the original study has splenomegaly and 
has suffered repeated episodes of pneumonia. This individual is currently 
undergoing detailed immunological and haematological studies carried out by 
his clinicians in Ohio to establish whether there is any evidence of impaired 
immune function. In light of a possible human immunodeficiency phenotype, 
secondary immunophenotyping of the Kptn-/- mouse is planned when the next 
colony is established. 
Although Wellcome Trust Sanger Institute in house data suggest that tissue 
obtained from mice homozygous for the Tm1a allele shows complete loss of 
KPTN function, it is theoretically possible that not all of the transcript is targeted 
for non-sense mediated mRNA decay. A Tm1b true KPTN knockout mouse 
model is currently being generated and it will be interesting to see if the 
phenotype matches that of the Tm1a homozygous mouse.  
Loss-of-function mutations in other mTOR-inhibitory genes besides PTEN such 
as TSC1, TSC2, or STRADA and gain-of-function mutations in mTOR activators 
such as PI3K or AKT3, result in aberrant brain development with generalised or 
regional brain overgrowth, several are also autistic spectrum risk factors (Parker 
et al., 2013, Crino et al., 2006, Lee et al., 2012, Poduri et al., 2012, Clipperton-
Allen and Page, 2014). Treatment with the mTOR inhibitor rapamycin has been 
shown to reduce seizure frequency and possibly improve receptive language 
and social interaction in individuals with Pretzel syndrome, a rare Amish 
disorder associated with a homozygous loss of function mutation in STRADA 
(Parker et al., 2013). 
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Autistic spectrum disorders are relatively common in the general population 
affecting approximately 1% of individuals. There appears to be a strong genetic 
component with a 90% concordance rate observed in monozygotic twins (Perou 
et al., 2013). This study has provided important information about the biological 
partnership between KPTN and the actin cytoskeleton, shedding further light 
onto the pathogenic processes that underlie megalencephaly, as well as 
highlighting mechanisms of potential relevance to autistic spectrum disorders. 
Mutations in Rab39B have been shown to cause an X-linked form of intellectual 
disability associated with seizures, macrocephaly and autistic features. 
Depletion of Rab39B in model cell systems was shown to disrupt the actin-
cytoskeleton and result in a reduction in neurite growth cones and dendritic 
arborisation (Giannandrea et al., 2010). The identification of more than one 
gene involved in actin biology and associated with a neurodevelopmental 
disorder and megalencephaly provides evidence of a common pathway 
associated with these features and further studies may reveal potential 
therapeutic targets much like with the mTOR pathway group of disorders. 
6.3 Chapter 5: Autosomal recessive mutations in closely 
linked WDR73 and WHAMM genes underlie a novel 
composite nephrocerebellar syndrome phenotype 
Chapter 5 describes the clinical delineation of two separate disorders which 
were previously thought to possibly be the same entity, described as 
“Hershberger syndrome” in McKusick’s pioneering 1960s Amish studies. Both 
disorders cause profound neurological impairment and are present at extremely 
high frequency within the ultraconservative Swartzentruber Amish group. 
Molecular studies were able to help determine that one of these disorders was 
caused by homozygosity for a founder mutation in SAMHD1. This gene was 
previously associated with the highly genetically heterogeneous and 
phenotypically diverse type 1 interferonopathy Aicardi Goutières syndrome 
(Rice et al., 2009).  
The second disorder described in Chapter 4 (nephrocerebellar syndrome) is 
new to medical science and appears to be a composite phenotype resulting 
from homozygous mutations in two closely linked genes WHAMM and WDR73. 
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All but one of the children identified are homozygous for founder mutations in 
both WHAMM and WDR73, and that child lacked the renal features of the 
condition. The two founder mutations are 1.7Mb apart and it is difficult to know if 
both arose in the same individual at the same time, or if one arose 
subsequently in cis with the other mutation. Despite the extensive screening of 
family members and Amish controls only two individuals have been identified as 
heterozygous for one (WDR73) and WT for the second (WHAMM) variant. The 
SNP haplotype of these individuals is distinct around the WT WHAMM 
sequence, suggesting that they have recombined the WHAMM mutation out. 
This evidence suggests that the two mutations occurred either in the same 
individual at the same time, or if not in very quick succession.  
This work shows the benefit of access to expert next generation sequencing 
services, as the WHAMM mutation was missed by our collaborative partners at 
CSC (through the Broad Institute), but was picked up by the Wellcome Trust 
Sanger Institute. This likely reflects the complex and repetitive nature of 
WHAMM, which also rendered confirmation of this mutation by Sanger 
sequencing challenging. 
Features that are common to both Aicardi Goutières syndrome and 
nephrocerebellar syndrome include profound psychomotor retardation, 
microcephaly of post-natal onset, a dystonic movement disorder, seizures, 
irritability, cortical visual impairment and abnormal eye movements.  
Distinguishing features include glaucoma and inflammatory skin and oral 
lesions in Aicardi Goutières syndrome and hypoplastic yellow coloured dentition 
and nephrotic syndrome in nephrocerebellar syndrome. Aicardi Goutières 
syndrome is associated with significant intrafamilial variability. In the classic 
form individuals are profoundly neurologically impaired, but some individuals 
may be only mildly affected, with essentially normal cognitive development and 
normal brain growth but features of arthropathy or chilblain lesions (Crow, 
1993). All known cases of nephrocerebellar syndrome make little if any 
developmental progress. The predominating neurological finding in Aicardi 
Goutieres syndrome is peripheral spasticity and hyperreflexia, whereas all the 
children with nephrocerebellar syndrome are hypotonic with normal reflexes. 
The most frequent finding on neuroimaging from nephrocerebellar cases was 
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cerebellar hypoplasia and in Aicardi Goutières syndrome cases due to 
SAMHD1, was intracerebral calcification and large vessel vasculopathy 
(Ramesh et al., 2010). 
Interestingly, the original description of “Hershberger syndrome” by Cross and 
Mckusick described it as a complex spastic paraplegia with onset of spasticity 
from 5 months of age (Cross and McKusick, 1967). This seems most 
compatible with Aicardi Goutières syndrome, where the majority of children 
have a period of apparently normal development followed by a subacute onset 
of severe encephalopathy and sterile pyrexia. Onset of neurological impairment 
follows the insult (Crow, 1993). The Swartzentruber Amish have historically had 
little interaction with modern medicine although that has been changing in some 
of the younger families. It is likely that this played a big part in the difficulty with 
separating these two disorders in the past. 
The natural history of Aicardi Goutières syndrome presents a window of 
opportunity to treat affected individuals before brain disease progresses. 
Treatment trials with antiretroviral medications commonly used in the 
management of human immunodeficiency virus as well as other 
immunomodulatory therapies have been proposed (Crow et al., 2014). The 
Amish population represent the ideal group in which to carry out such clinical 
trials. The condition occurs at extremely high frequency particularly amongst the 
most conservative Amish group, the Swartzentruber Amish. Newborn screening 
for this condition is a viable option in this population and the potential benefits to 
affected children, their families and the wider Amish community of an effective 
treatment for SAMHD1 related Aicardi Goutières syndrome are enormous. 
SAMHD1 deficiency is associated with abnormalities of the cerebral vasculature 
and a concurrent high risk of stroke (Permanyer et al., 2010), it remains to be 
seen if any of the proposed therapies will be of benefit in reducing this risk. 
However even in the absence of a medication, the possibility of neonatal 
diagnosis in the Amish community presents the opportunity to monitor and 
intervene surgically in some cases. 
The dental abnormalities and seizure predisposition in nephrocerebellar 
syndrome seemed somewhat reminiscent of those seen in Kohlschütter Tonz 
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syndrome, a condition associated with homozygous loss of function mutations 
in ROGDI. The neurological phenotypes of the two conditions though seem 
quite distinct, with spasticity the predominate neurological feature of 
Kohlschütter Tonz syndrome (Mory et al., 2014) ROGD1 encodes a relatively 
uncharacterised protein expressed at high levels in the brain (Schossig et al., 
2012) . It remains to be seen if one or other of the molecules implicated in 
nephrocerebellar syndrome interacts with this molecule. 
Much is left to be learnt about the two molecules implicated in the Amish 
nephocerebellar syndrome. WHAMM is a well characterised molecule and the 
cellular data we acquired is highly suggestive of, at the very least, a disease 
modifying effect. It is interesting that despite the nature of the genetic mutation, 
the transcript appears to at least partially escape nonsense mediated mRNA 
decay and result in a protein that lacks the C-terminal of the molecule. 
Consequently it is possible that this molecule may retain some functionality, 
perhaps alleviating some of the clinical features that may result with complete 
loss of function of this molecule. Another possibility is that one of the number of 
WHAMM pseudogenes could be transcribed, which may also compensate for 
the loss of function of the molecule. A role in autophagy had not previously 
been ascribed to WHAMM, and this and the results of the other cellular studies 
presented in this thesis were used as preliminary data to support our recent 
successful collaborative NIH grant application to look at WHAMM function and 
its involvement in the nephrocerebellar syndrome in more detail. 
Fibroblasts from individuals affected by nephrocerebellar syndrome lack 
autophagosomes at steady-state and undergo intracellular vacuolation when 
autophagic flux is blocked, but re-introduction of wild type WHAMM can restore 
normal autophagy functions to these cells. To test the hypothesis that WHAMM, 
microtubules, and the Arp2/3 complex function together in autophagosome 
biogenesis, the role of these cytoskeletal factors in autophagosome assembly 
and trafficking could be assessed by using WHAMM rescue constructs in 
nephrocerebellar syndrome fibroblasts and using RNA intereference in cultured 
neuronal cell lines. The activities of functional versus defective WHAMM 
derivatives in assays of actin nucleation, phospholipid interaction, and 
microtubule binding could also be assessed in vitro. 
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Under native cellular conditions, WASP-family members exist in multi-subunit 
protein complexes that control their activities. To test the hypothesis that 
WHAMM is also found in a complex that influences its function, a WHAMM-
tagged derivative could be isolated from cultured cells using a tandem affinity 
approach, and native WHAMM could be extracted from brain tissue by 
conventional chromatography, it would then be possible to determine the 
composition of each ‘WHAMM complex’ by mass spectrometry. Measurement 
of the ability of each complex to nucleate actin, interact with phospholipids, and 
bind microtubules in vitro could then be undertaken. RNA interference could 
also be used to determine which members of the complex contribute to 
autophagosome remodeling in cells. 
Completion of these analyses would provide key insights into cytoskeletal 
dynamics and autophagosome remodelling and help to establish the role of 
WHAMM in the nephrocerebellar syndrome phenotype. 
Abnormal functioning of the WDR73 protein is almost certainly the predominate 
cause of the neurological phenotype seen in nephrocerebellar syndrome, but in 
what way these effects are mediated remains largely speculative. 
Nephrocerebellar syndrome fibroblast cells grow very poorly and have abnormal 
morphology which limits the possible functional assay that can be performed 
using these precious resources. Protein localisation studies will be carried out 
by transiently transfecting epitope-tagged WDR73 constructs into SH-SY5Y 
human neuronal cells and HEK-293 human embryonic kidney cells, and then 
examining the protein’s subcellular localisation. The most likely outcome of the 
WDR73 mutation is loss of protein function, and therefore additional 
complimentary experiments are planned using siRNA knockdown to deplete the 
WDR73 protein in HeLa and primary fibroblast cell lines. 
Mouse models of both the WHAMM and WDR73 mutations as well as the 
double homozygote are currently being generated through our collaborators at 
the Wellcome Trust Sanger Institute. These models will be an invaluable 
resource in terms of trying to determine which molecule is responsible for which 
aspects of the nephrocerebellar phenotype. It will be particularly fascinating to 
compare the brain histology of these animals to the human histopathology that 
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we observed in one of the affected children. Lastly, mouse cell lines can be 
utilised for downstream studies of both WHAMM and WDR73 function. 
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6.4 Concluding remarks 
6.4.1 Clinical benefits of community studies to the Amish community 
This study stemmed from a long-running clinical-genetic project, called 
‘Windows of Hope’ (WOH), based amongst the Amish communities of Ohio. 
The aims of the larger project are to determine the genetic basis of inherited 
diseases which occur in the Amish community and to translate the findings of 
this research into direct diagnostic and medical benefit, both within this 
community and the general population. The project has enjoyed considerable 
success and has to date discovered the genes for 16 novel conditions which 
occur in the community. These findings have formed the basis of an extensive 
molecular genetic testing and counselling program for the Amish. As 
widespread knowledge of these recently described disorders is still lacking, and 
the carrier frequency in the community is high, many of these children and their 
families undergo needless, costly and sometimes painful investigations. 
Improved awareness of the clinical features and incidence of these conditions 
amongst both the community and the local and specialist healthcare providers 
would circumvent this problem. The comprehensive genetic, molecular and 
clinical studies described in this thesis have empowered us with specialist 
knowledge of these syndromes which can now be used to facilitate appropriate 
medical care and follow-up for affected individuals. Knowledge of the full 
phenotype also permits screening for additional syndromic associations, and 
early intervention to prevent potentially serious complications such as the 
nephrotic syndrome associated with nephrocerebellar syndrome. All of the 
research results generated from the Windows of Hope project are fed back 
promptly to the community. This involves organisation of family support group 
meetings, community liaison and generation of disease specific and community 
appropriate information. Educational meetings for local health care 
professionals are also held, with the aim being to improve health care outcomes 
through improved knowledge of the different types of inherited conditions found 
within the community, effective management strategies and developing and 
increasing the availability of diagnostic testing for newly identified conditions. 
Recently, based on work within and related to this thesis I was awarded an 
Alexander Fleming dissemination award from the MRC, Medical Research 
Foundation. The purpose of this award is to support the dissemination of MRC 
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funded research results beyond the scientific peer reviewed press, to patients, 
participants and policy makers. This funding was given in recognition of the 
previous success of the community and healthcare worker engagement 
activities and to allow their further development. 
The technological advances in genetics have rapidly increased the speed and 
scope of diagnostic genetic testing. The impact has been even more significant 
in the field of neurodevelopmental disorders, where conditions show significant 
phenotypic and genetic heterogeneity. Next generation sequencing 
technologies permit the screening of multiple potentially causative genes in 
parallel, which means that recognition of the precise phenotype of an individual 
is no longer completely essential. This has particularly application in 
communities like the Amish, where founder mutations are commonly causative, 
greatly facilitating the development of diagnostic gene panels for this type of 
disorder. Such panels can even be targeted to specific Amish church groups 
such as the Swartzentruber community, where specific inherited conditions are 
more prevalent. A longer term vision of the Windows of Hope project is to 
harness these technologies to work towards developing a newborn screening 
program, with the aim being to provide early diagnosis of conditions prevalent in 
the Ohio Amish community so that management strategies can be put in place 
promptly, resulting in improved outcomes for children and their families.  
6.4.2 Benefits of community based studies to the wider society 
The benefits to the wider society of these community based studies are 
numerous and wide ranging. Due to their marriage patterns and ancestry the 
Amish comprise an endogamous community, in which mutations responsible for 
certain genetic conditions have become enriched, greatly facilitating their 
identification. Importantly, almost all genetic conditions initially described and 
identified amongst the Amish have subsequently been found outside of the 
community, validating the importance of Amish genetic studies and widening 
the impact of such discoveries.  
A good example is a recently published study which I was heavily involved in 
where mutations in the B4GALNT1 gene were described in association with a 
variable condition best classified as complex form of spastic paraplegia (GM2 
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synthase deficiency). The disorder is present at high frequency in the Amish 
community, but we also identified it in Kuwaiti and Italian-Canadian families in 
parallel (Harlalka et al., 2013b). Cartilage hair hypoplasia is another well known 
example of an important genetic syndrome initially described in the Amish 
(McKusick et al., 1965). Certain conditions which are associated with a higher 
incidence outside of the Amish community have been found to be associated 
with the presence of more than one founder mutation within the community, 
notable examples include Cockayne syndrome and phenylketonuria (Xin and 
Wang, 2013, Strauss and Puffenberger, 2009). The identification of two founder 
mutations in KPTN in the same Amish community make it even more likely that 
this gene will be subsequently shown to be an important cause of non-Amish 
cases of neurodevelopmental disorder with macrocephaly. 
Over the last 5-6 years, the advent of next generation sequencing technologies 
has led to rapid progress in identifying the genetic basis of disorders of brain 
development and intellectual disability. Consequently new pathways have been 
highlighted as crucial for normal human neuromorphogenesis. As mentioned 
earlier, disorders of neurodevelopment are genetically heterogeneous and 
distinct phenotypes can be hard to distinguish. Large scale general population 
based studies such as the Deciphering Developmental Disorders study based 
at the Wellcome Trust Sanger Institute and The Forge Canada study have been 
set-up to harness the power of new genetic technologies in an attempt to 
identify new genetic causes of abnormal human development, particularly those 
affecting the brain. These studies have been relatively successful, particularly in 
establishing a wider phenotypic spectrum associated with some genes than had 
previously been suspected. However, relatively few novel disorders have been 
identified through these studies to date, particularly given the number of 
individuals recruited, whereas studies within endogamous communities or of 
consanguineous pedigrees have been significantly more productive in this 
regard. Large scale targeted resequencing of exons within homozygous tracts 
in 136 consanguineous families with autosomal recessive intellectual disability 
identified 50 novel candidate genes emphasising the power of this approach 
(Najmabadi et al., 2011). Within the Amish community alone since starting this 
work in 2010, a total of ten new genetic causes of neurological impairment have 
been identified and published (Puffenberger et al., 2012, Cai et al., 2011, Xin et 
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al., 2010, Crosby et al., 2010, Harlalka et al., 2013a, Harlalka et al., 2013b, 
Lahiry et al., 2013), further demonstrating the scientific, clinical and financial 
advantages presented by such community based studies. 
6.4.3 Scientific benefits of community based studies 
The value of studying rare disorders is now widely recognised. Valuable insights 
into biological pathway are provided by such studies, often highlighting new 
candidate genes for related disorders. A good example of this is the study of 
autosomal recessive primary microcephaly. All of the genes associated with this 
condition to date have been identified through mapping studies of individuals 
born of consanguineous unions and all have been shown to be involved in 
mitosis usually through direct or indirect centrosomal interactions. Some of 
these genes are also implicated in primordial dwarfism, a group of disorders 
where both brain and body size are profoundly reduced. 
An example relating more directly to the work in this thesis is the recent 
identification of an Amish founder mutation in the HERC2 gene which when 
present in the homozygous form results in a neurodevelopmental disorder with 
striking clinical similarity to Angelman syndrome. This condition occurs at high 
frequency in the Old Order Amish. The mutation leads to a dramatic reduction in 
HERC2 protein levels, increased protein instability, and a dose dependent 
reduction in UBE3A activity, the primary molecule implicated in Angelman 
syndrome pathogenesis (Harlalka et al., 2013a). Although the HERC2 and 
UBE3A genes are situated within close proximity to each other on chromosome 
15, no functional link between the two encoded proteins and the Angelman 
syndrome phenotype had ever been proposed. This study provided important 
information about the biological partnership between UBE3A and HERC2, 
shedding further light onto the pathogenic processes that underlie Angelman 
syndrome, as well as highlighting mechanisms of relevance to other seizure and 
movement disorders. 
As mentioned earlier, GM2 synthase deficiency is a disorder of ganglioside 
biosynthesis which occurs with high frequency amongst the Amish. 
Gangliosides are sialylated derivatives of glycosphingolipids. Although many 
glycosphingolipid catabolic defects have been defined only one inherited 
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disease arising from a defect in glycosphingolipid biosynthesis is known. This 
disease, arising due to defects in the first step of ganglioside biosynthesis (GM3 
synthase), results in a severe epileptic disorder with profound intellectual 
impairment also found at high frequency amongst the Old Order Amish, but 
otherwise rare. Biochemical profiling of glycosphingolipid biosynthesis 
confirmed a lack of GM2 in affected subjects in association with a predictable 
increase in levels of its precursor, GM3 (Harlalka et al., 2013b). With the 
description of two neurological human diseases involving defects in two 
sequentially acting enzymes in ganglioside biosynthesis, there is the very real 
possibility that a previously unidentified family of ganglioside deficiency 
diseases exist. The study of patients and animal models of these disorders will 
pave the way for a greater understanding of the role gangliosides play in 
neuronal structure and function and may well provide insights into the 
development of effective treatment therapies. 
Recently increasing numbers of genes implicated in disorders of human brain 
growth and development have been identified. These studies provide 
unprecedented opportunities to understand the molecules involved in the 
normal brain development and what goes wrong when their cellular functions 
are perturbed. The next challenge to be faced is to use this knowledge to 
develop novel and innovative therapies targeted directly to circumvent the 
identified cellular defect. The promise of genetics to enable deliverance of such 
treatments looks increasingly likely to transform the practice of medicine.
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7 APPENDIX 
7.1 APPENDIX CHAPTER 3 
7.1.1 Chromosome 20 sequencing primers 
c20orf30 Exon1F ……………. TAAAGAGACAAACGCTTCCG 
c20orf30 Exon1R ……………. TGACTCGGAGCTTGATTTCG 
c20orf30 Exon 2F ……………. GAACAGCTGGCATCTAACAAAG 
c20orf30 Exon 2R ……………. TTTTCCTCCATAAAGTAACAAAGC 
c20orf30 Exon 3F ……………. GAAGTGTAAATTGCCCATTGC 
c20orf30 Exon 3R ……………. AATCCCCAAGGACAGTTAGC 
c20orf30 Exon 4F ……………. TCACGCCATTGCTCTCTAGC 
c20orf30 Exon 4R ……………. GGACGGACAAACACACACAC 
c20orf30 Exon 5F ……………. TGGTGGTATACAACTCAAAGAAAAA 
c20orf30 Exon 5R ……………. TCTGGCCATTATTTTCTTAAACA 
PCNA Exon 2F ……………. GGCATTAAACGGTTGCAGG 
PCNA Exon 2R ……………. CAGCCAATGAGGGCTAGG 
PCNA Exon 3-4F ……………. ATGGGTGAGAGTGGTAACCC 
PCNA Exon 3-4R ……………. CAGAGCCAAGACCCTGTCTG 
PCNA Exon 5F ……………. CTCTTGTTCCCTGGATGGTG 
PCNA Exon 5R ……………. TCGCAGATTTCAACAGTATCTC 
PCNA Exon 6F ……………. TAGCTCCCTCCAAAGTGACC 
PCNA Exon 6R ……………. TGTCCCATATCCGCAATTTT 
PCNA Exon 7aF ……………. CGGTGACACTCAGTATGTCTGC 
PCNA Exon 7aR ……………. GACCAGATCTGACTTTGGACTTT 
PCNA Exon 7bF ……………. TGCGGATATGGGACACTTAAA 
PCNA Exon 7bR ……………. TCAGGCTGCTCTAAACTGAAA 
CDS2 Exon 1F ……………. TGCTAAGGGAACTGTGAGCC 
CDS2 Exon 1R ……………. TCAGAGAACAAGACGACCCC 
CDS2 Exon 2F ……………. TTCTTAGGCCCTGTTTGGAG 
CDS2 Exon 2R ……………. AAGACCACGGGCTCTCTG 
CDS2 Exon 3F ……………. TCACGGTGAATCTGGAAAGG 
CDS2 Exon 3R ……………. GTCAATTCCCACAACCAACC 
CDS2 Exon 4F ……………. ATGGGTTTTCTGGAAGGCTC 
CDS2 Exon 4R ……………. TGCCTCTCCAGCATTTATCTC 
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CDS2 Exon 5F ……………. GCCCTCTGTCCCTTCCTC 
CDS2 Exon 5R ……………. CCCCTGCATGGTCACAG 
CDS2 Exon 6F ……………. GCTTTGACATTGTGCACTGG 
CDS2 Exon 6R ……………. AACCTAAATGGGCATTCTTCC 
CDS2 Exon 7F …………….  TGCTTCTCAGCAGTTTTCTATTTG 
CDS2 Exon 7R ……………. TGCAGAGGATTCTGATGTGG 
CDS2 Exon 8F ……………. TTTTATGGGTGATTTTGGTGC 
CDS2 Exon 8R ……………. CAGCTAGATTTCTTCTGTCTGCC 
CDS2 Exon 9F ……………. GGGGTTTTATGAAAGAAAGGTTC 
CDS2 Exon 9R ……………. TGGCCTCCAAAGACACTCTC 
CDS2 Exon 10F ……………. GCACCCTCAGGAACATGG 
CDS2 Exon 10R ……………. TTACAGCTTTGGGAAGGAGG 
CDS2 Exon 11F ……………. AGGCATCACCTCCCAGTG 
CDS2 Exon 11R ……………. CAGCCTAGTATTTTGGAGGGG 
CDS2 Exon 12F ……………. ATTGCCCTCAGCTACTCAGC 
CDS2 Exon 12R ……………. TTTGGGATGCTTTTCACTGG 
CDS2 Exon 13F ……………. TTCTGAGGCCTCCTGTCATC 
CDS2 Exon 13R ……………. CAGTGAGTTGAAGCCTCGTC 
C20orf196 Exon 2F ……………. AGCCTGGGCAACTTAGTGAG 
C20orf196 Exon 2R ……………. CTCCTGAAAGCTTTGCTTAGG 
C20orf196 Exon 3aF ……………. CCCATTGCCAGTTACTCAGG 
C20orf196 Exon 3aR ……………. CCGGGCCATTTGAAAACT 
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7.1.2 Ataxia telangiectasia is excluded as a cause of the phenotype 
Professor Malcolm Taylor excluded ataxia telangiectasia as a cause of the 
phenotype seen in the affected individuals described in chapter 3. 
In the figure below, there are two lanes per lymphoblastoid cell lysate, one 
unirradiated (-) and one irradiated (+, activated ATM). In lanes 1 & 2 are cells 
from a normal positive control, showing phosphorylation of the targets SMC1 
ser966 (panel C), KAP-1 ser824 (panel E), Nbn1 ser343 (panel G) and CREB 
ser121 (panel I). Also included, in panel A, is autophosphorylation of ATM at 
Ser 1981. There is a strong signal for each of these in lane 2 after activation. 
The total levels of SMC1, KAP-1, Nbn and CREB are also shown in panels D, 
F, H & J respectively. The negative control is cell lysate from a classical A-T 
affected individual is shown in lanes 3 & 4. There is no phosphorylation of these 
five targets in this individual’s cells in lane 4 – consistent with having A-T; there 
is also absence of ATM protein (panel B).  
05 and 06 cell lysates are in lanes 5 & 6 and 7 & 8 respectively. Panel B shows 
that both lysates have a normal level of ATM protein. Just as with the normal 
control (lane 2) both 05 and 06 cells show normal ATM kinase activity, indicated 
by phosphorylation of SMC1 ser966, KAP-1 ser824, Nbn ser343 and CREB 
ser121 as well as autophosphorylation of ATM in panel A, in lanes 6 and 8 
respectively. Also included in this analysis is a known ATM mutation carrier (+/-) 
in lanes 11 & 12. Even with half the level of ATM protein (panel B) there is 
normal ATM kinase activity.  
Western blot was used to look for any loss of proteins associated with an AT-
like phenotype. In Figure S2 below, lane 1 contains lysate of lymphoblastoid 
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cells from a normal individual, with a normal level of ATM and all the other 
proteins. In lane 2 is lysate from cells of a classical A-T patient, showing no 
ATM protein and in lane 3 lysate from an AOA2 patient with a reduced level of 
senataxin. 
Given that the affected Amish individuals showed ataxic symptoms and 
cerebellar hypoplasia, similar to that seen in A-T, other A-T like disorders were 
also a possible cause of the phenotype. These include A-T like disorder 
(ATLD)(caused my MRE11 mutation and reduction in Mre11 protein level), 
AOA2 (caused by reduction or loss of senataxin), AOA1 (caused by loss of 
aprataxin) and RIDDLE syndrome (caused by loss of RNF168). In lanes 4 & 5 is 
lysate from 05 and 06 lymphoblastoid cells showing normal levels of all the 
proteins tested.  
There is thus no suggestion of a reduced level of ATM protein in 05 & 06 nor a 
reduced level of ATM kinase activity compared with normal. The normal level of 
ATM kinase activity is consistent with absence of pathogenic ATM mutations, 
comprehensively excluding AT as a cause of the phenotype.  Normal levels of 
the proteins associated with ATLD, AOA1, AOA2 and RIDDLE syndrome in the 
context of the phenotype observed in the affected individuals effectively exclude 
these disorders as causative.  
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Cells homozygous for PCNA p.Ser228Ile have normal ATM kinase activity 
ATM kinase levels in unirradiated (-) and irradiated (+) lymphoblastoid cell extracts. Lanes 1-2 and 9-10 
are from a healthy control (WT) showing autophosphorylation of ATM (B) and phosphorylation of the 
targets SMC1 ser966 (C), KAP-1 ser824 (E), Nbn1 ser343 (G) and CREB ser121 (I). Lanes 3-4 and 11-12 
show an absence of phosphorylation of these targets in AT cells (A-T). ATM kinase activity is unaffected in 
cells from a heterozygous ATM mutation carrier (lanes 11-12) and in 05 and 06 cells which are 
homozygous for PCNA p.Ser228Ile (lanes 5-8). 
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Cells homozygous for PCNA p.Ser228Ile have normal levels of proteins mutated in AT-
like disorders 
Western blot of extracts from EBV transformed control cells (WT), Ataxia telangiectasia cells (A-T), AOA2 
cells (AOA2) and affected individuals homozygous for PCNA p.Ser228Ile (05 and 06). Normal levels of 
PCNA, ATM and additional proteins which when mutated cause AT-like disorders in cells derived from 
affected individuals.  
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7.1.3 PCNA functional studies 
Immunofluorescence. EdU staining was carried out using the Click-iT EdU 
Alexa Fluor 555 Imaging Kit (Invitrogen). Cells were seeded onto glass 
coverslips so as to be subconfluent at the time of fixation. At least 24 h after 
plating EdU was added to the culture medium to a final concentration of 20 µM 
and cells returned to 37°C for 10 min. Soluble proteins were extracted by 
rinsing once in PBS, once in CSK buffer (100mM NaCl, 300mM sucrose, 10mM 
PIPES pH 7.0, 3mM MgCl2), and then soaking in CSK plus 0.2% Triton X-100 
for 5 min on ice. After a further wash in CSK cells were fixed (ice-cold methanol 
for 20 min at -20°C), washed twice more in PBS, and then blocked (5% w/v 
bovine serum albumin (BSA) in PBST) for 30 min at room temperature. EdU 
staining was carried out according to manufacturer’s instructions. Coverslips 
were then incubated for 1 h at room temperature in blocking buffer containing 
anti-PCNA monoclonal antibody (PC-10) diluted 1:1000, followed by 3 washes 
in PBST and incubation in Alexa Fluor 488 goat anti-rabbit immunoglobulin G 
(Invitrogen) diluted 1:1000 in blocking buffer for 45 min. Cells were rinsed a 
further 3 times in PBST, and coverslips mounted in Aqua-Poly/Mount 
(Polysciences) containing DAPI at a final concentration of 1.5µg/ml. Slides were 
visualized using a Leica SP5 confocal microscope. 
DNA fibre analysis. Immunolabelling of DNA fiber spreads was carried out as 
described in (Unsal-Kacmaz et al., 2007), with minor modifications. Cells were 
incubated in IdU and CldU at a final concentration of 100 µM for 20 min each, 
and all antibody incubations were for 2 h at room temperature. Fibers were 
mounted in ProLong mounting medium (Invitrogen). 
Cell studies. Unscheduled DNA synthesis (UDS), recovery of RNA synthesis 
(RRS), fibroblast survival assays and lentiviral mediated complementation were 
performed as described previously (Lehmann et al., 1993, Lehmann and 
Stevens, 1980, Arlett et al., 1992, Nakazawa et al., 2012, Nakazawa et al., 
2010, Mayne and Lehmann, 1982). 
SILAC analysis. HeLa cells were grown in SILAC DMEM (Gibco) 
supplemented with 10% dialyzed FBS, 2mM CaCl2, 1mM MgSO4, 52mg/l L-
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leucine and 100mg/l L-lysine and L-arginine (for “heavy” extracts [13C6/
15N2] 
lysine and [13C6/
15N4] arginine (CKgas) were substituted). Extracts were made 
by lysing cells in a low salt buffer containing benzonase (Merck), then adjusting 
to 150mM NaCl. All protein interaction assays were performed in interaction 
buffer (25mM Tris pH 7.5, 25mm NaCl, 10% glycerol, 0.01% Igepal, 1mM 
PMSF). Proteins eluted from PCNA affinity columns with 500 mM NaCl were 
combined before 10-fraction mass spectrometric (MS-MS) analysis (MS 
Bioworks). Data was analyzed, and H:L ratios determined using MaxQuant 
software.  
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MaxQuant outputs from the three SILAC repetitions for the previously characterized 
PCNA interactors 
Protein Total 
spectr
a 
# 
unique 
peptide
s 
Ratio h:l 
normalize
d 
Total 
spectr
a 
# 
unique 
peptide
s 
Ratio h:l 
normalize
d 
 
 
Total  
spectr
a 
# 
unique 
peptide
s 
Ratio h:l 
normalize
d 
           
APEX1 141 28 0.11158 148 21 0.10287  28 15 1.5273 
BUB3 29 14 1.0902 41 13 1.0567  59 17 0.7862 
CDK1 12 8 1.0146 7 4 0.90092  7 6 1.0171 
CHTF18 31 19 0.60947 30 14 0.63974  13 8 0.84334 
DDB1 84 42 0.54328 38 24 0.50706  9 8 0.83215 
DNMT1 210 72 0.88423 176 56 0.91885  115 61 0.83092 
FEN1 43 21 11.544 63 18 18.617  20 14 0.10452 
HIST1H1D 16 6 1.5639 13 5 2.8628  2 2 0.90141 
LIG1 21 17 2.8494 22 11 3.2442  48 33 0.18195 
MCM3 39 20 2.5048 28 21 1.7699  24 22 1.1822 
MCM5 23 16 2.6787 21 9 2.0941  17 15 1.1049 
MPG 19 11 0.72417 11 6 0.91538  13 10 0.24551 
NAP1L1 27 8 0.80383 26 8 0.96409  71 14 0.23861 
NAP1L4 33 11 0.79225 75 14 0.97825  93 18 0.25283 
POLD1 161 58 0.41099 98 44 0.41942  79 46 2.5357 
POLD2 41 19 0.46639 26 13 0.43519  18 13 2.1806 
POLD3 33 13 0.42348 45 15 0.42695  24 12 1.7594 
RBBP4 10 7 1.0121 6 3 0.76488  3 2 0.31712 
RFC2 17 11 0.84726 17 11 0.87986  83 28 1.5911 
RFC3 12 7 0.91678 5 5 0.86628  19 13 1.8282 
RFC4 25 18 0.9077 29 16 0.92337  36 24 1.4823 
RNASEH2
A 
7 7 0.22837 7 5 0.32916  8 6 1.8569 
RNASEH2
B 
17 13 0.16996 17 8 0.20808  12 9 2.1405 
RNASEH3
C 
14 8 0.15057 12 5 0.16212  12 9 2.7715 
UNG 14 9 1.4155 12 5 2.0872  34 14 0.3147 
A summary of relevant data from the mass spectrometric analysis of proteins eluted from PCNA affinity 
columns is presented. Repeats 1 and 2 were performed in the forward direction (extracts with “heavy” label 
on the p.Ser228Ile PCNA column, “light” extracts on the wild-type PCNA column). Repeat 3 was 
performed in the reverse direction (“heavy” extracts on the WT column, “light” extracts on the p.ser228Ile 
PCNA column). The number of spectra from each run assigned to each peptide by the MaxQuant software 
is given, as is the number of unique peptides making up those spectra. The “ratio h:l normalized” column 
gives the ratio of signals corresponding to peptides with “heavy” arginine or lysine over unlabeled peptides 
from the same protein. These ratios are normalized such the total h:l ratio in the entire sample is set to 1, 
to correct for slight differences in initial protein extract concentrations. 
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Deficient recovery of RNA synthesis in P1 cells 
RNA synthesis measured by the incorporation of radiolabelled UTP 24 h after UVC-irradiation of non-
dividing cells with indicated doses. Plotted is the mean + SEM of three experiments. PCNA-P1 cells are 
defective in recovering RNA synthesis, to an extent approaching the defect seen in cells from a Cockayne 
syndrome (CS) patient, heterozygotes Het1 and 2 cell lines are normal. 
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Lentiviral mediated ectopic expression of PCNA has little effect on recovery of RNA 
synthesis in wild-type cells 
Ectopic expression of wild-type or p.Ser228Ile PCNA was achieved by lentiviral transduction or GFP– or 
FLAG-tagged PCNA cDNAs. Virus infection was performed 48hours before RRS assays and viral infection 
efficiency (>85%) was confirmed by immunofluorescent staining. RNA synthesis was measured 
fluorescently by the incorporation of 5-ethynyluridine 12h after UVC-irradiation of non-dividing cells with 
indicated doses, revealed by copper-catalyzed fluorescent azide conjugation reaction (Click reaction). 
Plotted is the mean + SEM of three experiments. 
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7.1.4 Site directed mutagenesis (SDM) primers used to generate 
PCNAp.Ser228Ile mutant constructs: 
SDM oligonucleotides were designed following the QuikChange kit guidelines. 
The mutated base is highlighted in yellow, incorporation results in the Ser228Ile 
aminoacid substitution in PCNA. 
Forward: 5'TTCAACGGTGACACTCATTATGTCTGCAGATGTACCC 3' 
Reverse: 5'GTACATCTGCAGACATAATGAGTGTCACCGTTGAAGA 3' 
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7.2 APPENDIX CHAPTER 4 
7.2.1 KPTN primer sequences 
Primer Name Forward Reverse 
KPTN1a CCTTGGTCCAGAAATGGAAA CAGCCCGTACACATTGCTCT 
KPTN1b GCTTAACTGAGGGGCATGAT GAGTCCTGACCACCATCACC 
KPTN2 CTCAGACCAGAGGGCATGAT GGGCTCGTAGTCGCAGTAAA 
KPTN3 GCCCTCCTCCTTACACACAT TGGAACGGAGTGAACTGGA 
KPTN4 CCGGCTCTGAGTACAACCTT CGGCTGGCATTTTAGTTTTC 
KPTN5 GAACAGGGATTGGCAAACTT GAAGTGCTGTTTTCTGTCTCCTT 
KPTN6 TGAGGGCTCGTTTCTACAGTT TAAGTCAGCCGTCAGCTTCA 
KPTN7 CCTGTGGGATTCACTGTGG CCCAATTCCTCTGAGGTCAA 
KPTN8 GGCGGTGAGACCTTAGAGAA AACCACTCTGACAGCCCAGA 
KPTN9 GGGTGGTGAGAATTGACCTC CTTATCCTCCTCCCCTACCC 
KPTN10 * GGGTGCAAATCTGGGTAGAA GGCTATTGCTGGGTGAGGTA 
KPTN11 GAGGCGGGGTTTTATCATGT TCCAGCTCTGGGTAATCCAC 
KPTN12 GCCTGAGAAGGGAAGCAGTA GGGCCCCGGTACTTATAACA 
KPTN13 GTGGGACCTGACAGTTGGAG AGGAACTGCCTCCCTGAAAT 
KPTN14 CAGGCTCTAGCGCAGTGA  TGGTGGCTCACACCTGTAAT 
KPTN15 CTGTCACAGAGGCCCATTC GGATCATCCCTGCTTTCAAAT 
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7.2.2 RT-PCR  KPTN cDNA primer sequences  
Forward: CCAGAGCTGACGAACCTGACCAGTAGC 
Reverse: CAGAGGACGCTGTCAAACTGGTCACTG 
7.2.3 Methodology relating to the functional analysis of the Kaptin 
protein 
7.2.3.1 Neuronal cell studies: 
Human kaptin was cloned from HEK293 cell cDNA obtained by RNA isolation 
and reverse transcription PCR as previously described (Pinyol et al., 2007). 
Full-length kaptin (amino acids 1–436) was generated by PCR using primers: 
BQ2046: AAGAATTCATGATGGGGGAGGCG 
BQ2047: AAGGATCCTTAAGAGGCTGCATT 
The PCR product generated was digested with EcoRI and BamH1 and cloned 
in-frame into pEGFP-c2 and subcloned into pCMV-Tag2. Primary rat 
hippocampal cultures were prepared and cultured as described (Ahuja et al., 
2007, Qualmann et al., 2004). Neurons were transfected with Lipofectamine 
2000 (Invitrogen) at day 3, 13 and 23 in vitro, fixed in 4% PFA in PBS for 7 min 
at RT 24 and 48 h after transfection, respectively, and processed for 
immunofluorescence microscopy (Qualmann et al., 2004). Confocal imaging 
was performed using a Zeiss AxioObserver equipped with an ApoTome and 
Zeiss Plan-Apochromat 63 x/1.4 and 40 x/1.3 objectives and an AxioCam MRm 
CCD camera (Zeiss). 
7.2.3.2 Generation of GFP tagged mutant Kaptin: 
p.M241_Q246dup kaptin mutant (GFP-kaptinM241-Q246dup) was generated by 
fusing an N-terminal portion carrying the mutation and a SmaI site introduced as 
a silent mutation (primers below). 
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BQ2046: AAGAATTCATGATGGGGGAGGCG 
BQ2050:TCACCCGGGAGATGGGCCCGTCTTGCAACACGCTCCACATCTGC
AGGACCGACCAC 
A C-terminal portion containing a SmaI site also introduced by silent mutation 
(primers below). 
BQ2048: ATCTCCCGGGTGATTGTGTTCAG 
BQ2047:AAGGATCCTTAAGAGGCTGCATT]) 
The p.S259X kaptin mutant (GFP-kaptin1-258) was generated by PCR (primers 
below).  PCR products were cloned in-frame into pEGFP-c2. 
BQ2046:AAGAATTCATGATGGGGGAGGCG 
BQ2070: AAGTCGACCtAGAGGCTGAACAC 
 
Cartoon showing the construct used to generate the KPTN mouse 
  
 276 
7.3 APPENDIX CHAPTER 5 
WHAMM and WDR73 genotypes of the healthy siblings of nephrocerebellar syndrome 
affected individuals (pedigree shown in Figure 43) 
 
7.3.1 SAMHD1 primers 
FORWARD:   CCTGGCCACTTTTTACAATTT  
REVERSE:   CATCTTTCTGTATTTTTCTAATTTGC 
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7.3.2 SAMHD1 RT PCR primers 
FORWARD:   CAGCAATTGACGACATGGAAGCCTA 
REVERSE:   TGCTCTGTTGGGGGCAGTCTTACAA 
7.3.3 WDR73 primers 
FORWARD:  CAGGGACAAAACGCTACCAT 
 
REVERSE:    CATGGTGAAACCCCATCTCT
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